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Abstract 
Urinary incontinence is the involuntary leakage of urine and affects one in twenty 
of the population across all ages leading to poor quality of life and can be very 
high cost to the nation. It is possible to reduce these costs by accurate diagnosis 
and appropriate management of the condition. Urinary incontinence is often 
associated with an overactive bladder or urethral sphincter weakness, or both as a 
result of interrupting the pathway to nervous communication between the brain 
and the bladder leading to uncoordinated activity in the lower urinary tract.  
Treatment options for overactive bladder include antimuscarinic drugs and 
implanted electrical stimulators. However these drugs have intolerable side 
effects, while implanting a stimulator is a surgical procedure which is associated 
with degree of risk and becomes ineffective due to habituation to the continuous 
stimulation. 
 The aim of the research was to develop a novel wearable anal device designed to 
deliver conditional neuromodulation. The device detects the electromyography 
activity in the lower urinary tract, and provides the transrectal stimulation to the 
Pudendal nerve when required, in order to suppress the bladder contractions while 
contracting the urethral sphincters.  
The clinical study included designing and manufacturing patient compatible 
model and conducting a clinical study to measure the safety and the efficacy of 
the device.  Electronics circuit design included amplifier, signal processing 
system and constant current stimulator based on the specification derived from 
the clinical study and finally focused on optimisation of the device electrodes for 
improving stimulating parameters. 
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Chapter 1 -  Introduction 
1.1 Background 
Urinary incontinence (UI) is the involuntary loss of urine which is objectively 
demonstrable and a social or hygienic problem [1]. UI affects one in three of the 
population at some stage in their adult lives [2].  According to the National 
Association for Continence (NAFC) 200 million people worldwide suffer from 
this problem [3] and is thought to affect about six million adults in the UK [2]. 
Urinary incontinence is common as people get older and more common in women 
and double the incidence in women who have had vaginal deliveries [4]. For 
developing countries these figures increase rapidly due to the lack of people’s 
health knowledge, embarrassment to discuss these issues with doctors and also 
insufficient health facilities [5]. 
Urinary incontinence can have devastating effects on the life of sufferers and their 
families and can be very high cost to the nation [5]. In adult women with urinary 
incontinence 60% avoid going away from their home, 50% feel odd and different 
from others, 45% avoid public transport while 50% report avoiding sexual 
activity through fear of incontinence [6]. 
The economic impact of incontinence on society is significant [7]. The cost 
includes medicine, absorbent products, catheters and loss of earnings. Also this 
needs to account the cost of primary and secondary care, nursing home and long 
term care. Between 2000 and 2003, the annual cost of incontinence to the NHS 
was £500 million and that is expected to rise to £2 billion by year 2020 [8]. It is 
possible to reduce these costs by accurate diagnosis and appropriate management 
of the condition. 
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There are four main types of urinary incontinence: stress incontinence, urge 
incontinence, overflow incontinence and mixed incontinence. Stress incontinence 
is the involuntary loss of urine during filling phase of the bladder when 
intravesical pressure exceeds maximal urethral closure pressure without any 
bladder contraction. Urge incontinence defined as the provoked or spontaneous 
detrusor contraction during the filling phase of the bladder when the individual is 
voluntarily inhibiting the micturition. When the urge incontinence is caused by 
neurogenic disorder, it is known as the neurogenic incontinence. Overflow 
incontinence results from over distension of the bladder due to bladder outlet 
obstruction or functional weakness of the bladder itself. Mixed incontinence is 
due to coexistence of bladder muscle overactivity and urethral sphincter weakness 
[9].  
This research focused on a device for treating UI due to neurogenic incontinence, 
which affects nearly 16.6% of UI population aged ≥ 40 years [10]. Neurogenic 
incontinence occurs as a result of interrupting the pathway to nervous 
communication between the brain and the bladder leading to uncoordinated 
activity in the lower urinary tract (LUT). This can be due to a variety of reasons 
such as spinal injury, stroke, multiple sclerosis (MS) and Parkinson’s disease. In 
neurogenic detrusor overactivity (NDO) also known as detrusor hyperreflexia 
(DH) the bladder contracts involuntarily during filling phase that leads to increase 
frequency and leakage of urine. This is often associated with detrusor sphincter 
dyssynergia (DSD), in which the bladder and sphincter contract together resulting 
voiding dysfunction. NDO together with DSD can cause high transient bladder 
pressure and may lead to vesicoureteric reflux, repeated bladder infections and 
renal failure if left untreated  [11-15]. 
The standard method of treating NDO is antimuscarinic (anticholinergic) drugs to 
relax the detrusor muscle in order to prevent incontinence [16, 17]. 
Anticholinergic drugs, for example, Oxybutynin, Tolterodine are relatively 
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expensive and need lifelong treatment. Furthermore clinical experience shows 
that up to 50% of patients with NDO cannot tolerate the side effects of the drugs 
such as dry mouth, drowsiness, constipation, skin reactions and blurred vision 
[18-20].  
For many years electrical stimulation (ES) has been a potential treatment to 
suppress detrusor contractions in patients with NDO [21-25]. The sacral anterior 
root stimulator implant (SARSI) has been proven to be an effective way of 
achieving good bladder emptying [26, 27]. Combining these two can replace the 
standard treatment. 
Whilst implants are successful, these have disadvantages such as implantation of 
the stimulator is a surgical procedure and is associated with a degree of risk, also 
it cannot be serviced or removed easily [28]. Sometimes the lower urinary tract 
symptoms change over time; therefore non-invasive and non-destructive 
treatment is preferred until symptoms improve [29]. Further, most of the 
electrical stimulator treatments for bladder overactivity, provide continuous 
stimulation to the nerves that control the bladder. In these, stimulation becomes 
ineffective due to habituation and may increase the risk of tissue damage [28]. 
High energy consumption [12] and absence of warning time before the leak are 
also disadvantages of such systems.  
A much better approach to this problem would be a wearable device, in which 
patients can experience the acute effect of stimulation before proceeding for an 
implantation and also to be used as a non-destructive treatment [29]. If the device 
can provide stimulation only when required, it will increase both battery and 
electrode life while reducing the effect of habituation [12, 28, 30, 30-32]. 
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1.2 Aim of the project  
The overall aim of the project is to develop a novel wearable anal device designed 
to deliver conditional neuromodulation1 and ultimately prove its principle in a 
small scale clinical study. The device detects the electromyogram (EMG) activity 
in the lower urinary tract, and provides the transrectal stimulation to the Pudendal 
nerve when required, in order to suppress the bladder contractions while 
contracting the urethral sphincters [34]. 
1.3 Publications 
The following work was published from the work mentioned in this thesis. 
• Craggs M, Edirisinghe N, Leaker B, Susser J, Al-Mukhtar M and Donaldson 
N.; “Conditional neuromodulation using trans-rectal stimulation in spinal cord 
injury”, Neurology and Urodynamics; Vol. 28; pp. 836-837; 2009.  
• Edirisinghe NA, Leaker B, Donaldson N. and Craggs MD; “A novel wearable 
medical device for controlling urinary incontinence by conditional 
neuromodulation”, Proc. Conference organised by Institution of Mechanical 
Engineers (Incontinence: The Engineering Challenge VII), December 2009, 
London, UK. 
• Edirisinghe NA, Leaker B, Susser J, Al-Mukhtar M, Donaldson N. and 
Craggs MD: “Assessment of a novel wearable conditional stimulation device 
for continence control”, Annual Scientific Meeting of South East Division of 
Institute of Physics and Engineering in Medicine, May 2009, Kent, UK.  
                                               
1
 The influence of activity in one neural pathway modulates the pre-existing activity in another 
through synaptic interaction [33]. 
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• Edirisinghe NA, Susser J, Al-Mukhtar M, Knight S, Leaker B, Donaldson N. 
and Craggs MD; “A novel wearable conditional neuromodulator for treating 
urinary incontinence in spinal cord injury”, Proc. Conference organised by 
UK Continence Society (Broadening Horizons), April 2009, Swansea, UK. 
• Edirisinghe NA, Donaldson N and Craggs MD; “A novel wearable medical 
device for controlling urinary incontinence by conditional neuromodulation”, 
Graduate School poster competition, UCL, March 2009, London, UK. 
Became the Runner-up in the Departmental category. 
• Edirisinghe NA, Donaldson N and Craggs MD; “Neuromodulation Device for 
Pelvic Dysfunction”, Graduate School poster competition, UCL, March 2008, 
London, UK.  
1.4 Thesis outline 
The project is based on development and testing of the novel wearable 
conditional neuromodulation (CN) device. This thesis comprises eight chapters, 
which are: 
Chapter 1 introduces the background problems, types of urinary incontinence and 
describes its severity. It briefly describes the current methods of treating UI and 
their drawbacks. Further the requirement of a new device to improve the quality 
of the life of the patients is described. Finally the chapter highlights the aim of the 
project. 
Chapter 2 describes some basic understanding of the problem based on current 
findings. It briefly describes the anatomy and physiology of the lower urinary 
tract and then moves onto the causes and treatment of NDO and specially focuses 
on literature review on electrical stimulation as a treatment option. 
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Chapter 3 focuses on the study design. The chapter starts with a brief requirement 
of the device and then moves on to explaining the basic principle behind the 
operation of this device.  
Chapter 4 describes the actual process of making the prototype device. It starts off 
with a previous model that is being used for similar applications and then talks 
about the design considerations based on biocompatibility and anatomy of the 
LUT. All the design steps involved are explained in detail within this chapter. 
Chapter 5 explains the testing of the device within the clinical environment to 
find out its efficacy. It describes the patient selection, equipment setup and then a 
series of experiments that were carried out. These results were then analysed 
using statistics to assess its clinical significance. 
Chapter 6 derives the specification for the required electronic circuitry to make 
this model as a stand alone device. Then it describes the building of the actual 
circuit and testing of the prototype system. Design considerations are mentioned 
for each part of the circuitry.  
Chapter 7 summarises the work included in the thesis. The results presented in 
each chapter are analysed to see the direct benefit to the patient. Finally it finishes 
with a brief description of future work required for further development.  
Chapter 2 –Bladder inhibition – beyond nature 
_______________________________________________________________ 
- 25 - 
Chapter 2 -  Bladder inhibition – beyond nature 
2.1 Introduction 
As explained in chapter 1, urinary incontinence is a wide problem to the society 
and treatment modification is required to increase the quality of life of the 
sufferers and also to reduce the cost to the NHS. In order to assess the problem of 
neurogenic detrusor overactivity, it is helpful to understand the basic mechanism 
of filling and emptying of the bladder.  
This chapter provides some basic understanding of the term “urinary 
incontinence”, which is the main focus of the thesis. The discussion starts off by 
explaining the anatomy and the physiology of the lower urinary tract of a healthy 
adult. Then the explanation moves onto the causes for bladder dysfunction and to 
explain how it affects the physiology of the bladder. The latter part of the chapter 
talks about currently available treatments and special attention is given to past 
research based on electrical stimulation to treat bladder dysfunction.  
2.2 Anatomy and physiology of the lower urinary 
tract 
2.2.1 Anatomy of the lower urinary tract 
The urinary bladder is a temporary store of urine from kidneys and empties 
through the urethra. The bladder varies in its size, shape and position according to 
the amount of urine it contains. When empty it lies entirely within the pelvis, but 
as it fills up it expands and extends upwards into the abdominal cavity [35]. 
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The smooth muscle of the bladder is called the detrusor muscle (Figure 2:1) 
arranged in spiral, longitudinal and circular bundles. The contraction of the 
detrusor muscle is responsible for emptying the bladder during micturition [36]. 
 
Figure 2:1 - Coronal section of the male near urinary bladder. 
The bladder is formed from smooth muscle named detrusor muscle. External urethral sphincter 
provides continence during the filling phase of the bladder [37]. 
Muscle bundles pass either side of the urethra and formed internal urethral 
sphincters, which is involuntary. These fibres do not encircle the urethra. The 
function of these sphincters is to prevent retrograde ejaculation of the semen into 
the bladder [37]. Further along the urethra is a sphincter of skeletal muscle, the 
sphincter at membranous urethra is known as external urethral sphincter (EUS), 
which is mainly responsible for continence [35]. 
2.2.2 Innervation of bladder and sphincter 
The lower urinary tract is supplied from the vesical plexus of nerves which is 
made up of parasympathetic, sympathetic and somatic systems. All of these 
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contain afferent (sensory) and efferent (motor fibres) and the innervations of the 
bladder and the sphincter are highlighted in Figure 2:2 [35].  
Parasympathetic nerve supply 
The parasympathetic system provides the major excitatory input to the detrusor 
muscle and is inhibitory to the urethral sphincters. These nerves arise from the 
pre-ganglionic neurons in the intermediolateral grey column of the S2-S4 sacral 
segments and travel in pelvic splanchnic nerves, synapse at the inferior 
hypogastric plexus and prostatic nerve plexus. Parasympathetic ganglionic cells 
are situated in the walls of the bladder and the ureter with postganglionic axons 
directly innervating the smooth muscle [38-41]. 
Afferent axons in the parasympathetic nerves travel back to the S2-S4 segments 
of the cord, and have their cell bodies in the sensory ganglia at those segments. 
These axons convey the information that is particularly important in producing 
the detrusor contraction in response to the bladder fullness [38]. 
Sympathetic nerve supply 
The sympathetic efferent are said to be inhibitory to the detrusor and stimulatory 
to the smooth muscles of the bladder neck [35]. These nerves arise in the 
intermediolateral grey column of T10 –L2 of the cord. These pre-ganglionic 
axons travel via splanchnic nerves and synapse in lower preverterbal ganglia, 
especially the inferior mesenteric. From here, new axons form the hypogastric 
nerve, which runs on the posterior abdominal wall into the pelvis [38, 40]. 
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Figure 2:2- Block diagram of the neural control of the lower urinary tract.  
The Innervation of the urinary bladder and urethral sphincters are from three types of nerves, which 
are parasympathetic (green), sympathetic (blue) and somatic (red). Contractions are shown as”+”, 
while inhibitions are “-“. Urethral sphincters represented as “US”. 
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Many axons in the hypogastric nerve are sensory. The afferent axons 
accompanying the sympathetic nerves are responsible for sensation of the bladder 
fullness. Cell bodies of these nerves are in the sensory ganglia of the lower 
thoracic spinal root [38]. 
Somatic nerve supply 
Somatic nerves provide the voluntary control to the striated muscle of the external 
anal and urethral sphincters and pelvic floor muscles [38, 41]. These nerves arise 
from the motor neurons in Onuf’s nucleus, a specialised group of anterior horn 
cells originating from S2-S4 segments [40]. After emerging from the pudendal 
(Alcock’s) canal, this divides into the inferior rectal nerve, perineal nerve and the 
dorsal penile nerve [39]. 
The somatic afferent axons of the pudendal nerve have cell bodies in the sensory 
ganglia of S2-S4. These sensory fibres convey the sensation of urine passing 
through the urethra, felt at the conscious level [38]. 
2.2.3 Physiology of urination 
In healthy individuals, the lower urinary tract has two discrete functions.  
• A storage function is brought about by autonomic bladder relaxation and 
tonic contraction of the external urethral sphincter. 
• Micturition is brought about by voluntary relaxation of the external 
urethral sphincter and pelvic floor, along with reflex contraction of the 
detrusor muscle. 
The urinary pathways that control these two functions have two states [42]. This 
analogy is illustrated in Figure 2:3. 
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Figure 2:3- Micturition cycle of a healthy adult. 
The filling and voiding events are recorded by cystometry and sphincter EMG traces as shown in the diagram. (A) As the bladder fills sympathetic reflexes suppress the 
parasympathetic pathways to the detrusor muscle while increasing the tone of bladder neck and the urethra. (B) By the time first desire to void, the “guarding reflex” begins 
and increases the tone of the sphincter (electromyography) further. (C) As the desire to void increases further, the voluntary contraction increases the tone of the sphincters to 
its maximum. (D) At an appropriate social condition the voiding reflex begins by opening the sphincters and contracting the detrusor muscle [43]. 
Chapter 2 –Bladder inhibition – beyond nature 
_______________________________________________________________ 
- 31 - 
 
Storage phase (The guarding response) 
According to law of Laplace, as the bladder accumulates increasing volume of 
urine, the tension to the bladder wall increases so does the radius of the bladder; 
resulting low intravesical pressure until the bladder is well filled [36]. The extent 
to which the change in volume (δV) occurs in relation to a change in intravesical 
pressure (δP), is known as the bladder compliance (δV/δP). The factors that 
contribute to this are the visco-elasticity of the bladder and the inhibition of 
parasympathetic nerves [14, 44]. 
As the bladder fills, sympathetic nerves inhibit the parasympathetic nerves from 
triggering bladder contractions. Sympathetically mediated reflexes cause the 
suppression of detrusor activity and contract the smooth muscle of the bladder 
neck and proximal urethra [14]. 
In the mean time urethral sphincters also contract via pelvic afferents to pudendal 
efferent reflex in order to prevent the leakage. This mechanism is known as 
“guarding reflex”, which generates the sphincter EMG during bladder filling [45]. 
Contraction of external urethral pressure coupled with that of internal urethral 
sphincter, maintains the urethral closure pressure. As long as the maximum 
urethral closure pressure is higher than the intravesical pressure, the continence is 
maintained [40, 43, 46]. 
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Figure 2:4 - Storage phase 
As urine accumulates, distension of the bladder activates stretch receptors, which trigger spinal 
reflexes, resulting in storage of urine [47]. 
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Voiding phase 
It is through the learnt ability to postpone the micturition until the socially 
acceptable conditions are present [33, 36]. Once the bladder reaches its full 
capacity, stretch receptors within the bladder wall trigger micturition reflexes, 
resulting in excitation of the parasympathetic pathways, while inhibiting 
sympathetic and somatic pathways. At this point the Pudendal nerve causes 
relaxation of the levator ani so that the pelvic floor muscle relaxes. This causes a 
downward tug on the detrusor muscle to initiate its contraction. Efferent fibres 
conduct the signal for sphincter relaxation, which results in lowering of the 
urethral pressure. 
Signals from parasympathetic nerve triggers the detrusor contraction and results 
the increase in intravesical pressure above the maximum urethral closure 
pressure. Thus the micturition process is initiated. The flow of urine can be 
interrupted at any point, by contracting the sphincters voluntarily through the 
somatic pathways [40, 43].  
The bladder can be made to contract voluntarily when it contains only few 
millilitres of urine. This is done by voluntary contraction of the abdominal 
muscle, which aids the expulsion of urine by increasing the intra-abdominal 
pressure [36, 46]. 
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Figure 2:5 - Voiding phase 
Voluntary inhibition of voiding reflex results in activation of the micturition centre of the PMC, which 
signals parasympathetic motor neurons that stimulates the contraction of the detrusor muscle and 
relaxation of the urinary sphincters [47]. 
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2.3 Causes for bladder dysfunction 
Continence is maintained by the coordinated action of the brain, spinal cord and 
the innervated nerves of the bladder as well as proper integrity of the detrusor 
muscle, the urethra and the sphincter. If a problem arises in any one of these 
bladder may become dysfunctional. 
2.3.1 Supraspinal lesions 
Lesions that are occurred in the central nervous system and involve the pontine 
micturition centre are known as supraspinal lesions. Symptoms of these diseases 
and their effect on bladder function are listed in Table 2-1. 
Table 2-1 - Supraspinal lesion diseases and the effect on the bladder function [46-48]. 
Disease Effect on bladder 
Dementia 
Incontinence may be caused due to both loss of judgement 
due to frontal lobe atrophy as well as loss of volitional 
control of detrusor reflex function. 
Parkinson’s 
disease 
Overactive bladder can be present due to increase in 
cholinergic activity in the brain as a result of deficiency of 
dopamine. 
Cerebrovascular 
accident 
After cerebral shock phase wears off, the bladder 
demonstrates detrusor hyperreflexia with coordinated 
urethral sphincter activity due to focal neurologic deficit. 
Multiple sclerosis 
Due to focal demyelinating lesion of the brain or the spinal 
cord or the axons, the nerves that control the continence 
mechanism can be blocked or delayed. The effect of this 
may be temporary or permanent and can be detrusor 
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hyperreflexia or detrusor areflexia. 
Brain tumors 
If the tumor is located closer to the pontine micturition 
centre, the detrusor areflexia or hypperflexia can occur. 
 
2.3.2 Spinal cord lesions 
With spinal cord injury, there is sudden (spinal shock phase) partial or complete 
loss of voluntary movements below the level of lesion associated with partial or 
complete abolition of sensation. As the spinal shock phase (6-12 weeks) wears 
off, the reflex activity increases [48]. 
If the injury is above the sacral division (Figure 2:6) of the spinal cord, the 
individual may experience detrusor hyperreflexia together with detrusor sphincter 
dyssynergia. Even though the bladder is trying to force out the urine, the 
sphincters remains contracted which prevents flow. 
Injuries occurring to the nerves which arise from the sacral cord may prevent the 
bladder from emptying. If the sensory fibres are damaged, the individual may not 
feel the bladder fullness or, if the motor fibres are damaged, the person feels the 
bladder is full, however the detrusor may not contract. This is known as detrusor 
areflexia. 
The most common cause for spinal cord lesion is road traffic accidents [49]. 
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Figure 2:6 - The lateral view of the spinal cord segments. 
The spinal cord segments can be divided into four main sections as Cervical (red), Thoracic (purple), 
Lumbar (green) and Sacral (blue) [50]. 
2.3.3 Peripheral nerve lesions 
The most common types of peripheral nerve lesions and their effect on bladder 
functions are highlighted in Table 2-2. 
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Table 2-2 - Types of peripheral nerve lesions and their effect on bladder functions [48, 51, 52]. 
Disease Effect on bladder 
Diabetic 
cystopathy 
After ten or more years of diabetes mellitus causes 
segmental demyelination and impaired nerve conduction. 
As symptoms arise by losing bladder filling sensation and 
motor function, the result is detrusor areflexia. 
Herpes zoster 
This causes inflammation of posterior nerve roots and may 
block nerve conduction. During the inflammation, detrusor 
areflexia may occur and normal bladder function will return 
once the infection is cleared. 
Pelvic surgery 
Bladder dysfunction may result from pelvic surgeries such 
as removal of prostate glands, hysterectomy and child birth 
injuries. Most commonly these patients experience 
temporary detrusor areflexia, which fades away with 
recovery from the surgery. 
 
2.4 Treating and managing urinary incontinence 
Neurogenic bladder dysfunctions may lead to irreversible renal damage and 
bladder wall destruction before incontinence becomes an issue. Therefore it is 
important to treat this condition at an early stage [53]. Although many different 
types of treatments are available in managing urinary incontinence, none has 
proved universally satisfactory. Some of the most common treatments and 
management methods are discussed in this section. 
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2.4.1 Medication 
For the vast number of people who suffer from urinary incontinence, drugs are 
the initial treatment. There are many drugs available on the market and all owing 
the same effects [19].  
If the problem is detrusor overactivity, the rational treatment is to give a 
medication that is capable of reducing the detrusor overactivity, possibly by 
blocking the parasympathetic transmission such as using anticholinergic drugs. 
Oxybutynin chloride and Tolterodine are two of the most commonly prescribed 
drugs. These drugs increase bladder capacity, decrease bladder filling pressure 
and improve compliance [53]. However the main problem of these is the short 
duration of action, therefore when the patient stops the medication, the symptoms 
return [18]. 
However clinical evidence shows that up to 50% of patients with NDO cannot 
tolerate the side effects of the drugs such as dry mouth, drowsiness, constipation, 
skin reactions and blurred vision [19, 54]. 
Recently a treatment known as botulinum toxin-A (“Botox”) was introduced to 
inhibit detrusor overactivity, which has effects lasting for about a year [55]. 
Botox inhibits the neurotransmitter release at the nerve endings, suppressing 
bladder contractions [56]. However the long-term effects of this injection are not 
yet known [41]. 
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2.4.2 Absorbent products 
These are the garments designed to absorb urine to protect the skin and clothing, 
and are mostly used as a temporary method until a permanent solution become 
available.  
There are two major types of absorbent products, which are body-worn products 
and bed pads. They come in many shapes and sizes. These also can be divided 
into disposable and washable products. Washable products are unsuitable for 
heavy leaking but generally provide better protection; whereas the disposable 
products are less vulnerable for urinary tract infections (UTI) but high in cost [5]. 
Improper absorbent products may contribute to skin breakdown and urinary tract 
infections. Furthermore absorbent products are generally not recommended for 
the spinal cord injured patients, which might lead to pressure source due to the 
lack of mobility.  
All the treatment and management methods described in section 2.4 are 
associated with their own side effects. They do not provide permanent solution to 
the problems associated with the bladder. In 2001 Creasey and Dahleberg 
concluded that the neural prosthesis2 for bladder and bowel management is less 
costly than the conventional methods (Figure 2:7 and Figure 2:8) [58]. 
                                               
2
 A neural prosthesis is a device or technique used to supplement or replace lost or missing function in 
neurologically impaired individuals [57]. 
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Figure 2:7 – Annual cost of conventional methods 
Mean cost of conventional methods of bladder and bowel care before and after using electrical 
stimulation as a treatment was calculated using a sample size of 12 [58]. 
 
Figure 2:8 – Cumulative bladder and bowel care cost. 
Estimated cumulative cost over ten years of person using conventional bladder and bowel care 
methods or electrical stimulation [58]. 
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2.5 Electrical stimulation for bladder inhibition 
For many years electrical stimulation has been a successful treatment for 
problems of the lower urinary tract, especially urinary incontinence caused by 
sphincter weakness or bladder overactivity [32, 33, 59]. 
In humans, stimulation of the sympathetic nerves arising from T10-L2 spinal 
levels (Figure 2:2) results in relaxation of detrusor muscle and contraction of 
urethral sphincters causing inhibition of urination. Stimulating the 
parasympathetic pathway arising from S2-S4 (Figure 2:2) has the opposite effect 
[60].  
2.5.1 Neurostimulation and neuromodulation 
Electric stimulation can be mainly divided into two categories as 
neurostimulation and neuromodulation. In neurostimulation nerves or muscles 
directly stimulated to achieve immediate responses [60]; whereas in 
neuromodulation the influence of activity in one neural pathway modulates the 
pre-existing activity in another through synaptic interaction (alters the 
neurotransmission process) [33]. 
2.5.2 History of neural prostheses 
The first reported case of attempted neuromodulation in patients with bladder 
dysfunction is by the Danish surgeon Saxtroph in 1878 to treat urinary retention  
[60, 61]. Since then there have been many discoveries in this field and some of 
them are highlighted in this table. 
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Table 2-3 – History of electrical stimulation for bladder dysfunction. 
Table shows the discoveries by scientists regarding electrical stimulation to treat bladder dysfunction 
over the past century. 
Year Scientist Discovery 
1895 M.H. Saxtroph 
Intravesical stimulation of the bladder to treat 
urinary retention [60, 61]. 
1895 J. Griffiths 
Electrical stimulation of proximal stump of the 
cat’s pudendal nerve resulted in a pronounced 
relaxation of the bladder, if its wall is in the 
contracted state [62]. 
1937 
Langworthy and 
Hesser 
Detrusor inhibition on vaginal or anal dilatation 
has been observed [25, 63]. 
1954 Boyce 
Bladder wall stimulation implant was developed 
to induce bladder emptying [61, 64]. 
1955 Ingersoll 
Pelvic nerve stimulation studies on cats and dogs 
[65]. 
1963 Caldwell 
Electrodes implanted in urethral and anal 
sphincters to deliver electrical stimulation. This 
is reported as the first attempt in management of 
incontinence [66]. 
1963 
Kock and 
Pompeius 
Vesical motor activity has been inhibited by anal 
stimulation [67]. 
1963 Habib 
Electrical stimulation of the sacral anterior roots 
of human and animal study [68].  
1964 Rossier and Bors 
Detrusor inhibition in human by pin-prick 
stimuli applied in the perineal region [69].  
1968 
Alexander and 
Rowan D 
Radio controlled implant and also external 
electrode systems with vaginal and anal 
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electrodes that stimulated the anal sphincters, 
pelvic floor muscles and pelvic nerves to control 
incontinence. The stimulation increased the 
urethral resistance and inhibited the bladder [22]. 
1969 Brindley 
Finetech-Brindley sacral anterior root stimulator 
first tested on animals [26]. 
1969 
DeGroat and 
Ryall 
Demonstrated inhibitory postsynaptic potentials 
and inhibition of discharges of parasympathetic 
neurons due to spinal reflex with a pudendal 
afferents of a cat. Also reported that stimulation 
of these somatic afferents may have both 
excitatory as well as inhibitory influence on the 
bladder depending on the intravesical pressure 
low or high [70]. 
1972 
Sundin and 
Carlsson 
Stimulation of pudendal afferents was shown to 
induce bladder inhibition due to pudendal to 
hypogastric spinal reflex [71]. 
1974 Sundin 
Stimulation of pudendal afferents was shown to 
induce bladder inhibition due to pudendal to 
pelvic spinal reflex. Assumed to be of main 
importance for detrusor inhibition in humans 
[72]. 
1975 Godec 
First use of electrical stimulation explicitly for 
bladder inhibition using functional electrical 
stimulation applied to the anal sphincters [73]. 
1978 Brindley 
Sacral anterior root stimulator first implanted on 
patients [26]. 
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1978 Fall 
The pudendal to spinal reflex mechanism was 
activated by intravaginal electrical stimulation in 
cats [74]. 
1979 Janez 
Urethral and bladder response to anal electric 
stimulation were evaluated by cystometry in 55 
patients with bladder dysfunction [24]. 
1982 Kondo 
Mechanical stimulation (squeeze) of the penis 
for bladder inhibition [75]. 
1983 McGuire 
Bladder inhibition was achieved through tibial 
nerve stimulation [76]. 
1983 Lindstrom 
Showed the activation of sympathetic 
vesicoinhibitory neurons and inhibit the 
parasympathetic vesical motor neurons. Also 
shown the sphincter muscle contraction is not 
necessary to achieve detrusor inhibition by 
afferent stimuli in animals [77]. 
1984 
Nakamura and 
Sakurai 
Detrusor activity was suppressed using 
transcutaneous electrical stimulation applied to 
the penis [78]. 
1985 
Brindley and 
Donaldson 
An implantable system, where pudendal nerve 
stimulation was controlled by detrusor pressure 
was tested for six months [41]. 
1986 Vodusek 
It was shown that, in human the bladder 
inhibition can be achieved by stimulating the 
pudendal afferents of the dorsal penile 
stimulation and showed that all that is required 
for bladder inhibition is depolarising the 
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pudendal afferents. Furthermore detrusor 
inhibition was achieved by direct pudendal nerve 
stimulation using needle electrode and using low 
currents [79]. 
1988 Schmidt 
Implantable stimulator connected to an electrode 
making contact with S3 nerve root [33]. 
1991 
Fall and 
Lindstrom 
Concluded that dorsal penile/clitoral nerve 
stimulation activates inhibitory sympathetic 
bladder pathways and inhibits the preganglionic 
bladder motor neurons through a direct route of 
sacral cord [80]. 
1996 Sheriff 
Neuromodulation of detrusor hyperreflexia by 
multi pulse magnetic stimulation of the sacral 
roots [81]. 
1996 Hansan 
Transcutaneous electrical stimulation of the 
sacral dermatomes to treat idiopathic detrusor 
instability [82]. 
2000 Grill and Craggs 
First implantation of “BION” micro stimulator, 
which delivers chronic stimulation of the 
pudendal nerve. This can be implanted using 
minimally invasive techniques [83]. 
 
The attempts to use electrical stimulation for the treatment of bladder dysfunction 
have found their way into clinical practice [61]. One of the best examples is the 
Finetech-Brindley stimulator (Figure 2:9), that so far has been implanted in more 
than 2500 patients over the last twenty years [84]. The implant is very reliable 
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and there was an average one fault in the implant for every 19.6 implant-years 
and some patients having the implant for more than twenty three years [27]. 
 
Figure 2:9 – SARSI 
The Finetech-Brindley Sacral Anterior Root Stimulator Implant. The implantable receiver (Internal 
Stimulator) is connected by cables to electrodes placed next to the sacral nerves carrying motor fibers 
to the bladder detrusor muscle [83]. 
Electrical stimulation is recommended prior to any other treatment for bladder 
dysfunction provided the following criteria are met  [25]. 
• Underlying conditions should be treated accordingly prior to electrical 
stimulation treatment. 
• Conditions such as urinary tract infections, vaginal discharge should be 
treated prior to stimulation.  
• Patient’s cooperation and ability to manipulate the device is essential. 
• Neuromuscular structure involved in urinary storage must be at least 
partially preserved. 
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Short term electrical stimulation is non-invasive, practical and generally well 
accepted by the patient, the devices are reasonable costly and the risk for the 
patient is negligible [25]. 
Although electrical stimulation methods are widely accepted, these treatments 
still have greater potential for use of urology than currently realised [85].
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Chapter 3 -  The project concept 
3.1 Introduction 
The chapter initiates by showing the background leading to a requirement of a new 
device and highlights its advantages.  Section 3.4 discusses the different detection 
and treatment methods that can be used. The basic principles behind the project are 
explained in section 3.5.  The chapter describes the overall thesis hypothesis and 
introduces the basic principle of the device operation. The chapter finishes with a 
discussion of how this “proof of principle study” can be realised with the available 
facilities.  
3.2 Background 
Urinary incontinence is a major medical and social problem, which affects nearly 
200 million people worldwide [3].  Approximately 16% of the urinary incontinence 
population suffers from incontinence as a result of detrusor overactivity [10]. Urinary 
incontinence has devastating effects on the life of sufferers and their carers as well as 
enormous cost to the nation [5] and the cost of incontinence to the NHS is expected 
to reach £2 billion by year 2020 [8]. The conventional treatment for overactive 
bladder is anti-muscarinic drugs [17, 19, 43, 86]. However research has shown that 
nearly 50% of neurogenic patients can become refractory to these oral agents [20, 
87] or cannot tolerate the side effects [12, 19]. Therefore improved management and 
treatment methods are required to reduce the long-term cost.  
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3.3 Design requirements 
The conventional management and treatment methods described in chapter 2 have 
their own disadvantages [58]. Even though electrical stimulation for bladder 
overactivity is a better treatment than conventional methods [58], further 
modifications are required in order to be accepted by the wider community.  These 
modifications are addressed as design requirements of the novel device described in 
this thesis. 
3.3.1 Wearable device 
Most of the currently acceptable electrical stimulation devices for achieving good 
bladder capacity, deliver stimulation through implanted electrodes [88] and have 
certain disadvantages.  
• Implanting electrodes is a surgical procedure and associated with degree of 
risk [61].  
• Reliability of the implantable system is an issue and repair requires another 
operation [61].  
• Implants cannot be used on children due to their rapid growth. 
• Some bladder dysfunction symptoms change over time and non-destructive 
treatment is preferred [89]. 
• Unpublished data of a recent study suggested that electrical stimulation as a 
treatment option for women with overactive bladder reduces their infertility 
rate [90]. In such a condition this would be an ideal treatment.  
• Sometimes patients prefer to experience the acute effect of stimulation, before 
making the decision to have an implant.  
Chapter 3 – The project concept 
_________________________________________________________________ 
- 51 - 
 
• Some women experience mild incontinence due to overactive bladder during 
their menstrual cycle. For such a condition, a wearable device would be an 
advantage. 
All of these points lead to the requirement for a non-invasive device. 
3.3.2 Conditional stimulation 
Electrical stimulation can be applied in two different ways, continuous [91] or 
conditional [31, 32]. In continuous mode, the stimulation is applied throughout 
filling of the bladder while in conditional mode the stimulation is applied only when 
a hyperreflexic contraction occurs [92]. Current systems for long term stimulation 
use the continuous mode [31].  Although a continuous stimulation system is easy to 
design [31], it would have many disadvantages when compared to conditional 
stimulation [92]. 
• The effectiveness of bladder inhibition may be limited by habituation 
resulting from repetitive activation of spinal reflexes [12, 30-32, 86, 93, 94].  
• On average conditional stimulation increases the bladder capacity by 6% to 
18% when compared to continuous stimulation [92, 94, 95, 95]. 
• Also conditional stimulation has been shown to increase the bladder capacity 
by 79% to 250% over no stimulation [31, 92, 96, 97]. 
• It may cause tissue and neural damage [12, 32, 86, 98]. 
• It reduces electrode life [31, 32, 61, 86]. 
• As the stimulator be switched on throughout the day power consumption is 
high, therefore low battery life [12, 30, 31, 61, 86]. Recent study showed that 
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the conditional stimulation reduces the stimulation time by 73%, when 
compared to continuous stimulation [95].  
In principal detrusor inhibition is only necessary during an involuntary contraction 
and thus stimulation can be turned off between contractions [30]. Studies have 
proved, applying stimulation at the start of a contraction can completely suppress it, 
while increasing the bladder capacity [94].  
The above factors suggest that conditional stimulation has more benefits over 
continuous stimulation.  Therefore the novel device explained in this thesis will 
provide stimulation upon satisfaction of a condition related to detrusor contraction. 
3.3.3 Warning indicator 
Most neurogenic patients with urge incontinence have little or no sensation prior to a 
detrusor contraction [41]. By using a conditional stimulation system, it is possible to 
inform the patient when the stimulation is applied [31, 61], using body area network 
(BAN) or wireless communication link. In this way patient is aware about the status 
of the bladder and can determine when to empty [12, 30, 86].  
3.3.4 Cost 
The cost of electrical stimulation devices is a strong limiting factor for patients using 
the therapy. The currently commercially available systems such as Medtronic 
“InterStim” (Figure 3:1) device costs around £10,000 [87]. In this project, the device 
is designed to keep the cost as low as possible so that it can be used widely in the 
health system.  
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Figure 3:1 – “InterStim” implant. 
“InterStim” is an implantation neurostimulation system that sends mild electric pulses to the sacral nerve, 
the nerve near the tailbone that influences bladder control muscles [99]. 
3.4 Design principle 
The novel device has incorporated all the features described in the design 
requirements in section 3.3 to become more user-friendly. The design principles 
behind this device for detecting and treating detrusor overactivity are discussed in 
this section. 
3.4.1 Detecting NDO 
As this is a conditional neuromodulation system a certain condition needs to be 
satisfied in order to deliver the stimulation. This condition should relate to detrusor 
contraction and over the past few years many methods have been demonstrated to be 
related. Some of these are highlighted in the Table 3-1. 
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Table 3-1 - Methods for detecting detrusor contraction. 
This table compares the detection methods suggested by researchers and remarks the outcome of the study 
in order to determine a reliable method. 
Detection Method Remarks 
Patient 
activation  
[12, 100, 101] 
Allowing patients to switch 
on the stimulation when a 
contraction is felt. 
During ambulation, the mean 
detection is about 23% and 
stimulation was switched on 
after mean delay of 57s since the 
start of contraction. Is not 
suitable method for activating 
stimulation as the reliability is 
highly limited. 
Electroneurogra
phy of sacral 
roots  
[92, 94, 102, 
103] 
Recorded afferent nerve 
activity related to 
mechanical activity of the 
bladder by placing nerve 
cuff electrodes on the S3 
roots. 
Requires a surgical procedure, 
thus associated with risk. 
Improvements in recording 
quality and sophisticated signal 
processing methods are 
required. 
Measuring 
detrusor pressure 
[12, 30, 31, 100] 
By placing catheters in the 
bladder and the rectum to 
obtain the pressure 
difference. A contraction 
was identified when detrusor 
pressure exceeds 8-
12cmH20. 
Patient’s mobility is restricted 
due to this method. This cannot 
be used as a chronic solution. 
External urethral Record the electrical activity Provides a reliable method for 
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sphincter EMG 
[86] 
of the muscles which 
correlate with pelvic floor 
by inserting fine wire 
electrodes. 
detecting contractions, but may 
not be feasible for everyday use. 
External anal 
sphincter (EAS) 
EMG  
[59, 95, 104] 
Record the electrical activity 
of the sphincters through 
needle electrodes inserted 2-
3cm deep into EAS. 
Provides a reliable method for 
detecting bladder contractions; 
however this can only be used as 
a temporary method due to the 
usage of invasive electrodes. 
 
Considering the tabulated information, the method for recording EMG from urethral 
or anal sphincters could be modified to be non invasive and practical method for 
daily use. Considering these two sphincters, it is hard to place electrodes of a 
wearable device adjacent to the urethral sphincters; therefore the better option 
appears to be the external anal sphincters.  
The external anal sphincters, which are also innervated by the pudendal nerve 
exhibits bursts of activities associated with bladder contractions in cats, rats as well 
as in humans [104-106]. In 1981, Blaivas concluded that during dyssynergia, the 
increase in activity in the sphincters occur coincident or immediately after the onset 
of the detrusor contraction [107]. These studies suggest that EMG of the external 
anal sphincters is robustly modulated during NDO and thus can be utilised as the 
trigger signal for conditional stimulation.  
Chapter 3 – The project concept 
_________________________________________________________________ 
- 56 - 
 
3.4.2 Treating NDO 
As explained in section 2.5, electrical stimulation has been shown as an effective 
treatment to inhibit the detrusor contraction. 
Table 3-2- Electrical stimulation treatment for NDO 
The table compares some currently available electrical stimulation treatments, in order to determine the 
best method for the novel device. 
Treatment Method Remarks 
Dorsal genital 
nerve (DGN) 
stimulation 
[12, 30, 31, 
91, 95, 100, 
108, 109] 
Placing cutaneous electrodes 
over the dorsal base of penis 
[110] in males and just 
cranial to clitoris [111] in 
females.  
Simple, effective and non-invasive. 
However not reliable methods as 
placement of electrodes are difficult 
and is not a practical solution.  
Intravesicular 
stimulation 
[60]
 
Direct stimulation of the 
bladder via a catheter with a 
special stimulation electrode. 
The intravesicular electrode is 
a cathode.  
Higher current intensities are 
required, thus it is painful.  
Magnetic 
stimulation 
[81] 
A specially designed coil 
(9cm focal point) placed over 
the sacrum and connected to a 
high frequency stimulator. 
Produces consistent and predictable 
acute inhibition of detrusor 
hyperreflexia. It’s a non invasive, 
but due to placement of a coil on 
the pelvis, the practicality of the 
device will be limited. Also chronic 
effects are not yet know. 
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Percutaneous 
Tibial nerve 
stimulation 
(PTNS)  
[60, 112-114] 
A stainless steel needle 
electrode is inserted 
approximately 3-4cm into 
medial malleolus. A stick-on 
electrode is placed on the 
same leg near the arch of the 
foot. These are connected to a 
low voltage stimulator. 
Provides a reliable treatment option 
for NDO, however regular visit to 
the clinics are required because the 
patient cannot perform the 
procedure by himself.  
Vaginal 
electrical 
stimulation 
[115-117, 
117] 
The vaginal device shown in 
(Figure 3:2) was inserted to 
the vagina of the female 
patient and constant voltage 
stimulation was applied. 
Showed significance increase in 
bladder capacity with minimal 
supervision. High currents are 
required for the stimulation and 
also the treatment is limited to 
females.  
Intra-anal 
stimulation 
[23, 115, 116, 
118] 
The anal device shown in 
(Figure 3:2) was inserted to 
the anus of the patient and 
constant voltage stimulation 
was applied. 
Long lasting bladder inhibition was 
recorded and the treatment can be 
used for both male and female. 
Minimal supervision is required. 
However high stimulating currents 
are required. 
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Figure 3:2 - Anal (left) and vaginal (right) electrode carriers.  
Shows the intra-anal and intra-vaginal electrodes used by Ohlsson and Fall, to study the effect of external 
and direct pudendal nerve maximal electrical stimulation  [115].  
According to Table 3-2, there are many methods available for treating NDO of which 
the dorsal genital nerve stimulation is the most used due to the non-invasive 
procedure. However dorsal genital nerve stimulation, PTNS and magnetic 
stimulation limits the mobility of the patient. Therefore the methods that can be 
incorporated into a wearable device that can be used by the patient daily is intra-
vaginal and intra-anal stimulation.  
In 1989, Ohlsson compared the intra-anal and intra-vaginal stimulation and showed 
that long lasting bladder inhibition can be achieved with a device delivering intra-
anal stimulation [115, 116]. Furthermore intra-anal stimulation can be used for both 
male and female patients. Therefore in this study trans-rectal stimulation to the 
Pudendal nerve is applied through intra-anal device. 
Chapter 3 – The project concept 
_________________________________________________________________ 
- 59 - 
 
3.5 The project concept 
Based on the detection and treatment methods discussed in section 3.4, a closed loop 
electrical control system to treat urinary incontinence can be realised as shown in the 
Figure 3:3.  
3.6 Study design 
With the concept of the project being set, the overall hypothesis of the project can be 
described as “the novel wearable conditional neuromodulation device can be used to 
treat urinary incontinence” and the device can be named as “ACONTI” (Anal 
Conditional Neuromodulator for Treating Incontinence). 
There are certain design steps involved in proving this hypothesis.  
• First, is to come up with a suitable design of the plug, based on the anatomy 
of the anal canal and an evaluation of previous models, that had been 
designed for this purpose.  
• Test the method on people with NDO and to see whether the detrusor 
contractions can be detected and the continence be maintained as a result of 
trans-rectal stimulation through the device. 
• Design, build and test the required electronic circuitry for data processing, 
which can then be integrated to the device. 
• Finally, evaluate whether the device delivers optimum stimulation to the 
nerves of interest.  
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Figure 3:3 – The project concept 
Electrodes of the device detect the EMG signals from the anal sphincters, acting as a surrogate to the urethral sphincters. The signal is then processed 
and when it exceeds the predetermined threshold, activates the stimulation of the pudendal nerve to suppress the bladder and to contract the sphincters 
[119]. 
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3.7 Other considerations 
3.7.1 Clinical setting 
Even though the device is designed for all types of neurogenic incontinence such as 
multiple sclerosis, Parkinson’s disease etc, the initial experiments were carried out 
mainly on spinal cord injured people. The reason for this was the easy access to the 
facilities and the patients, in the Royal National Orthopaedic Hospital (RNOH) and 
the involvement of the principle supervisor Prof. Michael Craggs and the assisted 
nurse Judith Susser being a part of the hospital research staff. 
Acute traumatic spinal cord injury (SCI) remains a costly problem to the society. A 
report published in 2005, showed that nearly 131,623 SCI cases reported worldwide 
each year [120] and in UK it is estimated nearly 40,000 people living with chronic 
SCI [121]. Approximately 54% of this population has some degree of urinary 
incontinence [122]. A recent survey showed that, among the SCI community bladder, 
bowel and sexual dysfunction was their primary concern to be resolved [49, 123]. 
Chronic renal failure was the most common cause of death following SCI [81, 124]. 
Figure 3:4 shows the priorities of the spinal cord injured people.  
Even though the device was designed for both men and women, the experiments 
were carried out only on men. This is because there is higher percentage of men 
(81%) with SCI compared to women (19%) [125] and the easiness of carrying out 
the procedures in men, such as collection of urine. 
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Figure 3:4 - Priorities of the spinal cord injured population – United States [49, 123]. 
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3.7.2 Ethics approval 
All research projects involving data collection from human participants require 
prior ethics approval. This is to ensure the safety, rights, dignity and well-being 
of the participant and those of the researcher. This study has received approval 
from the Local Research Ethics Committee of the Royal National Orthopaedic 
Hospital NHS Trust via the National Research Ethics System (NRES). 
Participants were invited for the assessment through an official invitation letter 
together with the patient information sheet. Patient involvement required fully 
signed informed consent. The patient consent form is attached in the Appendix 1. 
3.7.3 Diagnosing bladder dysfunction 
Although history and physical examination are used for the initial evaluation of 
patients with NDO, more exact measurement is required to identify the nature of 
the bladder dysfunction [126]. Some of the diagnostic methods are detailed in the 
Table 3-3. 
Table 3-3 - Bladder dysfunction diagnostic procedures [127] 
Diagnosing method Remarks 
Postvoid residual urine 
(PVR) 
If the PVR is high, the bladder may be acontractile 
or the bladder outlet may be obstructed. 
Uroflow rate 
Uroflow rate is the volume of urine voided per unit 
time and mainly uses to evaluate bladder outlet 
obstruction. 
Subtracted cystometrogram 
Assess the bladder capacity, integrity of the 
sphincter mechanism and the presence of detrusor 
instability while filling the bladder with a liquid 
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(mostly sterile saline) and measuring the bladder and 
rectal pressure. 
Urethral pressure 
profilometry 
Measure functional urethral length and maximal 
urethral closure pressure to determine the presence 
of stress incontinence. By combining static and 
voiding cystogram, the degree of urethral motion, 
bladder neck and urethral sphincter function during 
filling and voiding can be assessed. 
Electromyography 
Helps to identify the presence of coordinated and 
uncoordinated activity in the sphincters. EMG 
allows accurate diagnosis of detrusor sphincter 
dyssynergia, which is common in SCI. 
Cystoscopy 
Used to evaluate any bladder lesions or bladder 
stone. 
Videourodynamics 
Is the standard evaluation of patient with 
incontinence. This allows to visualise vesicoureteral 
reflux as well as the pressure-flow relationship 
between the bladder and urethra. 
 
Considering the methods mentioned above, in order to evaluate the efficacy of the 
“ACONTI”, cystometrogram combined with electromyography were used to 
evaluate neurogenic detrusor overactivity. 
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Chapter 4 -  Realisation of the design 
4.1 Introduction 
Having revealed the concept of the project and explained why the specific 
approach was taken when compared to the currently available methods, the next 
step is to find out how the design can be achieved practically. The previous 
chapter highlighted the requirements of a wearable device, which delivers 
stimulation upon satisfaction of a certain condition. In this case the condition is to 
detect bladder contractions related to the detrusor overactivity. Another 
requirement of the design is low cost. Major design requirements of the device 
are it should consists of electrodes for detecting bladder contractions, a signal 
processing unit and electrodes to deliver the stimulating current. 
This chapter starts by discussing the models that were used in the past, which was 
the foundation of the new development. Section 4.3 illustrates how the shape of 
ACONTI was obtained considering the anatomical structure of the pelvis. Having 
obtained the required shape, the next step was to determine the materials for the 
body and the electrodes. Once all the design factors are collected the actual 
building of ACONTI is described in the section 4.5 and the chapter finishes with 
a summary.  
4.2 Previous models 
Table 4-1 analyses advantages and disadvantages of the anal and vaginal devices 
that have been used over four decades to treat urinary incontinence. 
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Table 4-1 – Analyse some of the non invasive wearable devices used in the past to treat UI through electrical stimulation. 
Device Design Advantages and disadvantages 
“Anal continence aid” 
Hopkinson and 
Lightwood 1967 
[25, 128] 
Made by Cardiac Recorders Limited and shown in 
Figure 4:1(a) 
When the device is in place and the stimulation 
turned to full strength motor fibres of the 
pudendal nerve do not stimulate; only reflex 
activity is detected with latency of 65ms. 
“Portex”  pessary 
(Figure 4:2) 
Alexander and Rowan  
1968  
[128, 129] 
Pessary is modified to carry two stainless steel wire 
wound (10 turns, 25 SWG) stimulating electrodes, 
which lie anteriorly in the vagina. The electrodes 
mid-point subtends at an angle of 600 – 700 to the 
centre of the pessary. These wires are then led 
within the pessary, in zig-zag to a midpoint of the 
electrodes and connected to a miniature stimulator 
under the axilla through a conventional cable. 
Devices Implants Ltd designed this pessary. 
The method of construction ensures that the 
leads can withstand the mechanical stresses 
which take place within the pessary, particularly 
during insertion. Normally the stimulator is 
switched on and only switched off to permit 
micturition. However it failed to produce 
maximal contraction of the relevant muscles and 
hardly obstruct the micturition at the greatest 
strength of the stimulation. Out of 28 patients, 
the success rate was 46% [130]. 
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Vaginal device 
Soldenhoff and 
McDonnell 1969  
[25, 128, 131] 
An electrode pessary similar to tampon inserted 
into the vagina and connect it to the stimulator box, 
which is powered by 9V battery. This system was 
made by Vitalograph Limited. 
Voluntary micturition in all subjects is 
unimpeded or nearly so by these when they are 
fully switched on. Reported 80% success rate on 
28 women with stress incontinence [130]. 
Intra-anal plug 
Hopkinson 1972  
[23] 
The shape of each patient’s anal canal was 
determined by using soft wet plaster of Paris inside 
the finger-piece of a thin plastic glove. A Perspex 
plug was made to the determined shape with two 
parallel circumferential electrodes 1cm apart, 
placed to lie above and below the neck of the plug 
(presumed site of recto-pubalis). 
Five different sizes were used (Figure 4:3a). The 
plug needs to be manoeuvred to obtain the best 
possible contraction. The success rate was 
greater in children as the plug fits better. The 
plug has not proved a better treatment as most of 
the patients cannot keep it in. Success rate of 
57% on 63 patients [130]. 
Anal plug 
Brindley, Rushton and 
Craggs 1975  
[128] 
The device (Figure 4:1b and Figure 4:1c) has two 
internal electrodes arranged to lie near the 
pudendal nerve (at the anorectal junction) and two 
external electrodes. 
Stimulation caused only slight or no pain. 
Voluntary perineal contraction caused no visible 
movement of the device. Direct stimulation of 
the motor fibres activated external urethral 
sphincters as well as left or right 
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(independently) of the ischiocavernosus muscle 
and caused maximal contraction through both 
sexes, sustaining continence against 110mm of 
Hg. 
“Continaid”  
(Figure 4:3b)            
Merrill, Conway and 
DeWolf 1975  
[132] 
The transrectal stimulator consists of bipolar rectal 
tampon, a flexible cord and a small plastic case 
containing the 9V battery. The tampon is inserted 
so that the bulbous portion of the tampon lies 
within the rectal sphincter. 
The device is switched off during micturition. In 
some patients the device caused abdominal 
cramps and mild diarrhoea. It was proved to be 
a good method of assessing a requirement for a 
chronic stimulator. 
Anal plug  
(Figure 4:4a) 
Sotiropoulos 1975  
[133] 
The stimulator can be kept inside a pocket or 
attached to the belt and powered by a 9V battery. 
There are two parallel electrodes which are 1cm 
apart on the surface of hour glass shaped Perspex 
plug. Once the device is positioned inside the anal 
canal electrodes rest in close contact with the anal 
wall above and below the level of the pubo-rectalis 
Plugs are commercially produced in four 
different sizes: 25mm (large), 24mm (medium), 
20mm (small) and 15mm (infant) in diameter. 
The product showed better response among the 
younger ones. 
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muscle. 
“Incontan” device 
(Figure 4:4b)    
Eriksen 1987  
[116] 
The complete system consists of 12V battery, 
electronics and electrodes integrated in plastic plug 
housing. The stimulator is automatically activated 
when the ring electrode touches the wall of the anal 
canal. 
The device is intended to strengthen pelvic 
muscles by continuous stimulation. The device 
caused anal soreness and changes in bowel 
function in some of the patients. However the 
device fits the anal canal well, making it 
possible for the patient to sit in comfort and 
move around normally with the stimulator in 
place. 
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Figure 4:1- (a) Anal plug used by Hopkinson and Lightwood. (b) and (c) show lateral and 
anterior view of the anal plug used in Brindley, Rushton and Craggs experiment [128]. 
 
 
Figure 4:2 - The x-ray of ‘Portex’ electric pessary [134]. 
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Figure 4:3 – (a) The small portable electrical stimulator and range of five Hopkinson's intra-
anal plugs to fit most patients [23]; (b) The external transrectal stimulator “Continaid” [132]. 
 
 
 
Figure 4:4 – (a) Sotiropoulos anal plug [133]; (b) The “Incontan” device with the top and the 
battery removed [116]. 
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Since the 1970’s there has not been major development of the anal devices to 
treat urinary incontinence through electrical stimulation. However some devices 
have been developed as pelvic muscle toners (Figure 4:5) in which some ideas 
can be utilised in the design of ACONTI.  
 
Figure 4:5 - Commercially available pelvic muscle toners.  
(a) Anuform, (b) Liberty electrode, (c) Anal electrode PR13. The body of these devices made out of 
GE plastic MG47 and the electrodes are made out of stainless steel [135]. 
Hopkinson’s anal device provides the foundation in designing ACONTI. Over the 
years some modifications have been made to this, however the basic shape 
remains the same. Whatever the design, it should be easy to manipulate and 
should be well accepted by patients. Furthermore it should provide satisfactory 
retention in the anal canal during stimulation. 
4.3 Shape consideration – anatomically 
The device is to be inserted into the anal canal.  In order to deliver successful 
neuromodulation three main criteria need to be satisfied. Those are; 
• anatomical stability of the device during patient’s activity. 
• effective recording of EMG signals from the external anal sphincters. 
• optimal stimulation to the Pudendal nerve. 
In order to derive the shape of ACONTI, it is better to understand the structural 
anatomy of the anus and the rectum (Figure 4:6).  
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Figure 4:6 – Coronal plane cross-section of the anus and the rectum of an adult [136].
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The anal canal is about 4cm long and passes downward and backward from the 
rectal ampulla to the anus. The anal canal is a narrower, tubular structure and it 
continues to the wider muscular tube called the rectum [35].  
4.3.1 Anatomical stability of ACONTI 
The ACONTI has to be easy to insert, without causing much pain. Once in place 
it should be secure and should not move due to movement or stimulation. The 
points that should be considered in designing its shape relate to stability. These 
are listed below. 
• The head of ACONTI should be narrow and the diameter should gradually 
increase (similar to the anal plug used in Brindley’s experiment in the 
Figure 4:1b and Figure 4:1c) to provide easy insertion.  
• The device should be flexible in order for it to follow the 4.120/mm 
curvature of the ano-rectal junction [137]. 
• The part of the device that sits on the anal canal (stem) should be narrow 
to be held easily without applying much pressure to the walls of the anus, 
in order to minimise discomfort. 
• To stop ACONTI moving during stimulation, an approach similar to 
“Anuform” (Figure 4:5a) can be adopted; by making an isthmus near the 
end of the device so that the anal verge can be made to sit around it.  
• To prevent the device sliding further in to the orifice, a small guard can be 
introduced at the end of ACONTI similar to the modification Glen [138] 
introduced to the Hopkinson device (Figure 4:7). This also makes the 
device easy to remove and as a support for holding the cables. 
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Figure 4:7 - (a) Hopkinson's continence aid anal plug, (b) the modified plug introduced by Glen 
[138]. 
4.3.2 Effective recording of the EMG signals 
The effectiveness of conditional neuromodulation depends on how well the 
condition for stimulation is detected. The main consideration is how specific 
muscle signal currents can be recorded without significant interference unrelated 
to the function is required. 
The lateral wall of the anal canal is kept in apposition by the levator ani muscle 
and the anal sphincter. The anal canal comprise of inner longitudinal muscle layer 
as an internal anal sphincter enclosed by external sphincter [139]. The external 
sphincter is formed with three main parts (shown in the Figure 4:6). A 
subcutaneous part which encircles the lower end of the anal canal, a superficial 
part which is attached to the coccyx posteriorly and perineal body anteriorly and 
finally the deep part of the anal sphincter encircles the upper end of the anal canal 
[140]. 
During bladder filling, the activity in the longitudinal muscle increases, therefore 
it is accepted that bipolar surface electrodes for recording striated muscle EMG 
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are usually placed in the direction of the muscle fibre [141]. Due to the structural 
anatomy the recording electrodes should be constructed considering the following 
factors. 
• The two recording electrodes should be placed along the axis of ACONTI 
and should be equally separated on the circumference. 
• Recording end of the device should be wider than the stem in order to 
push the electrodes towards the wall of the anal sphincters as similar to the 
“Anuform” (Figure 4:5a). 
• The reference electrode should be placed somewhere electrically inactive 
such as the stem, therefore the stem should be wide enough to hold the 
ground electrode. 
4.3.3 Optimal stimulation to the Pudendal nerve 
It is important to ensure that when a nerve is stimulated, that electrical current is 
delivered to the nerve in an adequate amount to generate an action potential as 
well as the stimulating currents be focused such as to minimise unwanted 
stimulation of other nerves. 
The ano-rectal junction is the closest part of the gastro intestinal tract to the 
Pudendal nerve. Therefore if the stimulating electrodes can be made to sit on the 
ano-rectal junction, the stimulating current can be directed to Alcock’s 
(Pudendal) canal. As the Pudendal nerve runs bilaterally at 10 o’clock and 2 
o’clock position (Figure 4:8), it will be beneficial if there are two sets of 
stimulating electrodes.  
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Figure 4:8 - Shows the transverse plane image of the male pelvis at the ano-rectal junction.  
Pudendal canal is marked in red circles, and for optimal stimulation the stimulating electrodes ideally be located in grey circles [142]. 
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As the rectum is much wider than the anus, the stimulating head can be made 
wider too, giving more space to place the embedded electronics as well as to push 
the stimulating electrodes more towards the Pudendal canal. The anode can be 
made bigger than the cathode, to increase the current density near the cathode as 
the stimulation occurs close to the cathode. 
Based on these considerations, the shape of ACONTI can be derived and is 
shown in Figure 4:9. 
4.4 Material consideration 
Having derived the shape of ACONTI based on anatomy, the next step is to 
determine the suitable material for the device and the electrodes. The main factors 
that need to be addressed in determining the materials are bio-compatibility 
within the body and patient compliance. 
4.4.1 Device material 
The anal and vaginal devices discussed in Table 4-1, use perspex for the device 
body. As ACONTI is to be non-implanted, the material does not have to be 
implant grade, but should be biocompatible. Due to its elastic nature (availability 
of different grades), silicone rubber is a better choice than perspex and this will 
make the device easier to follow the curvature of the anal canal. In addition to the 
elastic nature, silicone also has low surface tension, chemical and thermal 
stability which made it to be used widely in the healthcare [143]. As the silicone 
polymers are structured with an inorganic backbone, which minimise the 
chemical reaction with living organic system, good biocompatibility results in 
devices in this nature [144]. 
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Figure 4:9 – Final shape of the ACONTI represent to a scale shown. 
The top figure shows the axial view while the bottom figure shows the longitudinal view. Small 
circular dots represent the cathodes; large circular dots show the position of the two anodes. Round 
rectangular electrode on the stem is the ground electrode, and that near the end is one of the two 
recording electrodes. 
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The silicone rubber that is available in liquid form is widely used in injection 
moulding applications and available in different grades with a range of hardness 
of the cured rubber. In order to determine the suitable grade cylinders with 
dimensions 5cm in length and 1cm in diameter was made in LSR10-LSR90. 
These cylinders were then analysed for their elasticity and the ability to hold 
electrodes. Based on this analysis it was concluded that LSR40 is the best grade 
for ACONTI. Therefore MED-49403 two part liquid silicone rubber from NuSil 
Technology was used in this application. This is restricted rubber, which can be 
used on external devices or implantation for less than 29 days [145].  
4.4.2 Electrode material 
Most electrodes that are used for electrical stimulation are polarisable electrodes. 
However to reduce the complexity of using two electrode materials; the same 
material is used for both recording and stimulating electrodes. Polarisable 
electrodes are either made of noble metals like platinum, iridium, gold or non-
noble metals/alloys such as titanium or stainless steel [146].  
 
 
 
 
Table 4-2 highlights material properties of some commonly used bio electrodes.  
                                               
3
 This is the medical grade (restricted) silicone rubber, which has the hardness grade similar to as 
LSR40. 
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In the devices mentioned in Table 4-1 and the pelvic muscle toners in the Figure 
4:5 the choice of electrode material is medical grade stainless steel. Stainless steel 
is a cost-effective engineering material with good corrosion resistance and a 
range of mechanical and physical properties coupled with inert, easily cleaned 
surfaces that are well suited to a wide variety of medical applications, where 
hygiene is a major requirement. AISI-316 (medical grade) stainless steel is 
specially produced with enhanced chemical composition in order to be suitable 
for close and prolonged contact with human tissue [147]. Therefore medical grade 
stainless steel was used as the choice of material for both recording and 
stimulating electrodes. 
4.5 Manufacturing of the device 
With the basic shape of the device being derived based on the previous devices 
described in Table 4-1, the next stage was to make some devices to be tested in 
clinical studies.  In order to have a repeatable design with accurate measurement 
and method of filling with liquid silicone rubber, it was decided to produce a 
mould. This procedure was handed over to pattern maker.   
In order to design the mould for filling the rubber, a prototype device was made 
using epoxy which is shown in Figure 4:10. 
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Figure 4:10 - The master model of the device. 
The master model was made by the pattern maker using epoxy to the exact measurement shown in 
Figure 4:9. 
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Table 4-2 - Desirable material properties for some metals commonly used as bio electrodes [148]. 
 Platinum Iridium Gold Silver Tantalum Titanium 
Stainless 
steel 
Corrosion resistance X x x  x x x 
Biocompatibility X x x  x x x 
Electrical conductivity   x x    
Chapter 4 – Realisation of the design 
_______________________________________________________________ 
- 84 - 
 
In determining the size and the shape of the electrodes, the surface area of the 
recording electrode should made to the maximum allowable size to minimise the 
electrode impedance. As explained in section 4.3.3, a pair of stimulating 
electrodes will be added to the device for bilateral stimulation and the anode was 
made bigger than the cathode. Sample electrodes produced by the pattern maker 
are shown in the Figure 4:11.  
 
Figure 4:11 – Sample electrodes. 
The electrodes are made out of medical grade stainless steel. (a) recording electrodes are round 
rectangular shape of 5mm x 10mm, (b) circular shape cathode electrodes of diameter 5mm and (c) 
circular shape anode electrodes of diameter 8mm. 
The electrode connection in the device is shown in the Figure 4:12. 
 
Figure 4:12 – Shows how the electrode is connected when it is in the device, embedded in silicone 
rubber. 
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Using the master model shown in the Figure 4:10, a mould was made out of 
aluminium loaded epoxy (Figure 4:13). 
 
Figure 4:13 - The main mould for filling rubber.  
The two halves of the mould will be screwed together before filling. The rubber will be injected into 
the mould from I. The electrodes were glued to the mould temporarily. 
A two part liquid silicone rubber (MED-4940) was mixed 1:1 and then injected to 
the mould. The mould was then put into the oven and left for more than 24 hours 
at 700C. When the mould was checked, the rubber was not cured. It was left in the 
oven further 2 days, but still the rubber was not cured properly. Therefore this 
approach failed for the following reasons.   
• The rubber was inhibited by the mould material 
• The cables used for connecting the electrodes had an overall diameter of 
5mm. Due to this cable and the support to hold the electrodes injection of 
the rubber was hard.  
• It was difficult to keep the electrodes in place by using temporary glue. 
In order to overcome these problems a new method was developed: the design 
stages are described in Table 4-3.  
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Table 4-3 - Highlights the problems faced in the previous approach and the solution to overcome them. 
Stage 
Problem faced in the previous 
design 
Solution Design procedure 
(a) 
Rubber was not curing due to the 
reaction of rubber with epoxy and 
not enough heat transferred to the 
inside of the mould. 
Made the mould out of heat 
transferrable material. 
Melted metal was poured over the master model when 
it is resting inside a block. 
(b) 
It was hard to push the rubber 
because the mould was blocked by 
the cable and the support to hold 
the electrodes in the opposite side.  
Kept all the electrodes on the 
same half, so they can be held 
using the mould itself. 
Orientation of the device in the mould was changed 
and the recording electrodes that were 1800 apart were 
brought to 1200 (4 and 8 o’clock positions).  
(c) 
Keeping the electrodes steady 
during the filling. 
Attached the electrodes to the 
mould using fishing line: and 
can be cut at the end to 
release the electrodes. 
A hole of 1mm was made in each electrode, through 
which can pass a fishing line and tie on the other side, 
so that it stops the electrode moving.  
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(d) 
Wires touching the wall of the 
mould so they are not embedded in 
the device. 
Wrapped the wires around 
rubber tubing in the middle. 
Used enamelled copper wires 
of thickness 0.125mm. 
The wires were soldered to the electrodes (using 
phosphoric acid to dissolve the oxide layer). These 
were wrapped around the silicone rubber tubing, which 
was held using 1mm rod passing through the middle of 
the mould. When the rubber is set this rod can be 
pulled out. 
(e)  
Curing the rubber and preventing 
air bubbles. 
Used the pressure chamber 
and the hot plate. 
The rubber was then vacuum centrifuged and then 
injected into the mould. This mould was kept inside a 
pressure chamber at a pressure of 1atm. This system 
was then kept overnight on a hot plate.  
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Figure 4:14- Shows the design stages explained in the Table 4-3.  
(a) The mould which is made out of low melting point metal. (b) All the electrodes are in the same 
plane. (c) Electrodes are held in place using a fishing line. (d) The copper wires are connected to the 
electrodes and wrapped around the rubber tubing. (e) The rubber free from air bubbles was injecting 
through the inlet. 
The resultant device (shown in the Figure 4:15) is up to expectation. This new 
version of ACONTI was tested clinically, and gave promising results which will 
be described in chapter 5.  
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Figure 4:15 – ACONTI device in 3-dimensional plane 
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4.6 Conclusion 
The foundation for the design of the novel wearable bladder control device was 
derived from the Hopkinson’s anal device. The electrodes position of ACONTI 
was based on the anatomy and neurophysiology of the ano-rectal region. 
The chapter described the actual manufacturing of the device together with the 
problems faced thus led to design limitations such as increasing the distance 
between the recording electrodes. These limitations can be overcome by using 
more sophisticated method.   
Based on the anatomy and practical experience, it was assumed that the 
stimulating head of ACONTI sits on the ano-rectal junction. However precise 
measurements have not being taken. The position could be measured by taking 
MRI images of ACONTI when it is in the pelvic orifice of a patient. Once those 
images are produced further details regarding positioning electrodes can be 
analysed.  An experiment to optimise the stimulating electrodes of ACONTI is 
described in the chapter 7. 
With these two results ideal positions for the electrodes can be obtained. Once all 
the relevant information is known, this device will be redesigned to be built using 
an industrial method. 
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Chapter 5 -  Clinical efficacy of the ACONTI 
5.1 Introduction 
Once a satisfactory design was obtained, as described in chapter 4, the next stage 
is to perform some clinical studies to determine the efficacy of the design. This 
chapter starts by recapping the background leading to the clinical experiments 
and then moves onto describing the aim and the objectives of these experiments. 
Section 5.4 explains the patient selection and the equipment set-up. Then the 
chapter divides into two main sections based on the experiments, where section 
5.5 describes detecting NDO and 5.6 describes treating NDO. Each of these 
sections talks about the objective, method, results and analysis and discussion. 
5.2 Background 
Urological problems following SCI, mainly neurogenic detrusor overactivity 
and/or detrusor sphincter dyssynergia, cause severe urinary incontinence [12, 32, 
49, 95, 101, 122]. Approximately 54% of the SCI community suffer some degree 
[122] of incontinence and restoring bladder, bowel and sexual function is their 
main priority [40, 49]. Even though anti muscarinic drugs remain the common 
management [5, 12, 17, 20, 28, 43, 86, 95], 50% of neurogenic patients cannot 
tolerate the side effects of these drugs and have poor compliance [20, 87]; leading 
to a need for alternative treatment modalities such as electrical stimulation [12, 
28, 95]. 
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Most of the currently available devices were set to deliver continuous stimulation 
[31, 100]. The principle of conditional neuromodulation was introduced in order 
to overcome some of the problems associated with continuous stimulation such as 
stimulation becoming ineffective due to habituation and high power consumption 
[12, 28, 31, 33, 86]. Accordingly, a condition must be satisfied to deliver the 
stimulation. Most previous studies used rise in intravesical pressure as the trigger 
for the stimulation [30-32, 41, 92, 149]. As explained in chapter 4, ACONTI sits 
in the anal canal and monitors the muscle activity of the external anal sphincters, 
which act as surrogates for the urethral sphincter during DSD to trigger the 
stimulation of the pudendal nerve [40].  
5.3 Aim and objectives 
The aim of the research is to develop a wearable conditional neuromodulator 
device to treat NDO and restore continence for the people with neurogenic 
incontinence. This aim can be divided into two main questions as objectives, 
which are:  
• Does the device detect the surrogate external anal sphincter EMG with 
related to the detrusor activity during NDO? 
• Does the device stimulate the pudendal nerve suppressing NDO, leading 
to increase in bladder capacity? 
The two experiments described in the sections 5.5 and 5.6 are intended to answer 
these questions. 
5.4 Clinical set up 
As explained in 3.7, the study was conducted in the spinal injury unit of the 
RNOH. In order to commence the study appropriate patient group and the 
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necessary equipment must be set up as described in this section. The patients 
participated in the study required a fully informed consent. The study was 
conducted in the context of good clinical practice.  
5.4.1 Participant selection 
Twelve complete and incomplete SCI men were selected for the study based on 
appropriate inclusion and exclusion criteria. 
Inclusion criteria 
• Participants must be aged between 18 years to 75 years due to their 
independence in taking decision.  
• Participants must have had their injury at least twenty-four months prior to 
the study. This is to ensure that the time for natural recovery and 
physiological instability has finished.  
• Individuals must have a complete or incomplete supra-sacral spinal cord 
injury at upper motor neurone because lesions at the vertebrae below T10 
may have denervation [150].  
• Participants must have proven NDO and/or DSD as indicated by previous 
urodynamics studies.  
• For the practical reasons and to improve the acceptability as well as to 
avoid any confounding errors during analysis, only men were considered 
at this stage. 
Exclusion criteria 
• Patients with any other neurological disorder.  
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• If the patient had a history of any implanted device for bladder function, or 
if they had a surgical intervention at any time to the bladder, sphincters or 
any infection in the rectum.  
• To minimise autonomic dysreflexia during cystometry, patients with any 
past or present cardiovascular conditions.  
• Also if the patient gets recurrent resistant urinary tract infection or 
reported any of the symptoms on the day, patient was excluded from the 
study until they are positively treated.  
• Patients who had botulinin toxin interventions to either bladder or bladder 
outlet [151]. 
• If the patient is participating in any other drug study they were excluded in 
order to avoid conflicting drugs. 
In addition to these, the participant will be requested to stop anti-cholinergic 
drugs or other drugs being taken for their bladder condition (such as oxybutynin, 
toltarodene or detrunorn) for a period of 5 days (7 days if it is xl4) prior to the 
assessment. If the subjects proved to have history of UTI, a single dose of 
Genitamicin (80mg) was given intramuscularly against any possible UTI caused 
by the repeated catheterisation.  
Those who met these criteria and were included in the study are listed in the 
Table 5-1. These details were extracted from the patient’s notes and by further 
discussion with them. All subjects who participated in the study signed a consent 
form having first been fully briefed and given the opportunity to have their 
questions answered. 
                                               
4
 Modified release version of the drug. 
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Table 5-1 - Patient details.  
CISC = intermittent self catheterisation, M = medication, FC = Foley catheter, IP = incontinence pad 
Patient Level of injury Complete/ Incomplete ASIA grade Date of injury Bladder management 
P1 T11-T12 Incomplete - May 2006 CISC, M 
P2 T10-T11 Complete A March 2005 CISC, M 
P3 C3-C7 Incomplete D October 2002 CISC, M 
P4 T4 Complete A September 2007 CISC, M 
P5 T12 Incomplete D April 1998 M, FC 
P6 L5-S1 Complete - 1992 CISC, IP 
P7 T11-L1 Complete - August 2005 CISC, M 
P8 C4-C6 Incomplete - September 1997 CISC, M 
P9 C6-C7 Incomplete D 2000 CISC, M 
P10 T6 Incomplete C June 2007 CISC, M 
P11 T3-T4 Complete - January 2001 CISC 
P12 T2 Complete - 1987 CISC, M 
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In the Table 5-1, the injury levels of the patients are shown according to the 
relevant vertebral level. In some of these patients, multiple vertebral sites are 
shown either due to the several injury sites of the spinal cord or due to the fact 
injury is located in between the particular vertebrae.  
One of the inclusion criteria of the selection of the patients was that the injury 
should be above T10. However patients P1, P2, P5, P6 and P7 have their injury 
below T10. The reason for including them for the study was, these patients were 
taking oxybutynin for bladder control and previous urodynamics investigations 
have shown hyperreflexic bladder. 
5.4.2 Experimental setup 
The experiments were carried out in the Royal National Orthopaedic Hospital 
(RNOH) in Stanmore. The experiment session was supervised by Professor 
Craggs (consultant clinical scientist) and the clinical work with regards to the 
patient was carried out by a specialist urology nurse.  
Performing cystometrogram 
According to the bladder dysfunction diagnostic methods, described in chapter 3, 
it was concluded that standard cystometrogram proved to be the best method for 
assessing the efficacy of the device. Cystometry is a method to obtain 
pressure/volume curve by filling the bladder with physiological saline at a 
constant rate while monitoring changes in intravesical pressure. Any detrusor 
contractions greater than 15cmH2O are considered abnormal [152]. Detrusor 
pressure is obtained by standard subtraction cystometry, which is the subtraction 
of the abdominal (rectal) pressure from the intravesical (bladder) pressure [153].  
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First of all, the patients were laid flat on the bed in a comfortable position. In 
order to measure the bladder pressure, standard 4.5Fr blue catheter (Figure 5:1a) 
inserted into the bladder through the urethra, and a  4.5Fr rectal line inserted 
through the hole at the midline of ACONTI (Figure 5:1b) was used to measure 
the rectal pressure.  
 
Figure 5:1 – Bladder and rectal lines 
Shows the 4.5Fr (a) bladder line and (b) rectal line to measure the intravesical and the abdominal 
pressure respectively. 
The other ends of these catheters were connected to the Digitimer pressure 
transducers, which then were connected to 10ml syringe containing sterile saline 
to flush the pressure lines. These lines were calibrated (zeroed to the air), before 
connecting to the Lectromed amplifier system. Subtraction of these two pressure 
values (showed the detrusor pressure) was done in the software. 
Volume assessment involved filling the bladder with saline via the filling line. 
The filling line was 10Fr catheter and was connected to the pump with sterile 
saline infusing at room temperature. This filling line was also used for 
catheterising the subject by connecting to a two way tap system. The filling line 
was connected to a pump (Lectromed, UK) with the room temperature sterile 
saline as the infusion fluid.  
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At the end of each filling a rest period of at least five minutes was obeyed, in 
order for the patient to change his position to minimise any tendency for pressure 
sores.   
This set up is shown in the Figure 5:2. 
 
Figure 5:2 - Cystometrogram set-up 
The figure shows the setup of the catheters to measure the abdominal (rectal line) and intravesical 
(bladder line) pressure. The other ends of these catheters are connected to pressure transducers. The 
filling line and the attachment to empty the bladder are connected to a two way tap system.  
ACONTI was inserted to the anal canal (facing the electrodes anterior) using KY gel. The cable of the 
device was connected to the amplifier through a connector box. Each individual has their own device 
and at the end of the experiment. At the end of the experiment this was washed and cleaned with 
Milton solution.    
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Signal processing 
For the purpose of clinical study, the EMG signal detected by the recording 
electrodes of the device was then passed onto the Lectromed amplifier. The 5361 
amplifier is a general purpose isolated preamplifier mainly intended for bio 
potential signals [154]. The input signal is AC coupled with a time constant of 
0.03s.  
This analogue signal is then passed to the data acquisition system by Cambridge 
Electronic Devices (CED), which was set to allow a pass band of 20 Hz to 10 
kHz and a sweep time of 200ms. This signal is post processed using SPIKE 
software also from CED. This software gives the freedom of post processing 
easily such as for filtering, rectifying etc; which simplifies the signal analysis. 
The final part of the system is a Digitimer DS7 electrically isolated constant 
current stimulator. This can deliver current up to 100mA with stimulus pulse 
duration varying from 50-2000µs.  The triggering signal for stimulation is 
provided through the Spike [155]. 
All of these systems are fully approved by the European EMC directive 
“89/336/EEC”. Arrangement of this system is shown in Figure 5:3. 
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Figure 5:3 - Shows the laboratory equipment set-up.  
The two pressure transducers and the EMG signal are connected to the Lectromed amplifier. These signal then converted to digital signals using CED 1401 data acquisition 
system, which then pass these information these information to Spike software for graphical user interface and for further signal processing. Finally this sends the signal to 
activate the stimulation pulses. 
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When recorded the raw EMG signal consists of the actual anal sphincter EMG as 
well as interference from other sources such as from mains. Therefore this raw 
EMG signal is first filtered using digital band pass filter with cut off frequencies 
60Hz – 500Hz, then this signal is full wave rectified and smoothed with a time 
constant of 1s. The reasons for using these parameters for processing the signal 
will be explained in chapter 6. 
5.5 Detecting NDO 
In order to suppress the detrusor contraction, it is important to start the 
stimulation early. Therefore, when using conditional neuromodulation the 
contraction should be identified easily and early, to prevent the leakage.  
5.5.1 Objective 
The objective of this experiment is to assess the relationship and its reliability of 
the EMG signals recorded from the external anal sphincters through the device, to 
the detrusor contraction.  
This part of the study measures the bladder capacity of the individual and helps to 
conform the presence of NDO. Further it analyses the level of the external anal 
sphincter EMG signal, which will be used as the trigger for conditional 
stimulation. 
5.5.2 Experimental protocol 
The bladder was drained of urine before each bladder fill. Once all the filling 
lines, catheters and the device were in place as explained in 0 and the informed 
consent was obtained, the standard cystometrogram was performed at non-
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physiological rate of 60 ml/min while recording anal sphincter EMG. At the start 
of the experiment the subject was asked to cough to ensure that the equipment 
was positioned and recording correctly [156]. Blood pressure monitoring was not 
carried out during cystometry, but signs or symptoms of autonomic dysreflexia 
were monitored. Maximum cystometric capacity (MCC) was established when 
there is leakage, patient discomfort or when 500ml volume was reached [157]. 
The volume at first sustained contraction (VFC) (when the Pdet > 15cmH20 above 
the baseline for at least 10s [40, 41, 95]0, MCC and the maximum Pdet were 
recorded. This procedure was repeated three times in order to determine the 
repeatability of the results. For the patients with no observed NDO present, the 
experiment was terminated at this point. 
5.5.3 Results and analysis 
Standard CMG with anal sphincter EMG and the processed signal are shown in 
Figure 5:4 and the urodynamics traces of each individual showing the detrusor 
pressure, raw EMG signal and the processed signal illustrated in the Figure 5.4. 
The pressure, volume data and the level of processed signal during DSD of each 
subject is shown in the Figure 5:5. 
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Figure 5:4 – Standard CMG with external anal sphincter EMG  
Pves, Pabd and Pdet represent the bladder, abdominal and detrusor pressures (by subtracting Pabd from Pves) respectively. EMG of the anal sphincters represents in 
“Raw EMG” and the waveform used for triggering is filtered, rectified, smoothed EMG shown as the “processed” signal. TEMG = time at which the processed signal 
crossed the threshold line, Tder = time at which the detrusor pressure reached above 15cmH2O the baseline.  
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Figure 5:5 - CMG traces of the twelve subjects 
These graphs are source scaled and only the important signals (related to setting the stimulation 
threshold) are shown to highlight the detrusor contraction. 
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Out of the twelve patients that participated in the study four had to be turned down 
due to absence of NDO. Subject P6 had a low compliant bladder, in which the 
detrusor pressure increased with the filling; however the MCC reached at 300ml. For 
the subjects P7 and P10, filling of the bladder was terminated when the pump infused 
500ml and 450ml respectively. The MCC were 550ml and 450ml including the 
natural filling. For these two subjects there were no high pressure present and the 
bladder can accompany any volume of saline. This might be due to the fact that all 
the neural pathways to the bladder may have damaged as a results of injury. 
Furthermore they had no NDO but instead acontractile bladders and show signs of 
overflow incontinence. Patient P8 did not show any increase in detrusor pressure or 
guarding reflex, however there was leakage and the MCC was approximately 300ml. 
This may be due to weak urethral sphincters. Considering all these observations P6, 
P7, P8 and P10 will not benefit from this study. 
Bladder capacity 
One of the objectives of this experiment was to measure the bladder capacity of each 
individual, so that it is easy to know when to expect a dyssynergic response in the 
next part of the study and also to conform the presence of NDO. Figure 5:6 and 
Figure 5:7 show the bladder volume at first sustained contraction and the mean 
variation of the maximum cystometric capacity respectively. 
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Table 5-2 - Volume at first contraction and the maximum cystometric capacity of the participants. 
The volume at first contraction was obtained by measuring time and multiplying it by the fill rate. The maximum cystometric capacity was obtained by measuring 
the amount of fluid withdrawn from the bladder after each fill.  
Subject Volume at 1
st
 contraction (ml) Max. cystometric capacity (ml) 
Fill 1 Fill 2 Fill 3 Fill 1 Fill 2 Fill 3 
P1 138 140 - 150 155 - 
P2 72 40 83 100 87 105 
P3 109 118 118 145 145 175 
P4 73 45 39 105 82 55 
P5 175 234 278 180 235 280 
P6 122 66 50 370 300 300 
P7 - - - 550 - - 
P8 133 157 91 245 307 370 
P9 231 205 246 257 212 255 
P10 300 300 - 466 425 - 
P11 283 330 291 410 395 355 
P12 279 307 205 450 500 337 
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Figure 5:6 - Shows the variation of the volume at first contraction  
The volume shown is the mean of the three fills of each individual and error bars represnt the standard 
deviation. 
 
Figure 5:7 - Shows the variation of the maximum cystometric capacity  
Chapter 5 – Clinical efficacy of the ACONTI 
_______________________________________________________________ 
- 111 - 
 
Capacity shown is the mean of the three consecutive fills on each individual and error bars represent the 
standard deviation. 
The maximum cystometric capacity of each individual varied from 55ml to 500ml 
and the mean MCC was 221 ± 128 ml. When bladders are filled artificially, there is a 
tendency for the detrusor muscle to stretch and accommodate more volume at each 
time.  Figure 5:8 highlights the increase in bladder capacity of each subject on each 
consecutive fill. 
 
Figure 5:8 - Shows the intra subject change in bladder capacity due to repeated filling. 
These data were analysed with Friedman test (used to detect differences in treatments 
across multiple test attempts [158]) in order to determine the significance in increase 
in the bladder capacity across the fills. The results were p = 0.9048 across all three 
fills, showing that increase in bladder capacity across each fill was not statistically 
significant. 
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Maximum detrusor pressure 
Another problem of NDO is high detrusor pressure, which may lead to vesicoureteric 
reflux, repeated bladder infections and renal failure if left untreated.  Figure 5:9 
shows the variation of the maximum detrusor pressure of each individual during 
detrusor sphincter dyssynergia [13]. 
Table 5-3 - Maximum detrusor pressure during the control study 
The maximum detrusor pressure is the highest peak recoded in the control study.  
Subject Maximum Pdet (cmH2O) 
Fill 1 Fill 2 Fill 3 
P1 59 55.54 - 
P2 78 83 97 
P3 99 110 93 
P4 118 116 84 
P5 148 167 99 
P6 57 48 27 
P7 13 - - 
P8 53 61 46 
P9 60 63 50 
P10 10 14 - 
P11 75 80 83 
P12 96 69 72 
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Figure 5:9 - Variation of the maximum detrusor pressure of each individual with error bars 
representing the standard deviation. 
The maximum detrusor pressure varied from 50 cmH2O to 167 cmH2O across all 
subjects and the mean pressure was 88 ± 27 cmH2O. 
Level of processed signal 
The main reason for carrying out this experiment is to determine the level of the 
processed signal during DSD of the neurogenic patients, so that it can be used as the 
trigger in conditional neuromodulation. Figure 5:10 shows the level of the processed 
signal of each individual at the start of the first sustained contraction at which the 
stimulation should be applied in order to suppress the contraction. 
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Table 5-4 - Levels of the processed signal 
These results were obtained by reading the level of the processed signal when a sustained contraction 
occurred (time at which detrusor pressure crosses 15cmH2O). 
Subject Level of processed signal (µV) 
Fill 1 Fill 2 Fill 3 
P1 5.15 10.99 - 
P2 2.25 4.17 3.7 
P3 15.2 9.08 8.31 
P4 3.8 3.45 9.1 
P5 36.5 32.4 35.6 
P6 283 280 254 
P7 - - - 
P8 4.1 5.0 3.6 
P9 25.4 33.5 35.5 
P10 4.9 3.3 - 
P11 7.6 5 4.6 
P12 8.1 10.6 10.7 
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Figure 5:10 - Variation of the level of the processed signal of each individual. 
 Error bars representing the minimum and maximum recorded values at the start of first contraction. 
The level of the EMG signal varies 2.25µV to 36.5µV on each individual depending 
on their lesion and the state of their sphincters. However for stimulation it is 
necessary to avoid any false negative situation, therefore the minimum level of the 
processed signal identified on this experiment will be used as the trigger level for 
each of the subject. 
Relationship of the processed signal to the detrusor contraction  
One of the objectives of this study is to determine whether the external anal sphincter 
EMG can be used as a reliable trigger signal with relation to detrusor contraction. 
For all the eight subjects with NDO, the time at which the rise in detrusor pressure 
and the time as which the there is a significant change in the processed signal were 
noted.  
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Table 5-5 - Time difference in detecting contraction by processed signal and detrusor pressure as 
indicated in Figure 6:6. 
Patient TEMG - Tdet (s) 
P1 15 
P2 12 
P3 0.1 
P4 - 0.6 
P5 - 2.09 
P9 1.5 
P11 -1.8 
P12 3.2 
According to the data shown in the Table 5-5; on average, using an EMG threshold is 
3.4s faster than setting the trigger level on the detrusor pressure. The stimulation 
could have been delayed only on three subjects, however this delay was less than 
2.1s.  
5.5.4 Discussion 
Serial cystometries were conducted in patients with NDO to assess bladder capacity 
and to find out the level of processed EMG signal in order to determine threshold 
levels for conditional neuromodulation. The mean bladder capacity of each of these 
subjects is 221 ± 128 ml. This capacity is very low compared to a healthy volunteer. 
This means the number of catheterisation per day is high; therefore this capacity 
needs to be improved using the proposed device. The smallest bladder capacity was 
found on people who had required a high dose of antimuscarinic drugs. Also this 
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study proved that increase in bladder capacity due to repeated filling is not 
statistically significant (p >0.05). 
The patients with NDO had high level of detrusor pressure with the mean of 88 ± 27 
cmH2O. If these high transient pressure were left untreated; may result chronic renal 
failure and repeated bladder infections [12].   
The mean value of the level of processed EMG signal during DSD is 13.7µV. This 
value varies with each person. For the next part of the study this signal will be used 
as the trigger for the stimulation. It is important to obtain the best level of the 
processed signal as the trigger, because missing a contraction or being delayed to 
apply stimulation will result leakage of the urine. Therefore the minimum level of the 
processed signal during DSD will be used as the trigger level for conditional 
neuromodulation. 
The level of processed signal is not very high on each of the patient, but this can be 
improved using amplifiers which will be discussed next chapter. Furthermore by 
increasing the size of the recording electrode the quality of the recorded EMG signal 
can also be improved. Finally if the recording electrodes can be pushed further into 
the sphincter muscle, by increasing the width of the device near the sphincters, better 
contact can be made with muscle resulting increase in amplitude of the EMG signals. 
However the limitation for this is; it can permanently stretch the tissues of the 
patient. 
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5.6 Suppressing the detrusor overactivity through the 
device 
Once the suitable patients with NDO and the relationship between the external anal 
sphincter and detrusor contraction were identified, the next stage was to focus on 
suppressing these contractions through transrectal stimulation using the mechanism 
of conditional neuromodulation; as per semantics of operation of ACONTI. 
5.6.1 Objective 
In incontinence due to neurogenic detrusor overactivity at low volumes, the detrusor 
muscle contract even though it does not satisfy the situation to urinate. However in 
most of the patients the urethral sphincters remains closed during detrusor 
contraction in order to prevent the leakage, which is known as detrusor sphincter 
dyssynergia. 
In order to treat NDO through conditional neuromodulation, whenever a detrusor is 
detected; the stimulation is applied to the Pudendal nerve. As a result of that 
continence is achieved in two ways, sphincter contraction to prevent the leakage as 
well as bladder suppression to increase its capacity.  
Objective of this study is to evaluate the efficacy of the Pudendal nerve stimulation 
in increasing the bladder capacity as well as preventing the leakage using the 
external anal sphincter EMG as the trigger for the conditional neuromodulation. 
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5.6.2 Method 
Experiment set up remains the same as explained in section 5.4. First part of the 
procedure is to obtain the intensity of the stimulating current.   
Setting the stimulating parameters 
It is important to set the stimulating current at the optimum level. Lowering the 
amplitude saves the battery life, but may not be enough to generate an action 
potential in the pudendal nerve. The stimulation was delivered through DS7 constant 
current stimulator by Digitimer.  
The sensory threshold was defined as the intensity at which the subject could initially 
feel the electrical stimulation through the device.  
For the incomplete SCI patients, the sensory threshold was determined by giving a 5s 
burst of stimulation and increased it from 5mA to 90mA, until the patient felt the 
stimulation.  
For complete SCI patient had no sensation of the stimulating current. Therefore the 
sensory threshold was obtained by evaluating motor evoked potentials (MEP) by 
direct motor efferent. For this 30 stimulating pulses were delivered at a given current 
(varying from 10mA) and the response was averaged using SPIKE software in order 
to remove the noise. This procedure was repeated until the motor response (M-wave) 
can be seen, and at that intensity was established as the sensory threshold.  
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The amplitude of the stimulating current was set at twice the sensory threshold [31, 
40, 95, 159, 160] to elicit the bulbocavernosus reflex [12, 108, 161].  
The optimum stimulation parameters for conditional neuromodulation (frequency of 
15 Hz and  pulse width of 200µs with the maximum allowable voltage set to 200V) 
were used for this procedure [25, 78, 91, 108, 162]. The duration of the stimulation 
was also set to 60s (1min of continuous stimulation train has shown to increase MCC 
by 144% [32], where as 10s on and off stimulation increased the MCC by 53%-66% 
[31]) [95]  and repeated after 5s, as long as the detrusor pressure is above 15cmH2O 
[31]. 
The trigger level for the stimulation of each subject was set to the minimum level of 
the processed signal as explained in the previous section. 
5.6.3 Experimental protocol       
When all the stimulating parameters were set, the experiment begins by catheterising 
the bladder. First of all, the conditional neuromodulation principle was tested on each 
subject by performing standard CMG at 60 ml/min with stimulation through the 
device to investigate whether the electrical stimulation could suppress the detrusor 
contraction. In case of the patient cannot tolerate the stimulation, the intensity was 
lowered during any point of the study to a bearable level. If this experiment was 
successful the final part of the experiment begins by performing standard CMG at 15 
ml/min (closer to the physiological rate). Filling was continued until there is leakage, 
patient discomfort or when the 500ml capacity was reached. [157] Signs or 
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symptoms of autonomic dysreflexia were monitored and if the patient complaints 
any discomfort the experiment was terminated at that point. 
5.6.4 Results and analysis 
Stimulating current 
Example motor evoked potential waveform, which was used to determine the 
threshold of the complete SCI subjects is shown in the Figure 5:11. Table 5-6 shows 
the sensory threshold and the stimulating current of each of the subject. 
 
Figure 5:11 – Motor evoked potential 
Shows the average of 20 samples of MEP recorded through the device electrodes, when stimulating with a 
current of 30mA in complete SCI patient. 
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Table 5-6 - Shows the sensory threshold and the stimulating current of each subject, which was 
utilised in delivering the stimulation. 
 Subject Sensory threshold (mA) Stimulating current (mA) 
Incomplete 
SCI 
P1 30 57 
P3 30 60 
P5 3 40 
P9 20 25 
Complete  
SCI 
P2 30 60 
P4 30 60 
P11 50 90 
P12 40 80 
 
Even though the subject P5 had sensory threshold of 3mA, the stimulating current 
was set to 40mA, this is because 6mA is too low and will not stimulate the nerve. 
Stimulating current of P9 was not doubled as 40mA was not tolerable for him.  
According to the Table 5-6, the mean stimulating current across all subjects was 
59mA with standard deviation of 20mA. 
The distance between the stimulating electrodes of the device and the external 
sphincter is about 5cm and from the Figure 5:11 the latency between the stimulating 
pulse and the start of M-wave is 2ms, results the velocity of conduction as 25m/s. 
The motor fiber that conducts this information is Aγ type in which the conduction 
velocity is between 15 - 30m/s [148, 163] showing that the stimulation resulted direct 
motor contraction.  
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Figure 5:12 illustrates the urodynamics traces with and without conditional 
neuromodulation using processed EMG signal as the threshold. Figure 5:13 shows 
the neuromodulation effect on the bladder condition of each individual. 
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Figure 5:12- Shows the effect on detrusor contraction with and without stimulation. 
(a) NDO contraction and DSD of P3; (b) neuromodulation through the device using EMG threshold set at the dotted line in the processed signal to 
trigger the stimulation while filling the bladder at 60ml/min. Thickening of EMG trace is due to stimulus artefact pulses. It can be clearly seen that 
detrusor contraction diminished with the stimulation.  
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Figure 5:13 - Shows the effect of single burst (60s) stimulation on detrusor pressure in each 
participatant. 
 The bladder was filling at 60ml/min, and the trigger level for activating stimulation was set on the 
processed signal. In some traces, only a part of the processed signal can be seen. This is due to the signal 
being saturated during the stimulation, but for triggering this saturation does not cause any problem. 
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According to the Figure 5:13, the conditional neuromodulation through the device 
has successfully suppressed the detrusor contraction on P1, P2, P3, P4, P5 and P11. 
For the patient P9, due to high sensitivity, the stimulating current used was 25mA 
(when his threshold was 20mA). Failure to produce enough current to generate 
action potential on the pudendal nerve resulted not being able to arrest the detrusor 
contraction [161]. For the subject P12, the symptoms of autonomic dysreflexia 
(sweating and headache) occurred during the experiment. Due to these reasons the 
experiment was terminated at this point for P9 and P11. 
Time between each contraction 
As the bladder being filled with saline, detrusor contractions become more frequent 
reducing the time between each suppressed contraction. At one point (when the 
bladder reached MCC), the stimulation can no longer inhibit the contraction resulting 
the discomfort to the patient or leak. This phenomenon is shown in the Figure 5:14 
and the measurements are shown in the Table 5-7. 
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Figure 5:14 - Sample conditional stimulation fill, starting with an empty bladder. t1-n represent the increase in catheterisation time as a result of 
neuromodulation. 
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Table 5-7 - Shows the time between each detrusor contraction of each individual. 
Subject Time between each contraction (s) 
t0-1 t1-2 t2-3 t3-4 t4-5 t5-6 t6-7 t1-n 
P1 648 72 - - - - - 132 
P2 240 210 300 - - - - 1710 
P3 928 385 292 221 78 27 - 1189 
P4 370 90 128 120 92 254 70 1672 
P5 507 136 112 98 67 52 41 570 
P11 597 220 139 75 60 57 - 623 
The graphical illustration of the data shown in the Table 5-7 is shown in the Figure 
5:15.  
 
Figure 5:15 - Time between suppressed hyperreflexic contractions during the continuous filling at 
15ml/min. 
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According to the figure the time between each contraction decreases with the 
increasing number of contraction. The decreasing line takes the shape of the 
exponential decay curve. However, for the subject P2, the time had increased 
between contractions 2 to 3, this because as his first contraction happened earlier 
compared to others and it required few blocks of stimulation bursts to inhibit. 
Therefore this effect of stimulation might have stretched his bladder.  
 
Figure 5:16 - Average time between each contraction across all subjects. Error bars represent the 
standard deviation. 
The average time between the contractions 1-2 is 9.13 ± 3.98min and that of 2-3 is 
3.09 ± 1.92min.  
As a result of conditional neuromodulation, the bladder compliance had increased 
resulting decrease in the number of catheterisation required. 
%100
10
1 ×=
−
−
t
t
compliancebladderinIncrease n  Equation 5-1 
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The mean increase in bladder compliance across all subjects is 179.21%. In other 
words, the catheterisation time of the patient had increased by an average of 2.8 
times (from 548s to 1531s).  
External anal sphincter EMG trigger level 
As explained the earlier experiment, the trigger level was set as the minimum value 
of the processed signal resulted in the three controlled fills. The threshold algorithm 
successfully detected all true contractions resulting no negative (true negative or 
false negative) detections.  
External anal sphincter EMG was not monitored during the stimulation, due to large 
stimulating artefacts and therefore 5s stimulation off period was left followed by 60s 
automatic stimulation. 
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Figure 5:17 - Show the real time implementation of the conditional neuromodulation based on the level on processed signal to trigger the stimulation.  
With the bladder filling, contractions become more and more frequent and at one point (contraction number 10), the bladder can no longer be suppressed. 
Processed signal been amplified to shows the trigger level.  
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Four false positive (1, 2, 3, 4) and six true positive detection (5, 6, 7, 8, 9, 10) were 
triggered by the algorithm. In order to visualise the trigger level, only half of the 
processed signal is shown here. This is due to stimulating artefact being picked up, 
and it is high compared to the trigger level. 
The positive predictive value (PPV) or precision rate of a test is the probability of 
true positive result [164].  
postiveFalsepositiveTrue
postiveTrue
valuepredictivePositive
+
=  Equation 5-2 
The PPV was calculated for all six patients participated for this study and is shown in 
the Table 5-8. 
Table 5-8 - Calculates the precision rate and the percentage of unwanted stimulation of a given 
threshold level for each patient. 
Patient 
Threshold 
level (µV) 
Negative Positive % of 
unwanted 
stimulation 
PPV 
True False True False 
P1 5.15 - - 2 - - 1 
P2 2.25 - - 9 - - 1 
P3 8.31 - - 13 5 14.17 0.72 
P4 3.45 - - 16 2 5.88 0.89 
P5 32.4 - - 6 4 22.28 0.6 
P11 4.6 - - 6 3 14.75 0.67 
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Across all these trials there were 52 true positive outcome and 14 false positive 
outcomes over 2hours and 55min trial period. On average there were 8.67 (± 5.12) 
true positive and 2.33 (± 2.06) false positive over a period of 26 min (± 9.5s), 
resulting the positive predictive value of 0.79.    
False positive outcomes are due to the fluctuation of abdominal pressure and this 
resulted to 9.13% of stimulation.  
Suppression of the detrusor contraction 
It is important to stimulation to be switched automatically immediately after the start 
of contraction. The Figure 5:18 shows the delay between the start of the contraction 
and time taken to suppress the contraction, while the mean values of each subject is 
shown in the Table 5-9. 
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Figure 5:18 - Time taken to start the stimulation and the time taken to suppress the contraction.  
ta = delay in starting the stimulation, tb = time taken for the detrusor pressure to reach its peak from the start of stimulation, tc = time taken for the from the start of 
stimulation to 50% decay of the contraction, tb = time taken for the detrusor pressure to reach 15cmH2O (from the base line) from the start of stimulation.  
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 Table 5-9 - The mean value of ta, tb, tc and td (indicated in the Figure 5:18 ) 
Patient ta (s) tb (s) tc (s) td (s) 
P1 1.795 3.17 6.77 9.31 
P2 1.127 26.327 38.497 78.737 
P3 1.187 110.285 167.892 233.305 
P4 5.31 27.05 37.42 55.4 
P5 2.18 6.81 12.45 48.2 
P11 4.05 3.28 7.74 25.85 
 
According to the table the stimulation starts after 2.6s (±1.7s, range 1.13-5.31s). 
Since the start of stimulation it takes nearly 29.5s (±41s, range 3.17-110.29) for the 
detrusor pressure to reach its peak. It takes 45s (±61.82s, range 6.77-167.89s) for the 
contraction to decay to 50% of its peak and 75.13s (±81.13s, range 9.31-233.3s) to 
reach the 15cmH2O above the base line.    
Table 5-10 - Shows the rise in detrusor pressure due to the delay in commencing the stimulation. 
Patient Stimulation delay (s) Change in Pdet (cmH2O) 
P1 1.795 8.12 
P2 1.127 3.21 
P3 1.187 1.0 
P4 5.31 25.41 
P5 2.18 6.05 
P11 4.05 18.15 
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Figure 5:19 - Correlation between the mean delay in stimulation, since detecting the contraction and 
the rise in the detrusor pressure during that time. 
The graphical representation in Figure 5:19 shows that the time delay is responsible 
for increase in detrusor pressure and follow linear regression. Statistical analysis on 
Pearson correlation resulted r=0.99 showing that the two parameters are highly 
related, while 2-tailed t test resulted p=0.0003 showing the values are highly 
significant. 
Detrusor pressure analysis 
The maximum detrusor pressure of each inhibited contraction was measure and 
shown in the Table 5-11. 
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Table 5-11 - The maximum detrusor pressure of each successfully inhibited contraction of each 
individual. 
Subject Maximum detrusor pressure (cmH2O) 
p1 p2 p3 p4 p5 p6 p7 
P1 27.85 56.44 - - - - - 
P2 40.74 48.89 72.96 - - - - 
P3 69.25 73.07 70.65 59.04 - - - 
P4 46.22 55.2 69.18 21.37 61.39 53.13 52.25 
P5 23.36 41.1 39.03 - - - - 
P11 39.64 43.89 48.14 48.84 - - - 
According to the Table 5-11, the mean of peak detrusor pressure was 48.52cmH2O 
(±10.25cmH2O, range 34.5-63.93cmH2O). The peak Pdet of the 1st suppressed 
contraction was 41.18 ± 16.2cmH2O. The 2nd and 3rd contractions were 129% and 
145.7% of the 1st contraction respectively. The Figure 5:20 highlights the mean peak 
detrusor pressure of each subject. 
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Figure 5:20 - Maximum detrusor pressure during conditional neuromodulation of each individual, 
the error bars represent the standard deviation. 
One of the objectives of the experiment was to reduce the maximum detrusor 
pressure during bladder filling. Table 5-12 compares the mean peak detrusor pressure 
before and after stimulation. 
Table 5-12 - Shows the mean of the maximum detrusor pressure across each fill during control 
study and with conditional stimulation. 
Patient 
Control Pdet (max) 
(cmH2O) 
Pdet (max) with CN 
(cmH2O) 
P1 57.27 42.14 
P2 86 54.2 
P3 100.67 63.93 
P4 106 51.25 
P5 138 34.5 
P11 79.33 45.13 
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Figure 5:21- Change in mean peak detrusor pressure across all subjects with and without 
stimulation. 
The mean Pdet of the control study was 94.5 ± 27.4cmH2O and that of conditional 
neuromodulation study was 48.5 ±10.2 cmH2O.  When the maximum Pdet of the 
control study and the conditional neuromodulation was analysed using Wilcoxon’s 
signed rank test resulted p value of 0.01. This shows the reduction in maximum 
detrusor pressure due to conditional stimulation was statistically significant. 
Maximum cystometric capacity 
One of the main criteria of this experiment is to measure the increase in bladder 
capacity due to conditional neuromodulation 
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Table 5-13 - Shows the maximum cystometric capacity across each fill during control study and 
with conditional stimulation. 
Patient Control MCC (ml) MCC due to CN (ml) 
P1 152 195 
P2 97 488 
P3 155 530 
P4 81 510 
P5 232 289 
P11 386 405 
 
 
Figure 5:22- Change in maximum cystometric capacity across all subjects with and without 
stimulation. 
The mean MCC of the control study was 183 ± 112ml and that of conditional 
neuromodulation study was 402 ±134ml.  When the maximum cystometric capacity 
of the control study and the conditional neuromodulation was analysed using 
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Wilcoxon’s signed rank test resulted p value of 0.03. This shows the increase in 
maximum cystometric capacity due to conditional stimulation was statistically 
significant. 
5.6.5 Discussion 
In every patient examined, conditional neuromodulation through the device increased 
bladder capacity by 220% compared to the control study. The increase in maximum 
cystometric capacity was statistically significant. However, it is possible that 
conditional neuromodulation over week or months would gradually increase capacity 
beyond the modest acute rise seen here, in a similar way to the gradual increase in 
capacity seen after posterior rhizotomy [31, 165].   
The later the stimulation starts during a detrusor contraction, the higher the detrusor 
pressure will become and therefore less chance there is to prevent incontinence. The 
average delay was 2.6s; hence having low EMG trigger level might benefit to 
suppress the contraction. Inhibitory stimulation must be delivered soon after hyper-
reflexic contraction, conditional neuromodulation may not be effective at 
suppressing contractions that begin during the 5s “off” phase [92]. The average time 
takes to suppress the contraction back to 15cmH2O was 75.13s. 
The ability to switch on stimulation is essential for effective conditional 
neuromodulation. This relies on two key factors; the precision of the threshold level 
and the delay between the detection and switching on the stimulation. The adaptive 
threshold should detect all true contraction (sensitivity of 100%) in order to avoid the 
leakage until the MCC is reached. The chosen threshold level for each subject 
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resulted the precision rate of 79% and the false positive outcome contributed to 
9.13% of stimulation.  This can be improved at any stage by keeping track record of 
all the activities (bladder diary) and reprogramming the threshold level to the 
required. There is high significant correlation between the delay in stimulation to the 
rise of detrusor pressure during that time.  
During the continuous filling with conditional neuromodulation switched on, the 
bladder contractions can inhibit, but with the filling contractions become more 
frequent. The average time between the 1st and 2nd contraction is 9.13%. Due to the 
continuous filling the bladder compliance increased by 179%, reducing the 
catheterisation by 2.8 times. 
In conclusion the conditional neuromodulation through the device proved to be an 
effective treatment for neurogenic detrusor overactivity. The initial study showed 
that increase in bladder capacity and reduction of detrusor pressure is highly 
significant. It also showed that the external anal sphincter EMG recorded through the 
device can be used as a trigger level for the conditional neuromodulation, resulting 
this device as a closed loop control in treating detrusor overactivity. 
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Chapter 6 -  Design and realisation of the 
electronic circuitry 
6.1 Introduction 
Although ACONTI was tested and used clinically, this does not allow patients to 
use this daily, as the device is not portable. Therefore the next stage in 
development is to include a self-standing system, which requires no external 
equipment while the device is being used. The electronic circuitry described in 
this chapter is a standard design and requires no special components. 
This chapter begins by stating the objective of designing the electronic circuitry. 
Then the chapter divides into two main sections as the amplification and signal 
processing (section 6.3) and the stimulator design (section 0). Each of these 
sections, starts by giving a background about the nature of the signals and 
highlights the design challenges. Then it discusses the system that is currently 
being used and moves on to derive the specification for the required circuitry. 
Under the realisation of the circuit (section 6.3.4 and section 6.4.4), each of the 
individual circuit is discussed together with their performance followed by the 
overall system testing. Results and discussion of these two sections are 
highlighted in section 6.6. The following specification in table 6-1 was resulted 
due to this circuit.  
Table 6-1 – The specification for the electronic circuitry 
Power supply Two 9V PP3 batteries 
Connection to the device Mini DIN connector 
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Gain of the recording circuit 20000 (in 3 stages) 
Input coupling AC coupled with time constant 0.03s 
Input impedance 5.6MΩ (differential) 
High pass filter cutoff 1Hz 
Low pass filter cutoff 500Hz 
Common mode rejection ratio 88dB 
Notch filter Tuned at 50Hz and 41dB attenuation  
Comparator reference voltage  Variable between 0V to 5V 
Stimulating current Variable between 10mA to 80mA 
Stimulation on time 60s 
Stimulation off time 3s 
Maximum stimulating supply voltage 200V 
Stimulating frequency 15Hz 
Stimulation pulse width 200µs 
Charge balancing RC circuit with 30ms time constant 
 
6.2  Aim and objectives 
It is very important that the device be simple as for the daily use. The aim is to 
increase the mobility of the device. At a first stage of this design, all the 
electronics will be mounted into a box, which can be worn on a belt. The 
connection to and from the device is made via a wire, which runs through the 
buttocks to the belt-worn box. Although this is a standard signal processing 
system, realising a circuit especially for ACONTI makes the circuitry simpler, 
which is important in miniaturisation and also allows future hardware and 
software modifications. This also provides some insight into the electronic 
circuitry. 
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Objectives of the design are listed below: - 
• Design amplifier which is capable of detecting low amplitude signal and 
amplify to a processable level. 
• Filter and process the signal so that the condition for stimulation can be 
determined accurately. 
• Design a constant current stimulator which provides stimulation pulses, in 
which the amplitude and the pulse duration can be varied depending on 
patient requirements. 
• Design a system, which consumes low power in order to maximise the 
battery life. 
6.3 Amplification and signal processing 
Often in biomedical engineering, current and voltage outputs must be amplified, 
attenuated or filtered safety in order to achieve the best possible electronic signal 
with minimal risk to the patient or the operator. 
In order to decide whether to apply the stimulation or not, it is required to 
compare the amplitude of the EMG to a pre determined level. In order to do this, 
the signal needs to be processed and as this is a low amplitude signal, it requires 
amplification. 
6.3.1 Background 
In order to achieve good signal processing, it is required to know some basic 
characteristics of the biomedical signals of interest. 
EMG signal characteristics 
Electromyography (EMG) is one of the widely used bioelectric signals, it 
represents the electrical activity of the muscle [166]. On arrival of an action 
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potential, each motor unit contracts and causes an electrical signal that is the 
summation of the action potentials of all of its constituent cells [167]. The 
characteristics of the recorded EMG signal varies with the tissues through which 
it passes and the type of the electrode used to detect it. The tissues, electrode-
electrolyte interface act as a low-pass filter and the rejects some high frequency 
components [168].  
The SENIAM recommendation for filtering EMG signal are to use a high-pass 
filter of 10Hz and a low-pass filter with cut-off frequency of about 500Hz [168]. 
This is a generalised frequency spectrum, but the results of the clinical testing can 
be used to determine the frequency spectrum in relation to external anal sphincter 
EMG.  
EMG signal processing 
In EMG signals, the maximisation of the signal to noise ratio should be done with 
minimal distortion. Therefore it is important that any detecting and recording 
device to process the signal linearly. The following characteristics are important 
for achieving this requirement [169]. 
• Differential amplifier – Any signal common to both electrodes will be 
removed only the difference signal will be amplified. Therefore relatively 
distant noise signals, such as ECG, motion artefact etc. The accuracy of 
this differential signal depends on CMRR, it is recommended for EMG 
amplification at least 90dB of CMRR.  
• Input impedance – In order to reduce the attenuation and the distortion of 
the EMG signal due to the effect of input loading, the input impedance of 
the differential amplifier should be large as possible. However in order to 
provide return path for the bias current, this amplifier’s input impedance is 
limited by the value of the bias resistors. In addition to these, the 
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difference in electrode impedance should be minimised to provide a better 
signal processing. 
• Filtering – The EMG signal contaminated with noise. The quality of the 
signal can be improved by filtering between 10-500Hz. It is advisable to 
use a filter such as Butterworth for this purpose, in order to preserve the 
linearity.  
Considering the safety of the patient, it is advised to power the circuitry by 
low voltage (3-15)V battery. This will also reduce power line interference 
distorting the signal [169].  
Noise and interference 
It is difficult to obtain high quality bio-electric signal, because the signals have 
low amplitudes (in the range of µV to mV) and so are easily corrupted by 
electrical noise and interference. EMG signals can be recorded either from 
‘surface’ electrodes on the skin above the muscle of interest, or ‘intramuscular’ 
electrodes inserted into the muscle [170]. Even though recording the surface 
EMG is more convenient, it also suffers from greater interference due to poor 
connection [171]. Interference comes from artificial sources, such as movement 
artefact, lights, electromagnetically coupled signals from power lines, radiated 
signals from mobile phones, radio/TV transmitters etc. Noise generated due to 
movement induced artefact can be removed using a high pass filter with a cut-off 
frequency between 2-20Hz, while the notch filter is used to remove power line 
interference [170, 172-174]. Furthermore by using an amplifier with high CMRR, 
can reduce the effect of common mode signal produced by the body. 
These issues need to be considered in order to obtain good signal processing and 
achieve the true sensitivity of the system. 
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6.3.2 System that is being used in clinical setting 
Currently for the clinical set up a commercially available amplifier system was 
used and is shown in the Figure 6:1. The amplifier system is a general purpose 
isolated preamplifier developed by Lectromed and mainly intended for bio 
potential signals. For the purpose of recording the EMG signals through the 
wearable device, certain settings of the front of the amplifier were adjusted and 
are shown in the table 6.1. 
 
Figure 6:1 – Shows the Lectromed 5361 differential amplifier,  
This amplifier is approved by the 89/336/EEC directive. The two pressure transducers and the EMG 
signals from the device are connected to the class II b electrically isolated bio-potential amplifier.  
 
Table 6-2 – The settings of the front end of the Lectromed amplifier [175] 
Gain 
1 (This is due to a fault in the system) 
and gain accuracy of ±2% 
Coupling AC coupled with time constant 0.03s 
Input impedance 5.6MΩ (differential) 
Low pass filter cutoff 500Hz 
Common mode rejection ratio (CMRR) 90dB 
Notch filter 
Tuned at 50Hz and set to 20dB 
attenuation at the notch frequency 
 
This amplified EMG analogue signal was then passed onto CED 1401 data 
acquisition system in order to convert to a digital signal, which can be further 
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processed through SPIKE software programme. This system was developed by 
Cambridge Electronic Devices. The analogue signal was sampled at a rate of 
333kHz [176]. 
 
Figure 6:2 – CED 1401 plus data acquisition system, act as an interface to the real time analogue 
signal and SPIKE digital signal [176]. 
This digital signal was then displayed through SPIKE graphical user interface. An 
example waveform is shown in the Figure 6:3.  
 
Figure 6:3 – Shows the EMG (green) and the detrusor pressure (blue) of a signal recorded 
through SPIKE programme.  
At this point digital signal processing can be added to the recorded signal, 
through SPIKE software. In order to analyse the frequency components present in 
this signal Fast Fourier Transform (FFT) can be applied and is shown in Figure 
6:4. 
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Figure 6:4 – The raw EMG waveform shown in the Figure 6:3 is transformed in to frequency 
domain by 512 Hanning window in order to assess its frequency components. 
 
According to the Figure 6:4, there is a large DC (0Hz) component present and 
most of the signal is concentrated below 500Hz. Therefore online band-pass filter 
was added to the system.  
The digitally programmed band-pass filter provided 70dB attenuation in the stop 
band. The reason for choosing 60Hz as the lower cut-off was to eliminate the 
50Hz mains interference, but better attenuation of mains interference can be 
obtained by using a 50Hz notch filter. 
The filtered signal was then rectified and smoothed in order to obtain the DC 
equivalent. These results are shown in Figure 6:5. 
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Figure 6:5 – Optimising the processing parameters. 
The raw EMG signal (green) was digitally filtered with band pass 60Hz-500Hz, to remove the noise 
and interference. This filtered signal was then rectified (grey) and smoothed with different time 
constants. Pink wave shows the smoothing time constant of 0.1s, where as the red is 1s. 
 
After testing with different values it was decided, that 1s is the best smoothing 
time constant to be used as the trigger signal for the stimulation. Even though this 
is comparatively slow time constant, in this application it did not cause any 
leakage of urine.  
The threshold detector for triggering stimulation was set on the smoothed signal. 
When the signal exceeds this level, the stimulation was activated automatically. 
All of the signal processing mentioned above is summarised in Figure 6:6. 
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Figure 6:6 - The bladder pressure is shown in Pves and the EMG signal recorded through 
ACONTI is shown in “Raw EMG” channel.  
This channel will then be band-pass filtered and shown as “Filt_EMG”. Finally this filtered signal will 
be rectified and smoothed and is shown as “Re_Sm_Filt”. 
6.3.3 Derivation of the required system 
Considering the system that is being used in the clinical study, the block diagram 
of the proposed circuitry can be derived as shown in the Figure 6:7. 
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Figure 6:7 - The block diagram of the proposed circuit.  
The EMG signal is amplified by the differential amplifier and then passed on to three stage filtering 
circuit to remove 50Hz interference, movement artefact, DC offset and high frequency components. 
This signal is further processed through a precise full wave rectifier, followed by the smoothing filter. 
This processed signal is compared with the pre determined threshold. If it crosses the threshold level, 
the stimulation will be activated. 
Section 6.3.4 describes the design and the testing of each of these functional 
units.  
6.3.4 Realisation of the circuit 
Pre-amplifier 
This is the heart of an EMG recording system. The basic requirement that 
biopotential amplifier has to satisfy are [177]: 
• The physiological process to be monitored should not be influenced by 
the amplifier. 
• The measured signal should not be distorted. 
• The amplifier should provide the best separation of signal and 
interference. 
• The amplifier should provide protection from any hazard. 
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Input impedance 
EMG of the external anal sphincters is recorded through the recording electrodes 
of the device. In order to obtain a less attenuated signal, the electrode skin 
interface should be low impedance. This can be achieved by maintaining good 
electrode skin contact and by using electrodes with low impedance. 
The electrodes’ impedance were measured when ACONTI was in saline solution 
using the Wayne Kerr 6500B precision impedance analyser. Figure 6:10 shows 
the impedance of the left and the right recording electrode of the device over the 
range of frequencies from 20Hz to 10kHz. According to Figure 6:10, at 1kHz the 
electrode impedance is around 92Ω, however when the device is in the body 
impedance of the left recording electrode relative to the ground electrode of the 
device was 11.79kΩ, whereas that of the right electrode was 9.98kΩ. 
This may be due to the electrodes not making good contacts with sphincter 
muscles. If the electrodes can be pushed toward the sphincters, by increasing the 
diameter of the recording part of the device, this impedance can be reduced. Also 
by applying KY-gel ensures good electrode conductivity. 
Another method to minimise the effects of  imbalance in electrode impedance is 
by using buffers at the amplifier input [178]. However as the signals are of low 
amplitude and by using an amplifier without a gain will reduce the signal to noise 
ratio. 
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Figure 6:8 - Each electrode is connected to a buffer amplifier, so that the mismatch of the 
electrode impedance can be minimised. 
 
An alternative approach to minimise the effect of high electrode impedance is by 
using an amplifier with high input impedance. This impedance should be at least 
100 times the electrode impedance to avoid attenuation of the input signal [168]. 
However the sensor circuit must provide a path for the input bias current of both 
inputs [179-181]. A simple circuit to solve this problem is by placing a resistor 
from each input terminal to the ground as shown in the Figure 6:9 [179]. 
 
Figure 6:9 - A simple circuit to provide the path for the bias current.  
Zd, Zc1 and Zc2 are the amplifier differential input impedance, common mode impedance of the input 
1 and the common mode impedance of the input 2 respectively. Rb1 and Rb2 are the two external 
resistors to the ground to provide the return bias current [179].  
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Figure 6:10- Shows the electrode impedance versus frequency, when the device is in a saline solution 
 (a) Impedance between the left recording electrode and ground (b) electrode impedance between the right recording electrode and the ground.
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When the device in the body, the impedance of the left and right recording 
electrodes at 200Hz (mid-band EMG frequency), were 10.303kΩ at -26.10 and 
8.83kΩ at -24.20 respectively. This can be represented using the model shown in 
Figure 6:11.  
 
Figure 6:11 - Model of the recording electrode 
Common mode rejection 
Using a single electrode would result two-phase depolarisation signal, which 
contains mains at approximately 100mV. This is considerably large compared to 
the EMG signal, thus the amplifier may saturate. This is overcome by using 
bipolar configuration, which is recording using two electrodes and a reference 
and passes onto a differential amplifier [168]. Strong rejection of common mode 
signal is one of the most important characteristics of a good bio potential 
amplifiers [177].  
The common mode rejection ratio (CMRR) is defined as the ratio of the 
differential mode gain (Ad) over the common mode gain (Ac). Ideally the 
common mode signal (Vcm) can be removed by using an amplifier with infinite 
CMRR and using electrodes with matched impedance ( 21 ZZ = ). 
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Figure 6:12 - Instrumentation amplifier with non-infinite CMRR and non-infinite input 
impedance. 
 
 
The common mode signal Vcm causes currents to flow through Z1 and Z2. 
Therefore the output of the amplifier is a combination of the common mode and 
the differential signal as shown in the  Equation 6-1. 
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where Ad = differential gain; Vb = biological signal and Zin = input impedance of 
the amplifier. 
In order to increase the amplifier performance the second and the third term of the 
Equation 6-1, CMRR of the amplifier should be increased and also the difference 
between the electrode impedance should be reduced, while increasing the input 
impedance of the amplifier [177]. 
Imbalance of the electrodes impedance is not uncommon in biomedical signals. 
The bias resistors are required for the return pathway of the current. Input 
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impedance of the amplifier is limited by the values of the bias resistors. The star 
configuration shown in the Figure 6:13, propose optimal bias circuit, to maintain 
the high common-mode input impedance and not to reduce the CMRR [179].  
 
 
 
Figure 6:13- An optimal biasing circuit with three resistors in a star configuration. 
 Zd, Zc1 and Zc2 are the amplifier differential input impedance, common mode impedance of the 
input 1 and the common mode impedance of the input 2 respectively. Rp1, Rp2 and Rp3 are the three 
external resistors to the ground [179]. 
 
In practice the perfect elimination of the mains hum is not possible, but it is 
recommended in biomedical applications to obtain CMRR of 10000 (80dB) or 
more [167]. 
AC coupling 
Figure 6:4 shows that the EMG signal being distorted with large DC component. 
It would be desirable to block this by simply adding a capacitor working as a 
passive high pass filter as shown in the Figure 6:14. 
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Figure 6:14 - AC coupled amplifier using simple RC filter.  
A capacitor C results charging effect from the input bias current. Perfectly matched capacitors are 
required at both inputs, to maintain high CMRR. The resistor R reduces the mismatch of the input 
impedance as well as provides the return path for the input bias current.  
This would eliminate the electrode offset potentials, which limits the gain of the 
amplifier due to saturation. Therefore this arrangement permits a higher gain 
resulting in high CMRR.  
Gain 
In order to provide optimum signal quality and adequate voltage level for further 
signal processing, the ratio of the input voltage to the output voltage should be 
large and in the range of 20,000. The presence of high level of interference signal 
restricts the gain of the pre-amplifier. The gain of the pre-amplifier is reduced and 
several amplification stages being added to the system [177].    
The required frequency response depends upon the frequencies contained in the 
EMG signal. About 95% of the EMG signal is normally in the range up to 400Hz 
[168]. Gain bandwidth product of the amplifier limits the bandwidth of the 
recorded signal, but most of the EMG amplifiers can easily meet such bandwidth 
with high gain. 
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Considering all these factors, the following circuit (Figure 6:15) was derived for 
initial amplification of the EMG signal. 
 
Figure 6:15 - Shows the circuit diagram of the pre-amplifier. 
 The amplifier shown is INA118 instrumentation amplifier and is powered by ±5V battery supply. The 
ref electrode and the ref pin of the amplifier are connected to the ground. 
The INA118 amplifier has a wider power supply range from ±1.35 to ±18V, but 
for this application it is powered by ±5V. The power supply lines are de-coupled 
using 100nF capacitors (C3 and C4.)  
R1, R2 and R3 were chosen to be high enough to increase the CMRR of the 
amplifier and should be low enough to prevent the saturation of the amplifier due 
to offset voltages. The bias resistors R1, R2 and R3 are 4.71MΩ, 4.71MΩ and 
10MΩ respectively. Furthermore C1 R1 and C2 R2 are passive high pass filters 
with cut-off frequency of 0.34Hz to block any DC signals. Therefore C1 and C2 
were chosen as 100nF each. All these resistors and capacitors are matched to 
0.01% tolerance using the impedance analyser. This capacitor resistor network, 
act as a high pass filter as well as a path for bias current. 
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The resistor R4 was used for setting the gain according to the Equation 6-2. 
GR
kG Ω+= 501  Equation 6-2 
The gain of the amplifier was set to 200, therefore RG = 251.3Ω. The gain 
bandwidth product of the amplifier is 800kHz, therefore with a gain of 200, the 
amplifier bandwidth limits to 4kHz. As most of the EMG frequencies are below 
500Hz, INA118 amplifier satisfies the bandwidth requirements.  
The frequency response of the amplifier (Figure 6:16) tested by injecting a 
sinusoidal wave using the TTi TGA1241 arbitrary waveform generator. 
 
Figure 6:16 - The gain vs frequency of the INA118 amplifier.  
The inputs of the INA118 are individually protected for voltages up to ±40V. If 
the input is overloaded, the protection circuitry limits the input current to a safe 
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value of approximately 1.5 to 5mA. These inputs are protected even if the power 
supplies are disconnected or turned off [180]. 
According to  Equation 6-3 this high pass filter has a time constant of 1.471s; 
therefore the cut-off frequency is 0.1081Hz (Equation 6-4).  
CR=τ  Equation 6-3 
τpi2
1
=f  Equation 6-4 
The common mode gain (Ac) and the differential gain (Ad) of the amplifier were 
calculated. 
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However this calculation does not take the imbalance in the electrode impedance 
into consideration. 
Common mode analysis of the amplifier 
Let Z1 and Z2 be the electrode impedances of RL and RR respectively. 
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Substituting the measured impedance values to equation 6-8 and equation 6-9 
gives, 
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Therefore the CMRR of the amplifier = 200 / 4.2 x 10-4 = 113.56dB 
Output offset voltage 
The DC levels of inputs and the output of the amplifier were measured using 
ISO-Tech IDM93N digital multi-meter and the values obtained are shown in 
Figure 6:17. This DC offset value limits the gain of the amplifier, which might 
cause saturation. 
 
Figure 6:17 - DC offset values of the amplifier measured by the digital multi-meter. 
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The bias resistors of the differential amplifier in Figure 6:15 are 14.71MΩ each. 
The manufacturer’s data sheet of the INA 118 specifies that there can be bias 
current typically in the range of ±1nA upto ±5nA. With the bias resistor 
configuration this can generate offset voltage upto 73.55mV. Even though there 
are capacitors to block any DC from the electrodes, there is still offset voltage 
generated at the amplifier input due to bias current. This is what was shown in 
Figure 6:17. The difference of the input offset voltages (22.4-19.8) is amplified 
with the gain of the amplifier (x200) to produce output offset voltage of 536mV. 
Noise calculation 
In general, the noise introduced by the biasing resistors diminishes as their value 
increases, provided that they are large enough [179]. Therefore, for the purpose of 
noise calculation the circuit can be simplified as in Figure 6:18. 
 
Figure 6:18 - Simplified recording electrodes and the amplifier. 
Noise from resistor A; 
nVBRTk 76.78240001025.93001038.144 323 =××××××= −  
Noise from capacitor B; 
nVBfCI NoiAmp 68.158140001064.63200414.12
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Noise from resistor C; 
nVBRTk 23.73040001005.83001038.144 323 =××××××= −  
Noise from capacitor D; 
nVBfCI NoiAmp 12.146440001075.68200414.12
1102
2
1
9
12
_
=
××××
××=×
−
−
pi
 
Noise from amplifier E = nV46.632400010 8 =×−  
Therefore the total noise in the amplifier front end; 
Vnnnnnn EDCBATotal µ5.222222 =++++=  
Notch filter 
The most frequent common mode signal coupled into a bio-potential system is 
the 50Hz, sinusoidal interference from the mains power [182]. Minimizing this 
interference signal requires shielded cables between the patient and the apparatus 
and use of narrow band rejection filter (notch filter) [177]. 
A simple notch filter is shown in the Figure 6:19 using a single op-amp, provides 
high performance using both negative and positive feedback around the amplifier 
[183].   
Chapter 6 – Design and realisation of the electronic circuitry 
_______________________________________________________________ 
- 169 - 
 
 
Figure 6:19  - Active operational amplifier notch filter circuit [183]. 
However the components should match at least 1% or better to obtain a notch 
depth 45dB. Also the quality factor (Q) cannot be varied in this arrangement. In 
order to ensure the optimum operation, the source impedance should be less than 
100Ω and the load impedance 2MΩ [183]. 
Therefore in order to be able to vary the Q and also impedance matching 
problems, active twin T notch filter circuit was used in this application.  
The variable Q function for the notch filter is provided by the 1kΩ potentiometer 
R4. The notch frequency is determined by  Equation 6-11. 
CR
f notch pi2
1
=  Equation 6-11 
In order to provide the notch frequency of 50Hz, the following component values 
were used. C1 = C2 = 1.49nF; C3 = 3.05nF; R1 = R2 = 2.12MΩ; R3 = 1.06MΩ. 
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Figure 6:20  - Active twin T notch filter circuit with variable Q [183]. 
The two amplifiers are from a TS358 dual operational amplifier package which is 
powered by ±5V supply. The power supply lines are decoupled using 100nF 
capacitors to reduce the power line interference.  
The resultant circuit was tested on the Tektronix TDS 2004B four channel digital 
storage oscilloscope. 
The potentiometer was adjusted until good rejection of the notch frequency is 
obtained. The frequency response of the notch filter is shown in the Figure 6:21. 
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Figure 6:21 - Shows the frequency response of the notch filter. The input to the notch filter is a 
sinusoidal wave with amplitude 10.2V. 
Analysing the above diagram, the notch frequency is at 50.026Hz and the 
attenuation at notch is 41.28dB. 
It is advantageous to lower the Q to ensure some rejection over wider range of 
frequencies [184]. 
High-pass filtering 
As shown in the Figure 6:17, the output of the pre-amplifier has a DC offset of 
536mV, this signal needs to be filtered before further amplification, otherwise 
this may cause saturation of the signal. As the signal needs high pass filtering as 
well as further amplification, a multiple feedback high pass filter with gain was 
chosen.  
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The designed filter is a 2nd order Butterworth multiple feedback filter with cut-off 
at 10Hz and gain of 10. In order to determine the component values, the 
following design equations were used. 
The transfer function is given by: 
22
2
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ss
As
V
V
ωαω ++
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=  Equation 6-12 
Where, A  = voltage gain; s  = complex frequency ( ωj ); cω  = cut-off frequency; 
α  = 1/quality factor (Q) = 
2
1 for Butterworth 
From Appendix 2, multiple feedback filter design: re-arranging the  Equation 
6-12 gives, 
41 ACC =  Equation 6-13 
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By solving the  Equation 6-13,  Equation 6-14 and  Equation 6-15 
the following components values were obtained. C1 = 100nF, R2 = 53.59kΩ, C3 = 
100nF, C4 = 10nF, R5 = 4.73MΩ 
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Figure 6:22 - Multiple feedback high pass filter 
The amplifier used is from the TS358 dual operational amplifier package and 
powered by ±5V, where the power lines are decoupled using 100nF capacitors. 
The filter was tested using the TTi TGA1241 arbitrary waveform generator and 
the Tektronix TDS 2004B four channel digital storage oscilloscope. The Figure 
6:23 represents the frequency response of the high pass filter. 
 
Figure 6:23 - Shows the frequency response of the high pass filter with gain of 10.  
The input to the filter is a sinusoidal wave with amplitude 520mV. 
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According to the Figure 6:23 the attenuation at 1Hz is 8.3dB (including the gain 
of 10). 
Low-pass filtering 
One of the SENIAM recommendation for filtering EMG signal is to use a low-
pass filter with cut-off frequency of about 500Hz to remove unwanted high 
frequency interference [168]. Further gain is also introduced at this stage using an 
active filter. The designed filter is a 2nd order Butterworth multiple feedback filter 
with cut-off at 500Hz and gain of 10. In order to determine the component values, 
the following design equations were used. 
The transfer function is given by; 
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Where, A  = voltage gain; s  = complex frequency ( ωj ); cω  = cut-off frequency; 
α  = 1/quality factor (Q) = 
2
1 for Butterworth 
From Appendix 2, multiple feedback filter design: re-arranging the  Equation 
6-16 gives, 
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RR 41 =  Equation 6-17 
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By solving the Equation 6-17, Equation 6-18 and Equation 6-19 the following 
components values were obtained. R1 = 10kΩ, C2 = 100nF, R3 = 8.92kΩ, R4 = 
100kΩ, C5 = 1.136nF 
 
Figure 6:24 - Multiple feedback low pass filter 
The amplifier used is from the TS358 dual operational amplifier package and 
powered by ±5V, where the power lines are decoupled using 100nF capacitors. 
The filter was tested using the TTi TGA1241 arbitrary waveform generator and 
the Tektronix TDS 2004B four channel digital storage oscilloscope. The Figure 
6:23 represents the frequency response of the low pass filter. 
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Figure 6:25 - Shows the frequency response of the low pass filter with gain of 10.  
The input to the filter is a sinusoidal wave with amplitude 520mV. 
 According to the Figure 6:23, the filter has a cut-off slope of 34.8dB/decade. 
Full wave rectification 
Currently the filtered EMG signal has two polarities; however it is required to 
determine the amplitude therefore this signal needs to be rectified. The 
conventional full-wave diode rectifiers cannot rectify signals whose amplitudes 
are less than threshold voltage (approximately 0.7V) of the diode [185, 186]. 
Precision rectifier is implemented with an op-amp and includes diode in the 
feedback loop. This effectively cancels the forward voltage drop of the diode, so 
very low level signals can still be rectified with minimal error [187]. There are 
various precision rectifier circuits available, but due to the simplified design and 
the easiness of choosing the components, the following design recommended by 
Burr-Brown was used.  
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Figure 6:26 - This precision rectifier requires two amplifier and the two resistors R1 and R2. 
The amplifiers used are TL082 low power dual FET operational amplifier. The 
main reasons for choosing this are low power, dual packaging and high gain 
bandwidth product (GBW) of 4MHz. An amplifier with high GBW is important 
for this application, as the rectified signal has high frequency component present. 
The amplifiers are powered by ±5V and are decoupled using 100nF capacitors.  
The input signal is high pass filtered with time constant 32ms (5Hz) to remove 
any further DC components present. R3 = 30kΩ for input bias current 
compensation, while C2 is 1.06µF.  
 
Figure 6:27 - (a) During the positive half of the cycle the circuit acts like a voltage follower. (b) 
During the negative half the circuit acts as a simple inverting amplifier. 
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During the positive input signal diode D1 become reverse biased. The current 
flows through the forward biased D2 to the non inverting input of the second 
amplifier. Since there is no feedback path, no current flows through R1 and R2. 
Therefore the second amplifier act as a voltage follower, resulting the Vout = 
Vin. During the negative half D2 becomes reverse biased and the output of the 
first amplifier drives the resistor R1 through forward biased diode D1. The 
second amplifier acts as a unity gain inverter, resulting Vout = - Vin. The 
capacitor C1 ensures the circuit is stable with the second amplifier in the 
feedback loop. According to the application bulletin [188] for good stability and 
best speed R1.C1 = 1/4th GBW of the second amplifier. Therefore calculation 
resulted C1 = 15.9pF. R1 = R2 = 10kΩ and matched to 0.001% using Wayne 
Kerr 6500B precision impedance analyser. R4 was chosen to be 20kΩ to provide 
path for bias current of the second amplifier.  
The full-wave rectification circuit was tested using the TTi TGA1241 arbitrary 
waveform generator by injecting sinusoidal waveform with different frequencies 
and the Tektronix TDS 2004B four channel digital storage oscilloscope for 
monitoring the output. 
According to the Figure 6:28, there is slight distortion of the leading edge of the 
rectified output for the input frequencies 250Hz and 500Hz. This can be 
improved by using an amplifier with higher GBW. For the EMG signal 
processing in this application, this will not be a problem. Therefore the circuit 
remains unchanged. 
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Figure 6:28 - Shows the input and the output to the full-wave rectification circuit at different frequencies. (a) 10Hz , (b) 100Hz, (c) 250Hz and (d) 500Hz.   
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Smoothing 
Smoothing is an essential part followed by full-wave rectification. In order to 
compare the processed signal with the set threshold, this ripples needs to be 
smooth. The easiest and cost effective method to remove this is by using RC 
filter. However there will be small ripple drop across the series resistor [189], but 
as the signal will be used for comparison it would not be a problem. The effect of 
RC filter to the ripple voltage is shown in the Figure 6:29 and in the  Equation 
6-21. 
 
Figure 6:29 – In a RC filter, at position 1, the voltage across the capacitor is V0.  
The capacitor discharges through the resistor for a time t until the voltage reaches position 2. From 
position 2 to 3, the capacitor recharges [190]. 
During the period from 1 to 2     
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In clinical studies to obtain required amount of smoothing digital filter with time 
constant is 1s was used. However this will slow down the response, therefore 
when building the electronic circuitry two stage of filtering being used. One is 
single pole passive low pass filter and the other is two pole active low pass filter. 
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The reason for choosing the passive filter is to get rid of the high frequency ripple 
before the active stage. 
The designed passive filter has a cut-off frequency of 5Hz and is shown in Figure 
6:30 . RC values were chosen according to the CR=τ  Equation 6-3 and 
τpi2
1
=f  Equation 6-4. 
 
Figure 6:30 - 1st order passive low pass filter with cut-off frequency 5Hz. 
The response of the passive filter is shown in the Figure 6:31. 
 
Figure 6:31 - Shows the frequency response of the 1st order passive low pass filter.  
The input to the filter is a sinusoidal wave with amplitude 1V. 
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According to the Figure 6:31, the filter has the cut-off slope of 17.07dB/decade. 
For the active filter stage Sallen-Key 2nd order low-pass filter was used. The 
reason for choosing the Sallen-Key is to obtain non-inverted signal at the output 
as well as to obtain faster response. The filter was designed using the calculations 
provided by Bronzite [191] and is shown in the Figure 6:32.  
 
Figure 6:32 - 2nd order Sallen-key filter with cut-off frequency 7.2Hz. 
 The amplifier used is TL082 and the power lines are decoupled using 100nF capacitors.  
The filter response is shown in the Figure 6:33. 
 
Figure 6:33 - Shows the frequency response of the 2nd order active low pass filter. The input to 
the filter is a sinusoidal wave with amplitude 1V. 
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According to the Figure 6:33, the filter has the cut-off slope of 24.08dB/decade. 
Comparator 
Comparator is a circuit that compares the input voltage with same reference 
voltage. The output voltage of the amplifier flips from one saturation limit to the 
other as the processed EMG signal reaches above the preset threshold. This 
threshold level can be varied by adjusting the potentiometer as shown in Figure 
6:34. 
 
Figure 6:34 - Simple comparator circuit designed using TL082 amplifier and is powered by 5V. 
The built circuit for the amplifier and the signal processing system is shown in 
Figure 6:35. 
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Figure 6:35 - Amplifier and signal processing circuit. 
6.4 Stimulator design 
When the processed EMG signal reaches above the predetermined threshold, a 
burst of stimulation should be delivered to the patient through the stimulating 
electrodes. Since the device is small and portable, the stimulator should be 
designed with few components. Section 6.4.1 describes some major 
considerations in designing a simple stimulator.  
6.4.1 Background 
Safety considerations 
Electric shock may result in fatal burns and can cause muscle and even heart to 
malfunction. Often the degree of damage depends on the magnitude of the current 
applied, how long the current applied and which points through the current passes 
[192]. 
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Type of stimulators 
Stimuli parameters vary widely according to the type of muscle stimulation, the 
number of channel and the type of electrodes. Many commercially available 
stimulators are constant voltage stimulators, in which delivered current level 
varies with change in electrode-skin impedance. Even though it is easy to design 
an additional circuitry is required to monitor the current level [193]. However in 
this device focus has been made to designing a simple constant current stimulator. 
6.4.2 System that is being used in clinical setting 
For the experiments described in the chapter 5, a commercially available constant 
current stimulator (DS7A) was used. The stimulation parameters were set in 
Spike software (Figure 6:36) and passed over to the stimulator via the data 
acquisition card shown as in the Figure 6:2. 
 
Figure 6:36 – Spike software code for setting the stimulator parameters. 
The software code shown opens up a dialog box to the user to enter the stimulation parameters. The 
stimulating frequency can be set between 1Hz to 100Hz and the stimulating period can be set between 
1s to 6000s. 
 
Even though the stimulating frequency and the period can be varied, in clinical 
experiments these parameters were set at fixed values of 15Hz and 60s 
respectively, which were said to be the optimum stimulating parameters from 
previous studies [162]. Reducing the variables simplifies the circuit design.  
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This stimulator was developed by Digitimer Ltd and is shown in the Figure 6:37. 
The specification of the DS7A stimulator is highlighted in Table 6-3. 
 
Figure 6:37 - Shows the Digitimer DS7A constant current stimulator. 
This is FDA and MDD compliant for clinical use. The trigger signal is connected to the stimulator 
through DAC. The output of the DS7A is connected to the stimulating electrodes of the device 
through 4mm shrouded sockets [194].  
 
Table 6-3 - The specification of the DS7A constant current stimulator [194]. 
Current 
0 to 99.9mA when the dial is in x10 
position 
Pulse duration (µs) 50, 100, 200, 500, 1000 and 2000 
Compliance Variable from 100V to 400V 
Trigger level +3V on the rising edge 
Maximum trigger input ±15V 
Minimum pulse duration for the trigger 5 µs 
Maximum trigger frequency 1000 pulses /s 
 
The stimulating current, pulse of width of 200µs and the compliance voltage of 
200V were set using the adjustments on the front panel of the stimulator. The 
stimulation off period of 3s was set using the software in order for the signal 
processing and the physiological function to recover following the stimulation.  
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6.4.3 Derivation of the specification for the stimulator 
Comparing the system that currently being used, the specification of the proposed 
stimulator circuit can be derived as shown in the Table 6-4. 
Table 6-4 - The specification for the simple stimulator circuit. 
Current Variable between 10mA to 80mA 
Stimulation on time 60s 
Stimulation off time 3s 
Stimulating voltage (maximum) 200V 
Frequency 15Hz 
Pulse width 200µs 
Charge balancing RC circuit 
 
The above specification was realised in the design shown in the section 6.4.4, 
while isolating the signal processing and the patient interface from the stimulating 
circuitry. 
6.4.4 Realisation of the stimulator 
The stimulator circuit is made up with four functional units. Those are circuits for 
adjusting the stimulation on and off time, the width of the stimulating pulse, 
isolation barrier and the delivering constant current pulse per each trigger signal.  
Stimulation duration adjustor 
When the output of the comparator goes high, 60s of stimulation needs to be 
delivered. At the end of this period, there is 3s stimulation off period whatever the 
output of the comparator. This stimulation off period allows the EMG amplifier 
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to recover after stimulating artefacts and also the bladder and sphincter muscles to 
recover following stimulation. 
 
Figure 6:38 – Logic circuit to adjust the stimulator duration. 
Output of the comparator, Q  of the Mono 60 and Q  of the Mono 3 connected to the three input 
NAND gate to generate 60s pulse for each time when the comparator output is high, while holding Q 
of Mono 60 low  
The above circuit was implemented using HEF4023BP Phillips triple 3-input 
NAND gate and 74HC4538N Phillips dual retriggerable precision monostable 
multivibrator. Detailed circuit diagram with all the sub components is presented 
in Figure 6:39. 
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Figure 6:39 - The stimulation duration adjustor circuit.  
HEF4023BP is the 3 input NAND gate and the 74HC4538N is a dual monostable multivibrator. 1Q is the 3s pulse output where as 2Q is the 60s pulse output. O3 is 
the output of the NAND gate. 
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74HC4538N and HEF4023BP both are powered by 5V power supply and the 
supply lines are decoupled using 100nF capacitors (C1 and C3). DR1  and  DR2  
are held high to prevent them resetting the output pulse immediately. In order for 
the circuit to act as a non-retriggerable monostable in which triggering will be at 
falling edge the following arrangement (Figure 6:40) was used as specified in the 
manufactures data sheet [195]. 
 
Figure 6:40 - Shows the arrangement of falling-edge triggered non-retriggerable monostable 
circuitry. 
The input is connected to the An and the nQ is connected to the nA . 
Diode D1 and D2 are 1N4148 diodes were used as a safety precaution. In an 
instance of sudden power drop the charge stored in capacitors C2 and C3 will 
discharge through the monostable and may damage the input protection diodes.  
The output pulse width was determined by the RC time constant and based on 
Equation 6-22  specified by the data sheet. 
tt CxRxT 7.0=  Equation 6-22 
Based on the calculations 3s pulse width require C2 = 1µF and R1 + R2 = 
4.105MΩ, whereas 60s pulse require C4 = 10µF and R3 + R4 = 8.205MΩ. 
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9.2.13 IQQO =  Equation 6-23 
O3 is the trigger input of the 60s pulse, and 2Q is the trigger input of the 3s pulse. 
The Figure 6:41 and Figure 6:42 show the verification of the above circuitry. 
 
Figure 6:41 – Monostable output - 1. 
The orange wave shows the output of the comparator goes high. At the active high edge of the 
comparator, the 60s pulse (blue waveform) goes high for 60s followed by 3s pulse (purple waveform) 
goes high. At the end of the 3s pulse, since the output of the comparator is low, the 60s pulse remains 
low. 
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Figure 6:42 – Monostable output – 2. 
At the active high edge of the comparator (orange) the 60s pulse goes high followed by 3s pulse. At 
the end of the 3s pulse, as the comparator still remains high another 60s pulse is triggered and this will 
repeat as long as the comparator output is high. 
The 60s pulse (2Q) is then connected to the astable in order to adjust the 
stimulation pulse width. 
Stimulation pulse width adjustor 
When the stimulation duration is determined, the next step is to adjust the 
stimulation pulses. According to the specification derived in section 6.4.3, the 
stimulation frequency should be 15Hz and each should be 200µs wide and should 
be as shown in the Figure 6:43. 
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Figure 6:43 - 200µs stimulation pulses. 
Duty cycle of an astable circuit is given in the  Equation 6-24. 
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For the circuit operation the duty cycle should be close to 50% or higher [196]. 
Therefore the astable was designed to produce opposite of what was required and 
then was inverted with the spare NAND gates on the circuit and multiply with the 
60s pulse. 
 
 
 
 
 
The above circuit was implemented using NE555P Texas Instruments precision 
timer and spare NAND gates were used to implement NOT and the AND gate 
and the circuit diagram is shown in the Figure 6:45. 
 
ASTABLE 
  & 
60s 
Figure 6:44 - Output of the astable was inverted and multiplied with the 60s pulse in order to 
produce stimulation pulses with duty cycle of 0.3%. 
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Figure 6:45 - The stimulator pulse width adjustor circuit consists of NE555 astable and NAND 
gates. 
The astable was powered using 5V supply and the supply line was decoupled 
using 100nF capacitor (C2). The reset pin was connected to 2Q (60s pulse), 
which switches on the operation of astable circuit.  
Capacitor C1 and resistor values were determines using the following formula, 
with the duty cycle set to 99.7%. 
( ) 1693.0 CRRt BAH +=  Equation 6-25 
( ) 1693.0 CRt BL =  Equation 6-26 
where RA = R3 + R4 + R5 and RB = R1 + R2. 
Using  Equation 6-25 and  Equation 6-26 the following component values were 
obtained RA = 9.54kΩ, RB = 28.8Ω and C1 = 10µF. 
The output of the astable (OUT) was then connected to the 3-input NAND gate, 
where all the inputs are connected together to act as an inverter. The output of the 
inverter (O1) and the 2Q (60s pulse) were NAND to produce the inverted 
stimulation pulses, which was connected to the optocoupler input. 
Chapter 6 – Design and realisation of the electronic circuitry 
_______________________________________________________________ 
- 195 - 
 
The Figure 6:46 shows the output of the stimulation pulse width adjustor circuit. 
 
Figure 6:46 – The output of the stimulation pulse width adjustor circuit. 
The orange wave shows the 60s pulse (2Q) and the blue shows the output of the astable (OUT). These 
two signals were then connected the NAND gate and the output of the NAND gate (O2) is shown in 
the purple waveform. The spacing between the stimulation impulses showed as non-linear, however 
when this signal is expanded, the stimulation pulses are linear. 
In Figure 6:46 some of the stimulation pulses are missing from the actual 
displayed image, this is due to the effect known as aliasing and in common in 
digital images. This can be occurred either sampling stage or the reconstruction 
stage. According to the oscilloscope user manual the sampling rate on each 
channel is 1GS/s, this is well above the Nyquist frequency; however at a certain 
recorded time, this oscilloscope can only display 2500 points across all channels 
and as the display is nearly 120s long, the number of pixels is not sufficient to 
display all the stimulation pulses.  
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The output of NAND gate (O2) was then passed on to stimulator circuit through 
the isolation barrier. 
Isolation barrier 
When the 200µs pulse reached the final stage, these pulses need to be passed 
through a constant current stimulator. As the high voltages are used in delivering 
the stimulation pulses, this section needs to be isolated with the rest of the circuit 
and the recording site of the patient. The reason for this isolation barrier is to 
avoid the artefact of the stimulation flowing into the reference electrode.    
The stimulator requires two supply voltages of 200V and 5V, which are isolated 
as well as the stimulation pulse adjustor signal. And the following components 
were used to provide this. 
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Figure 6:47 - Isolation power supply circuit for the stimulation consist of two DC-DC converters 
and an optocoupler. 
LME0505SC is a DC-DC converter by Murata Power Solution (Figure 6:48) 
which provides isolated 5V output for input of 5V and has an isolation voltage of 
1kV. 
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Figure 6:48 - LME0505SC 5V DC-DC converter. 5Vis is the isolated 5V output and GNDis is the 
isolated ground. 
C1 and C2 are 100nF decoupling polyester capacitors to remove high frequency 
interference; whereas C3 is 35V 33µF electrolytic capacitor to remove low 
frequency noise.  
PICO5A200S is an unregulated DC-DC converter by PICO Electronics (Figure 
6:49) which produces isolated 200V from 5V input and has an isolation voltage 
of 500V. 
 
Figure 6:49 - PICO5A200S 5V to 200V DC-DC converter. 200Vis is the isolated 200V output and 
GNDis is the isolated ground. 
C1 is low voltage 100nF decoupling capacitor and C2 is 10nF is 1000V 
decoupling capacitors to remove high frequency interference; whereas C3 is 
450V 10µF electrolytic capacitor to remove low frequency noise. Diode D1 is a 
220V zener diode to regulate the output of the DC-DC converter. 
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HCPL2503 is an optocoupler by Fairchild Semiconductor, which produces 
isolated output stimulating pulses for the input pulses and has an isolation voltage 
of 480V. 
 
Figure 6:50 - HCPL2503 is an optocoupler consist of LED optically coupled to a high speed 
photo detector transistor. 
The optocoupler is powered by isolated 5V supply and has a decoupling capacitor 
(C1) of 100nF. R1 is 10kΩ pull-up resistor. I/P to the optocoupler is from the 
output of the pulse width adjustor circuit and the output of this is passed to 
PMOS, which will be described later. Once the circuit is connected as shown in 
the Figure 6:50, there was a drop in input current to the optocoupler and this is 
shown in the Figure 6:51.  
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Figure 6:51 - Blue waveform is the output of the astable and the purple waveform is the input to 
the optocoupler when the HCPL2503 is in place. 
Therefore the current level needs to be boosted and for this purpose an emitter 
follower circuit was built and is shown in the Figure 6:52. 
 
Figure 6:52 - An emitter follower circuit to boost the current entering the optocoupler. 
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In order to provide the required current boost, R6 and R7 were chosen to be 430Ω 
and 100Ω. The output of this emitter follower was then connected to the input of 
the optocoupler. 
These isolated power lines and the isolated stimulating pulse will be used in 
constant current stimulator circuit to deliver the stimulating pulses.  
Constant current stimulator 
The final part of the circuitry is the constant current stimulator, which will be 
switched on and off for the input trigger pulse and also has an arrangement to 
vary the output current level. Figure 6:53 illustrates this arrangement.  
 
Figure 6:53 - Constant current stimulator circuit.  
The anode is connected to the 200V line and when the pulse reached the PMOS and passed over to the 
amplifier and the transistor setup the potentiometer R1 controls the amount of current to be passed 
through. 
The isolated trigger pulse connected to the gate of the p-channel MOSFET, which 
acts as a switch. The logic 0, switches on this MOSFET connecting the source to 
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the drain. The drain of the PMOS connected to the potentiometer R1 (100Ω), 
which varies the amplitude of the stimulating trigger pulse. 
 TLC251CP is powered by 5Vis and decoupled using 100nF capacitor. R3 was set 
to 10Ω and bias select pin of the op amp is connected to the GNDis to increase the 
amplifier performance [197].  
The difference in voltages of the inverting and non-inverting is fed to the base of 
the BF459. As the collector current increases due to increase in load voltage, the 
voltage at the inverting input also increases. This decreases the voltage 
difference, so does the base-emitter voltage, counteracting the increase in output 
current.  
R2 and C1 combination is charge balancing circuit. According to the Figure 6:53, 
the stimulation off time is about 66ms and if the stimulating charge to be 
discharges within half this time the values of R2 and C1 can be derived as shown 
below.  
1.2 CRdisc =τ  Equation 6-27 
If 2R  = 10kΩ and discτ  = 30ms, results 1C  = 3µF. Therefore a 250V 3.3µF 
capacitor was chosen as C1.  
The above design was tested on the oscilloscope with a load resistor of 1kΩ 
between the anode and cathode and the results are shown in Figure 6:54 and 
Figure 6:55 
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Figure 6:54 – Stimulation pulsesThe orange wave shows the 60s pulse (2Q) and the blue shows 
the output of the astable (OUT). Purple waveform shows the output of the optocoupler and 
stimulator pulses with a frequency of 15Hz shown in the green waveform. 
 
Figure 6:55 – Shows the stimulating pulse of pulse width of 200µs. 
The stimulating electrode impedance (726Ω at 26.350) was measured when the 
device in the body by measuring from the impedance analyser. The load was 
200µs 
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represented by using a resistor (680Ω) and a capacitor (20nF) by calculating the 
impedance at 1kHz.  
In order to determine the effect of supply voltage level, the transfer characteristics 
of the stimulator was measured. The DC to DC converter was disconnected from 
the circuit and replaced with a variable power supply. Differential probe of the 
oscilloscope was connected across the 680Ω resistor in order to measure the load 
current. When the supply voltage is at 200V the load current was set to 10mA, by 
adjusting the R1 potentiometer. The supply voltage was reduced from 200V to 
0V in steps of 10V, while measuring the load current from the oscilloscope. This 
experiment was repeated for the load currents of 40mA and 80mA, and the results 
are displayed in Figure 6:56. 
 
Figure 6:56 - Transfer characteristics of the stimulator 
The stimulator circuit that was built is shown in Figure 6:57. 
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Figure 6:57 - The stimulator circuit. 
6.5 Overall system testing 
All of the design and testing of the each individual unit were done using the 
bench apparatus. However the real situation cannot be demonstrated in this 
manner. Therefore it is essential to test the device with biological signals.  
In order to test the system using biological signals, the system was powered by 
two 9V PP3 batteries and monitored using the oscilloscope through a differential 
probe due to the safety considerations. EMG signals were recorded from the 
thenar muscle whereas the stimulating electrodes attached to the wrist using self-
adhesive surface electrodes. The skin was cleaned using alcohol wipes and 
conducting gel was applied to maintain good conductivity. The muscle was 
voluntarily contracted to investigate whether the output of the comparator goes 
high and the stimulator was set up to switch on automatically. Section 6.6 
highlights the output of each stage with biological signals.  
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6.6 Results and discussion 
 
 
 
 
 
 
 
 
Figure 6:58 – Testing the processing circuit on thenar muscle EMG  
EMG signals are recorded from the thenar muscle using three electrodes. (a) output of the pre-amplifier (b) output at the notch filter stage (d) output of the high pass filter (e) 
output after the low pass filtration (e) filtered rectified signal output just before smoothing (f) the smoothed signal (green) and threshold of  the comparator was set at 1.08V. 
 
 
 
Stimulator 
 
 
 
 
 
 
(a) (b) (c) 
(f) (e) (d) 
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At the output of the pre-amplifier, the EMG contraction and noise can be clearly 
distinguished. The noise level is further minimised at the output of the notch 
filter. This signal was then passed onto band-pass filtration to remove DC offset, 
movement artefact and high frequency noise. The full-wave rectification produces 
reliable output with low offset level. The three pole smoothing resulted a signal 
that can be used as a triggering signal for stimulation. The threshold level of the 
comparator can be varied and when an EMG contraction is detected, the signal is 
sent to the stimulator to deliver the pulses.  
6.6.1 Power management 
If the device is switched on throughout the day, the amplifier and the processing 
circuit will always be switched on. By measurement the recording part of the 
circuit consumes 25mA. Therefore the charge required to leave the device on for 
24 hours = 25mA x 24h = 600mAh. 
During the stimulation the current consumption in the stimulating circuit is about 
125mA, when stimulated with an average current of 60mA. For stimulation, 15 
pulses per second each of width 200 µs, therefore the time that the device is on 
for 60s stimulus duration is 200 µs x 15 x 60 = 180ms per stimulation 
Clinical studies showed that each fill, around 15-20 stimulation is required to 
increase the bladder capacity to 500ml, therefore during one day, the stimulation 
will be required about 60 times. Therefore the total duration of the stimulation 
required per day = 180ms x 60 = 10.8s 
If the maximum current used during stimulation is 125mA, the total charge 
required is 125mA x 10.8s = 0.375mAh. 
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Therefore the total charge requires per day is about 600mAh. If 1Ah battery was 
used, it can be used nearly 2 days without recharging.  
6.6.2 Other considerations 
Enclosure for the electronic circuit must be waterproof (IP67) and should be easy 
to hold and control using single hand. The battery changing compartment should 
be easily accessible by the user, and the enclosure must have a belt clip for the 
user to be worn it easily. The maximum allowable size of the box is 10cm x 7cm 
x 3cm. Furthermore the box should also be able to worn on the thigh.  
The box should have on/off switch and a button to override the stimulation. 
Furthermore an indicator for battery low sign and another indicator to show any 
fault in the system.  
The cable from the device should have a mini DIN plug and equivalent socket on 
the box too.  
6.7 Conclusion 
The overall system noise was not an issue in signal processing or picking up the 
EMG contractions. However the noise can be further reduced by the following 
methods. 
• When the system is integrated, the pick up from mains interference will be 
low (because picking up through cables). 
• The attachment of the pre-amplifier to the skin near the electrode site 
reduces noise pick up and minimise any degradation of the CMRR arising 
from the differences between the cable resistances [168]. 
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Introducing a notch filter does reduce the mains interference, but it cannot 
discriminate between hum and the component of the EMG signal at 50Hz, so that 
the filter distorts the signal [171] [170].  
The input signal processing and the stimulation system is isolated using DC to 
DC converters and optocoupler, which provides an isolation barrier of 480V.  
The stimulator supply voltage was set to 200V, however if the maximum voltage 
required during stimulation can be measured and the system should be modified 
accordingly, this might result in less current consumption. 
By using 1Ah battery, the system can run for 2 days, without needing to be 
recharged. However if the system can be modified with low power components, 
this time may increase.  
The system mentioned in this chapter was a prototype design, which can be 
modified with surface mount components in order to obtain the miniaturised and 
low power circuit. 
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Chapter 7 -  Conclusions and future work 
7.1 Summary 
Urinary incontinence affects one in three of the population at some stage in their 
adult lives.  This leads to a poor quality of life for sufferers and their families and 
has significant impact on society. Neurogenic detrusor overactivity is a common 
observation (16%) in patients with urinary incontinence and is characterised by 
involuntary detrusor contractions at low bladder volumes. The conventional 
method of treating NDO is antimuscarinic drugs to relax the detrusor muscle, 
which are not well tolerated by about 50% of patients mainly due to side effects. 
Electrical stimulation systems currently available for bladder dysfunction have 
disadvantages such as risk of implantation and stimulation becomes ineffective 
due to habitation. Therefore these systems are not widely acceptable among the 
patients. A novel device was developed in order to overcome the above stated 
problems. The background leading to this development is explained in detail in 
chapter 1 together with the aim of the project “to develop a novel wearable anal 
device designed to deliver conditional neuromodulation and ultimately prove its 
principle in small scale clinical study.” 
Chapter 2 describes the basic anatomy and physiology knowledge required in 
order to understand the working concept of the device. A review of electrical 
stimulation for treating bladder dysfunction, since its first use by a pioneering 
Danish surgeon in 1878 was described in this chapter. 
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Chapter 3 focuses on the semantics of the operation of the device. The design 
requirements were derived based on the disadvantages of currently available 
treatment options. Considering the design requirements, the best method for 
detecting NDO was by recoding external anal sphincter EMG, which acts as a 
surrogate to the urethral sphincters during dyssynergia. Similarly trans-rectal 
stimulation was decided as the best option for intra-anal device. Using these two 
techniques a closed loop electrical control system was realised and incorporated 
as the project concept. Furthermore the proposed device was named as 
“ACONTI” (Anal Conditional Neuromodulator for Treating Incontinence), based 
on its principle of operation.  
After deriving the principle of ACONTI operation, the next step was to come up 
with a patient acceptable model. The actual shape of the device was designed 
based on the anatomy of the anal canal as well as literature of anal and vaginal 
devices. Medical grade liquid silicone rubber was used as the device body 
material, while medical grade stainless steel was used for the electrodes. The 
ACONTI was made in clean room environment and the procedure was explained 
in the chapter 4. 
The next step was to determine the efficacy of the ACONTI within the clinical 
environment, which is described in chapter 5. There are two stages for detecting 
the conditional signal and treating NDO through neuromodulation. The clinical 
trials were carried out on spinal cord injured people with NDO in Royal National 
Orthopaedic Hospital, while giving special attention to good clinical practice. 
This study concluded that the external anal sphincter EMG recorded through the 
device provides a reliable signal with 100% sensitivity, for early detection of 
bladder contractions. Most importantly conditional stimulation through the device 
successfully suppressed the detrusor contractions in six out of eight patients, 
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resulting significant increase in their bladder capacity by 220% compared to the 
control study as well as significant reduction in maximum detrusor pressure by 
48%.  
In order for the device to be practical for daily use, it should act as a self-standing 
system. The design of the electronic circuitry required for this operation is 
described in chapter 6. The system consists of two main circuits for amplification 
and signal processing as well as for stimulation. The specification for these 
circuits was derived by evaluating the parameters that were used in the clinical 
study. The gain of the recording circuit was set to 20000, which can be modified 
easily and the amplifier has common mode rejection ratio of 88dB. The constant 
current stimulator can deliver stimulating currents between 10mA to 80mA with 
maximum stimulating voltage of 200V.  
7.2 Achievements 
Achievements of this research can be summarised as follows. 
• Derived a practical principle for the operation of the ACONTI.  
• Designed and implemented a patient acceptable model of ACONTI based 
on the anatomy of the anal canal. 
• The conditional neuromodulation through the device significantly 
increased the bladder capacity by 220%.  
• Designed an electronic circuit, which is capable of providing conditional 
neuromodulation through the ACONTI device. 
• Realised a system, which can be used to optimise the stimulating 
parameters of the device and verified that with the current configuration of 
electrodes do stimulate the afferent and efferent branches of the pudendal 
nerve.  
Chapter 7 – Conclusions and future work 
_______________________________________________________________ 
- 213 - 
 
7.3 Future work 
As the ultimate goal of this project is to increase the quality of life of people with 
NDO, there is further work that needs to be carried out to reach this goal. 
7.3.1 Clinical testing 
This was a proof of principle clinical study to test the operation of the device and 
demonstrated on spinal cord injured men. However, to determine the efficacy of 
the ACONTI on wider community, testing should be carried out on both men and 
women with NDO due to other causes such as multiple sclerosis, Parkinson’s 
disease. 
By modifying the device with pressure transducers may lead to use of the device 
for treating other types of incontinence such as stress and mixed incontinence. 
These transducers can be added to the superior position of the device. By 
measuring the abdominal pressure through these transducers, a trigger level can 
be set to activate the stimulation. As this is a simple modification, it would be an 
advantage of proceeding further with this concept. 
7.3.2 Optimising the device 
The current version of the ACONTI device is the first prototype model 
developed. In order to optimise the recording and stimulating parameters the 
ACONTI should be modified further. 
Shape 
Due to a manufacturing limitation, the recording electrodes are situated about 
1600 apart. The literature has shown if the two recording electrodes can be made 
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1800 degrees apart, will lead to an increase in the signal to noise ratio of the 
external sphincter EMG. A similar increase can also be expected by pushing the 
recording electrodes further into the external anal sphincter by widening the 
recording end of the ACONTI. 
The field experiment study should be conducted on different shapes, sizes of the 
electrodes as well as for the stimulating parameters to decide the best possible 
arrangement to achieve effective stimulation with a lowest possible current. The 
findings should be incorporated in to the design of the ACONTI.   
With the available anatomical literature it was assumed that when the ACONTI is 
in the anal canal, the stimulating head sits on the ano-rectal junction. Therefore, it 
is important to determine the exact positioning of the electrodes using MRI, when 
the ACONTI is in the anal canal. Results of this will demonstrate the variation of 
the ACONTI dimensions on different people and if required devices of different 
sizes should be constructed.  
Warning indicator 
Chapter 3 shows a requirement of a warning indicator for patients who are 
unaware about their bladder contractions. It would be ideal to introduce this 
feature into the ACONTI via a body area network or through a wireless 
communication link such as Zarlink ZL70100.  
Electronic circuitry 
The electronic circuit was designed on a matrix-board. It would be better to 
develop a printed circuit board (PCB) for this design and put this into a box, 
which will be attached to a belt for the person to wear. 
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Ultimately this electronic circuitry can be miniaturised and embeded inside the 
ACONTI with a rechargeable battery on the anchor handle. The Zarlink wireless 
communication system can be added for programming the system.  
7.3.3 Regulatory approval 
In order to carry out clinical testing on different types of incontinence, it is 
required to obtain the approval from Medicine and Healthcare products 
Regulatory Agency’s (MHRA). 
 
 
 
 
 
References 
 
 [1]  Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, 
vanKerrebroeck P, Victor A and Wein A. The standardisation of 
terminology of lower urinary tract function: Report from the standardisation 
sub-committee of the international continence society. American journal of 
obstetrics and gynecology 187[1], 116-126. 1-7-2002.  
Ref Type: Report 
 [2]  Bladder and bowel foundation. How common are bladder and bowel 
problems. Website . 2007. 9-4-2011.  
Ref Type: Electronic Citation 
 - 216 - 
 
 [3]  Vulker R, International Group Seeks to Dispel Incontinence "Taboo". 
Journal Of the American Medical Association 280, 951-953 (1998). 
 [4]  NHS. Urinary Incontinence.  30-4-2008. 17-5-2010.  
Ref Type: Report 
 [5]  The Royal College of Physicians. Incontinence - Causes, management and 
provision of services.  1995.  
Ref Type: Report 
 [6]  Norton PA, MacDonal LD, Sedgwick PM and Stanton SL, Distress and 
delay associated with urinary incontinence, frequency and urgency in 
women. British Medical Journal 297, 1187-1189 (1988). 
 [7]  Hu T, Moore K, Subak L, Versi E, Wagner T, Zinner N and Ouslander J. 
Economics of incontinence. 14, 965-983. 2002.  International continence 
society.  
Ref Type: Report 
 [8]  McDonagh D and Reid A. Living with Urinary Incontinence: Placing the 
individual at the heart of design research and product development.  2010. 
Department of Design and Technology, Loughborough University, 
Leicestershire. 1-6-2010.  
Ref Type: Report 
 [9]  Porth CM and Matfin G, Disorders of the bladder and lower urinary tract. 
In Essentials of pathophysiology: Concepts of altered health states. (Ed. 
Surrena H) pp. 659-678, Lippincott Williams & Wilkins, 2010. 
 [10]  Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J and Wein AJ, How 
widespread are the symptoms of an overactive bladder and how are they 
managed? A population-based prevalence study. BJU international 87, 760-
766 (2001). 
 [11]  Koelbl H, Mostwin J, Boiteux JP, Macarak E, Petri E, Schafer W and 
Yamaguchi O. Pathophysiology. 4, 203-241. 2002.  International 
continence society.  
Ref Type: Report 
 [12]  Opisso E, Borau A, Rodriguez A, Hansen J and Rijkhoff NJ, Patient 
controlled versus automatic stimulation of pudendal nerve afferents to treat 
neurogenic detrusor overactivity. Journal of Urology 180, 1403-1408 
(2008). 
 [13]  de Groat WC, Booth AM and Yoshimura N, Neurophysiology of 
micturition and its modification in animal models of human disease, in the. 
 - 217 - 
 
In Nervous control of the urogenital system: Autonomic nervous system. 
(Ed. Maggi CA) pp. 227-290, Taylor & Franci, 1993. 
 [14]  Yoshimura N, Bladder afferent pathway and spinal cord injury: A possible 
mechanisms inducing hyperreflexia of the urinary bladder. Progress in 
Neurobiology 57, 583-606 (1999). 
 [15]  Bates CP, Bradley WE, Glen ES, Melchior H, Rowan D, Sterling AM, 
Sundin T, Thomas D, Torrens M, Turner-Warwick R, Zinner NR and Hald 
T, Fourth report on the standardisation of terminology of lower urinary 
tract function. Terminology related to neuromuscular dysfunction of the 
lower urinary tract. British journal of urology 53, 333-335 (1981). 
 [16]  Andersson KE, Antimuscarinics for treatment of overactive bladder. Lancet 
Neurology 3, 46-53 (2004). 
 [17]  Lai HH, Boone TB and Appell RA, Pharmacologic treatment for detrusor 
overactivity. Current urology reports 3, 365-372 (2002). 
 [18]  Freeman R and Malvern J, Drug treatment for detrusor instability. In The 
unstable bladder. pp. 45-54, Butterworth & Co, 1989. 
 [19]  The Royal Pharmaceutical Society of Great Britain, Drugs for urinary 
frequency, enuresis and incontinence. In BNF. pp. 445-448, RPS, London 
2008. 
 [20]  Yarker YE, Goa KL and Fitton A, Oxybutynin. A review of its 
pharmacodynamic and pharmacokinetic properties, and its therapeutic use 
in detrusor instability. Drugs & aging 6, 243-262 (1995). 
 [21]  Hopkinson BR and Lightwood R, Electrical treatment of incontinence. The 
British journal of surgery 54, 802-805 (1967). 
 [22]  Alexander S and Rowan D, Electrical control of urinary incontinence by 
radio implant. A report of 14 patients. The British journal of surgery 55, 
358-364 (1968). 
 [23]  Hopkinson BR, Electrical treatment of incontinence using an external 
stimulator with intra-anal electrodes. Annals of the Royal College of 
Surgeons of England 50, 92-111 (1972). 
 [24]  Janez J, Pelvnik S and Suhel P, Urethral and bladder responses to anal 
electrical stimulation. Journal of Urology 122, 192-194 (1979). 
 [25]  Pelvnik S, Vodusek DB and Janez J, Electrical stimulation treatment of 
bladder instability. In The unstable bladder. (Ed. Freeman R and Malvern 
J) pp. 81-92, Butterworth & Co., 1989. 
 - 218 - 
 
 [26]  Brindley GS, Polkey CE, Rushton DN and Cardozo L, Sacral anterior root 
stimulators for bladder control in paraplegia: the first 50 cases. Journal of 
Neurology, Neurosurgery and Psychiatry 49, 1104-1114 (1986). 
 [27]  Brindley GS, The first 500 patients with sacral anterior root stimulator 
implants: general description. Paraplegia 32, 795-805 (1994). 
 [28]  Craggs MD. Neuromodulation device for pelvic dysfunction. 
[WO/2007/101861]. 6-3-2006.  
Ref Type: Patent 
 [29]  Ciancio SJ, Mutchnik SE, Rivera VM and Boone TB, Urodynamic pattern 
changes in multiple sclerosis. Journal of Urology 57, 239-245 (2001). 
 [30]  Hansen J, Media S, Nøhr M, Biering-Sørensen F, Sinkjaer T and Rijkhoff 
NJ, Treatment of neurogenic detrusor overactivity in spinal cord injured 
patients by conditional electrical stimulation. Journal of Urology 173, 
2035-2039 (2005). 
 [31]  Kirkham AP, Shah NC, Knight SL, Shah PJR and Craggs MD, The acute 
effects of continuous and conditional neuromodulation on the bladder in 
spinal cord injury. Spinal Cord 39, 420-428 (2001). 
 [32]  Dalmose AL, Rijkhoff NJ, Kirkeby HJ, Nohr M, Sinkjaer T and Djurhuus 
JC, Conditional stimulation of the dorsal penile/clitoral nerve may increase 
cystometric capacity in patients with spinal cord injury. Neurology and 
Urodynamics 22, 130-137 (2003). 
 [33]  Craggs MD and McFarlane J, Neuromodulation of the lower urinary tract. 
Experimental physiology 84, 149-160 (1999). 
 [34]  Craggs M, Edirisinghe N, Leaker B, Susser J, Al-mukhtar M and 
Donaldson N, Conditional neuromodulation using trans-rectal stimulation 
in spinal cord injury. Neurology and Urodynamics 28, 836-837 (2009). 
 [35]  Chaurasia BD, The urinary bladder and the urethra. In Human Anatomy 
vol. 2. pp. 345-351, CBS, New Delhi 2006. 
 [36]  Ganong WF, Renal function and micturition. In Review of Medical 
Physiology. pp. 675-703, McGraw-Hill, San Francisco 2002. 
 [37]  Moore KL and Agur AMR, Urinary Organs - Pelvis and Perineum. In 
Essential Clinical Anatomy. pp. 203-270, Lippincott Williams & Wilkins, 
Toronto 2007. 
 [38]  Mathers LH, The autonomic nervous system. In The peripheral nervous 
system. pp. 123-157, Addison-Wesley, California 1985. 
 - 219 - 
 
 [39]  Hansen JT, Pelvis and perineum. In Netter's Anatomy: companion 
workbook. pp. 1-22, Elsevier, New York 2007. 
 [40]  Balasubramaniam AV. A neurophysiological assessment of the bladder 
guarding response in spinal cord injury.  2007. London, Institute of Urology 
and Nephrology, University College London.  
Ref Type: Thesis/Dissertation 
 [41]  Fjorback MV. Electrical stimulation for management of the overactive 
bladder in patients with multiple sclerosis.  2006. Denmark, Centre for 
Sensory-Motor Interaction, Department of Health Science and Technology, 
Aalborg University.  
Ref Type: Thesis/Dissertation 
 [42]  de Groat, Integrative control of the lower urinary tract - preclinical 
perspective. British Journal of Pharmacology 147 Suppl 2, S25-S40 (2006). 
 [43]  Craggs MD, Balasubramaniam AV, Chung EAL and Emmanuel AV, 
Aberrant reflexes and function of the pelvic organs following spinal cord 
injury in man. Autonomic neuroscience 126-127, 355-370 (2006). 
 [44]  Chapple CR and MacDiarmid SA, Structure and function of the urinary 
tract. In Urodynamics made easy. pp. 5-17, Harcourt, Toronto 2000. 
 [45]  Park LM, Bloom DA and McGuire EJ, The guarding reflex revisited. 
British journal of urology 80, 940-945 (1997). 
 [46]  Fowler C, Integrated control of lower urinary tract--clinical perspective. 
British Journal of Pharmacology 147, 14-24 (2006). 
 [47]  Midland Technical College. The urinary system.  2011. 25.  
Ref Type: Slide 
 [48]  Hald T and Bradley WE, Neuropathology. In The urinary bladder - 
Neurology and dynamics. pp. 48-57, Williams and Wilkins, Baltimore 
1982. 
 [49]  Anderson KD, Targeting recovery: Priorities of the spinal cord-injured 
population. Journal of Neurotrauma 21, 1371-1383 (2004). 
 [50]  Spinal cord. The Internet Encyclopedia of Science . 2010. 17-6-2010.  
Ref Type: Electronic Citation 
 [51]  Daneshgari F, Liu G, Birder L, Ann T, Hanna M and Chacko S, Diabetic 
bladder dysfunction: current translational knowledge. The Journal of 
urology 182, 18-26 (2009). 
 - 220 - 
 
 [52]  Julia JJ and Cholham HJ, Herpes zoster-associated acute urinary retention: 
a case report. International urogynecology journal and pelvic floor 
dysfunction 18, 103-104 (2007). 
 [53]  Verpoorten C and Buyse GM, The neurogenic bladder: medical treatment. 
Pediatric Nephrology 23, 717-725 (2008). 
 [54]  Creasey GH, Grill JH, Korsten M, U HS, Betz R, Anderson R and Walter J, 
An implantable neuroprosthesis for restoring bladder and bowel control to 
patients with spinal cord injuries: a multicenter tria. Archives of Physical 
Medicine and Rehabilitation 82, 1512-1519 (2001). 
 [55]  Gomes CM, de Castro FJE, Rejowski RF, Trigo-Rocha FE, Bruschini H, de 
Barros FTE and Srougi M, Experience with different botulinum toxins for 
the treatment of refractory neurogenic detrusor overactivity. International 
Journal of Brazilian Society of Urology 36, 66-74 (2010). 
 [56]  Grosse J, Kramer G and Jakse G, Comparing two types of botulinum-A 
toxin detrusor injections in patients with severe neurogenic detrusor 
overactivity: a case-control study. BJU international 104, 651-656 (2009). 
 [57]  Hambrecht FT, Neural Prostheses. Annu Rev Biophys Bioeng 8, 239-267 
(1979). 
 [58]  Creasey GH. and Dahlberg JE, Economic consequences of an implanted 
neuroprosthesis for bladder and bowel management. Archives of Physical 
Medicine and Rehabilitation 82, 1520-1525 (2001). 
 [59]  Yoo PB and Grill WM, Minimally invasive electrical stimulation of the 
Pudendal nerve: A pre-clinical study for neural control of the lower urinary 
tract. Neurology and Urodynamics 26, 562-569 (2007). 
 [60]  van Balken MR, Vergunst H and Bemelmans BL, The use of electrical 
devices for the treatment of bladder dysfunction: a review of methods. The 
Journal of urology 172, 846-851 (2004). 
 [61]  Jezernik S, Craggs MD, Grill WM, Creasey G and Rijkhoff NJM, 
Electrical stimulation for the treatment of bladder dysfunction: Current 
status and future possibilities. Neurological Research 24, 413-430 (2002). 
 [62]  Griffiths J, Observations upon the urinary bladder and urethra - Part 3. 
Journal of Anatomy of Physiology 29, 254-275 (1895). 
 [63]  Langworthy OR and Hesser FH, Reflex vesical contraction in the cat after 
transection of the spinal cord in the lower lumbar region. Bulletins of the 
Johns Hopkins Hospital 60, 204-214 (1937). 
 - 221 - 
 
 [64]  Boyce WH, Lathem JE and Hunt LD, Research related to the development 
of an artificial electrical stimulator for the paralysed human bladder. The 
Journal of urology 91, 41-51 (1964). 
 [65]  Ingersoll EH, Jones LL and Hegre ES. Urinary bladder response to 
unilateral stimulation of pelvic nerves. Proceedings of the society for 
experimental biology and medicine. 88[1], 46-9. 1955.  
Ref Type: Conference Proceeding 
 [66]  Caldwell KP, The electrical control of sphincter incompetence. The Lancet 
2, 174-175 (1963). 
 [67]  Kock NG and Pompeius R, Inhibition of vesical motor activity induced by 
anal stimulation. Acta chirurgica Scandinavica 126, 244-250 (1963). 
 [68]  Habib HN. Neural trigger points for evacuation of neurogenic bladder by 
electro stimulation. Surgical forum 14, 489-491. 1963.  
Ref Type: Electronic Citation 
 [69]  Rossier A and Bors E, Detrusor responses to perianal and rectal 
stimulation in patients with spinal cord injuries. Urologia internationalis 
18, 181-190 (1964). 
 [70]  de Groat WC and Ryall RW, Reflexes to sacral parasympathetic neurones 
concerned with micturition in the cat. The Journal of physiology 200, 87-
108 (1969). 
 [71]  Sundin T and Carlsson CA, Reconstruction of severed dorsal roots 
innervating the urinary bladder. An experimental study in cats. I. Studies on 
the normal afferent pathways in the pelvic and pudendal nerves. 
Scandinavian journal of urology and nephrology 6, 176-184 (1972). 
 [72]  Sundin T, Carlsson CA and Kock NG, Detrusor inhibition induced from 
mechanical stimulation of the anal region and from electrical stimulation of 
pudendal nerve afferents. An experimental study in cats. Investigative 
urology 11, 374-378 (1974). 
 [73]  Godec C, Cass AS and Ayala GF, Bladder inhibition with functional 
electrical stimulation. Urology 6, 663-666 (1975). 
 [74]  Fall M, Reflex mechanism for bladder inhibition. Acta Pharmacol Toxicol 
43, 13-18 (1978). 
 [75]  Kondo A, Otani T and Takita T, Suppression of bladder instability by 
penile squeeze. British journal of urology 54, 360-362 (1982). 
 - 222 - 
 
 [76]  McGuire EJ, Morrissey S, Zhang S and Horwinski E, Control of reflex 
detrusor activity in normal and spinal injured non-human primates. Journal 
of Urology 129, 197-199 (1983). 
 [77]  Lindström S, Fall M, Carlsson CA and Erlandson BE, The 
neurophysiological basis of bladder inhibition in response to intravaginal 
electrical stimulation. Journal of Urology 129, 405-410 (1983). 
 [78]  Nakamura M and Sakurai T, Bladder inhibition by penile electrical 
stimulation. British journal of urology 56, 413-415 (1984). 
 [79]  Vodusek DB, Light JK and Libby JM, Detrusor inhibition induced by 
stimulation of pudendal nerve afferents. Neurourology and urodynamics 5, 
381-389 (1986). 
 [80]  Fall M and Lindström S, Electrical stimulation. A physiological approach 
to the treatment of urinary incontinence. The Urologic clinics of North 
America 18, 393-407 (1991). 
 [81]  Sheriff MK, Shah PJR, Fowler C, Mundy AR and Craggs MD, 
Neuromodulation of detrusor hyper-reflexia by functional magnetic 
stimulation of the sacral roots. British journal of urology 78, 39-46 (1996). 
 [82]  Hasan ST, Robson WA and Pridie AK, Transcutaneous electrical nerve 
stimulation and temporary S3 neuromodulation in idiopathic detrusor 
instability. The Journal of urology 155, 2005-2011 (1996). 
 [83]  Grill WM, Craggs MD, Foreman RD, Ludlow CL and Buller JL, Emerging 
clinical applications of electrical stimulation: opportunities for restoration 
of function. Journal of Rehabilitation Research and Development 38, 641-
653 (2001). 
 [84]  Rijkhoff NJM, Neuroprostheses to treat neurogenic bladder dysfunction: 
current status and future perspectives. Child's nervous system 20, 75-86 
(2004). 
 [85]  Fall M, Advantages and pitfalls of functional electrical stimulation. Acta 
obstetricia et gynecologica Scandinavica Supplement 168, 16-21 (1998). 
 [86]  Hansen J, Borau A, Rodrguez A, Vidal J, Sinkjaer T and Rijkhoff N, 
Urethral sphincter EMG as event detector for Neurogenic detrusor 
overactivity. IEEE transactions on bio-medical engineering 54, 1212-1219 
(2007). 
 [87]  Pathak AS and Aboseif SR, Overactive bladder: drug therapy versus nerve 
stimulation. Nature clinical practice Urology 2, 310-311 (2005). 
 - 223 - 
 
 [88]  Siegel SW, Management of voiding dysfunction with an implantable 
neuroprosthesis. The Urologic clinics of North America 19, 163-170 
(1992). 
 [89]  Gillenwater JY, Grayhack JT, Howards SS and Mitchell ME, Voiding 
Dysfunction: Diagnosis, Classification and Management. In Adult and 
peadiatric urology vol. 2. pp. 1115-1217, Lippincott Williams & Wilkins, 
Philadelphia 2002. 
 [90]  Edirisinghe DT. Electrical stimulation for bladder dysfunction may increase 
fertility rate in women.  2010.  
Ref Type: Hearing 
 [91]  Wheeler JS Jr, Walter JS and Zaszczurynski PJ, Bladder inhibition by 
penile nerve stimulation in spinal cord injury patient. Journal of Urology 
147, 100-103 (1992). 
 [92]  Wenzel BJ, Boggs JW, Gustafson KJ and Grill WM, Closed Loop 
Electrical Control of Urinary Continence. The Journal of urology 175, 
1559-1563 (2006). 
 [93]  Floeter MK, Gerloff C, Kouri J and Hallet M, Cutaneous withdrawal 
reflexes of the upper extremity. Muscle & nerve 21, 591-598 (1998). 
 [94]  Wenzel BJ, Boggs JW, Gustafson KJ and Grill WM, Detecting the onset of 
hyper-reflexive bladder contractions from the electrical activity of the 
pudendal nerve. IEEE transactions on neural systems and rehabilitation 
engineering 13, 428-435 (2005). 
 [95]  Horvath EE, Yoo PB, Amundsen CL, Webster GD and Grill WM, 
Conditional and continuous electrical stimulation increase cystometric 
capacity in persons with spinal cord injury. Neurourology and urodynamics 
29, 401-407 (2010). 
 [96]  Lee YH and Creasey GH, Self-controlled dorsal penile nerve stimulation to 
inhibit bladder hyperreflexia in incomplete spinal cord injury: a case 
report. Archives of Physical Medicine and Rehabilitation 83, 273-277 
(2002). 
 [97]  Kirkham AP, Knight SL, Craggs MD, Casey AT and Shah PJ, 
Neuromodulation through sacral nerve roots 2 to 4 with a Finetech-
Brindley sacral posterior and anterior root stimulator. Spinal Cord 40, 
272-281 (2002). 
 [98]  McCreery DB, Agnew WF, Yuen TG and Bullara LA, Damage in 
peripheral nerve from continuous electrical stimulation: comparison of two 
 - 224 - 
 
stimulus waveforms. Medical & biological engineering & computing 30, 
109-114 (1992). 
 [99]  The Urology Group. Conditions. Website . 2010. 23-7-2010.  
Ref Type: Electronic Citation 
 [100]  Fjorback MV, Rijkhoff N, Petersen T, Nohr M and Sinkjaer T, Event driven 
electrical stimulation of the dorsal penile/clitoral nerve for management of 
neurogenic detrusor overactivity in multiple sclerosis. Neurology and 
Urodynamics 25, 349-355 (2006). 
 [101]  Martens FMJ, van Kuppevelt HJ, Beekman JA, Rijkhoff NJ and 
Heesakkers J, Limited value of bladder sensation as a trigger for 
conditional neurostimulation in spinal cord injury patients. Neurourology 
and urodynamics 29, 395-400 (2010). 
 [102]  Kurstjens GA, Borau A, Rodríguez A, Rijkhoff NJ and Sinkjaer T, 
Intraoperative recording of electroneurographic signals from cuff 
electrodes on extradural sacral roots in spinal cord injured patients. The 
Journal of urology 174, 1482-1487 (2005). 
 [103]  Jezernik S, Grill WM and Sinkjaer T, Detection and inhibition of 
hyperreflexia-like bladder contractions in the cat by sacral nerve root 
recording and electrical stimulation. Neurology and Urodynamics 20, 215-
230 (2001). 
 [104]  Wenzel BJ, Boggs JW, Gustafson KJ, Creasey GH and Grill WM, 
Detection of neurogenic detrusor contractions from the activity of the 
external anal sphincter in cat and human. Neurourology and urodynamics 
25, 140-147 (2006). 
 [105]  Fedirchuk B and Shefchyk SJ, Membrane potential changes in sphincter 
motoneurons during micturition in the decerebrate cat. J Neurosci 13, 
3090-3094 (1993). 
 [106]  Thor KB and Muhlhauser MA, Vesicoanal, urethroanal, and urethrovesical 
reflexes initiated by lower urinary tract irritation in the rat. Am J Physiol 
Regul Integr Comp Physiol 277, R1002-R1012 (1999). 
 [107]  Blaivas JG, Sinha HP, Zayed AA and Labib KB, Detrusor-external 
sphincter dyssynergia: a detailed electromyographic study. Journal of 
Urology 125, 545-548 (1981). 
 [108]  Vodusek DB, Light JK and Libby JM, Detrusor inhibition induced by 
stimulation of pudendal nerve afferents. Neurology and Urodynamics 5, 
381-389 (1986). 
 - 225 - 
 
 [109]  Vodusek DB, Pelvnik S, Vrtacnik P and Janez J, Detrusor inhibition on 
selective pudendal nerve stimulation in the perineum. Neurology and 
Urodynamics 6, 389-393 (1988). 
 [110]  Yang CC and Bradley WE, Peripheral distribution of the human dorsal 
nerve of the penis. The Journal of urology 159, 1912-1916 (1998). 
 [111]  O'Connell HE, Sanjeevan KV and Hutson JM, Anatomy of the clitoris. The 
Journal of urology 174, 1189-1195 (2005). 
 [112]  MacDiarmid SA, Peters KM, Shobeiri SA, Wooldridge LS, Rovner ES, 
Leong FC, Siegel SW, Tate SB and Feagins BA, Long-term durability of 
percutaneous tibial nerve stimulation for the treatment of overactive 
bladder. The Journal of urology 183, 234-240 (2010). 
 [113]  Kabay S, Kabay SC, Yucel M, Ozden H, Yilmaz Z, Aras O and Aras B, 
The clinical and urodynamic results of a 3-month percutaneous posterior 
tibial nerve stimulation treatment in patients with multiple sclerosis-related 
neurogenic bladder dysfunction. Neurourology and urodynamics 28, 964-
968 (2009). 
 [114]  Amarenco G, Even-Schneider A, Ismael SS, Raibaut P, Demaille-Wlodyka 
S, Parratte B and Kerdraon J, Urodynamic effect of acute transcutaneous 
posterior tibial nerve stimulation in overactive bladder. The Journal of 
urology 169, 2210-2215 (2003). 
 [115]  Ohlsson BL, Fall M and Frankenberg-Sommar S, Effects of external and 
direct pudendal nerve maximal electrical stimulation in the treatment of the 
uninhibited overactive bladder. British journal of urology 64, 374-380 
(1989). 
 [116]  Eriksen BC, Bergmann S and Mjolnerod OK, Effect of anal 
electrostimulation with the 'Incontan' device in women with urinary 
incontinence. British Journal of Obstetrics and Gynaecology 94, 147-156 
(1987). 
 [117]  Suhel P, Adjustable non implantable electrical stimulators for correction of 
urinary incontinence. Urologia internationalis 31, 115-123 (1976). 
 [118]  Glen ES, Effective and safe control of incontinence by the intra-anal plug 
electrode. The British journal of surgery 58, 249-252 (1971). 
 [119]  Rectum and Anus. Website . 2010. 2-8-2010.  
Ref Type: Electronic Citation 
 - 226 - 
 
 [120]  Risk Hansen Spinal Cord Injury Resgistry. Spinal cord injury - Facts and 
statistics.  2005. 4-8-2010.  
Ref Type: Report 
 [121]  Gall A and Turner-Strokes L, Chronic spinal cord injury: management of 
patients in acute hospital settings. Journal of the Royal College of 
Physicians 8, 70-74 (2008). 
 [122]  Hansen RB, Biering-Sørensen F and Kristensen JK, Urinary incontinence 
in spinal cord injured individuals 10-45 years after injury. Spinal Cord 48, 
27-33 (2010). 
 [123]  Balasubramaniam AV. A neurophysiological assessment of the bladder 
guarding response in spinal cord injury.  2007.  Institute of Urology and 
Nephrology, University College London.  
Ref Type: Thesis/Dissertation 
 [124]  Geisler WO, Jousse AT, Wynne-Jones M and Breithaupt D, Survival in 
traumatic spinal cord injury. Paraplegia 21, 364-373 (1983). 
 [125]  Foundation for spinal cord injury prevention care & cure. Spinal cord injury 
statistics.  2009.  National Spinal Cord Injury Statistical Center, 
Birmingham, Alabama. 4-8-2010.  
Ref Type: Report 
 [126]  Lemack GE, Clinical evaluation: history and physical examination. In 
Neurogenic Bladder. (Ed. Corcos J and Schick E) pp. 413-417, Informa 
Healthcare, Canada 2008. 
 [127]  Rackley R, Vasavada SP, Firoozi F and Ingber MS. Neurogenic Bladder. 
Emedicine, Medscape . 2009. 4-8-2010.  
Ref Type: Magazine Article 
 [128]  Brindley GS, Rushton DN and Craggs MD, The pressure exerted by the 
external sphincter of the urethra when its motor nerve fibres are stimulated 
electrically. British journal of urology 46, 453-462 (1974). 
 [129]  Alexander S and Rowan D, An electric pessary for stress incontinence. The 
Lancet 1, 728 (1968). 
 [130]  Edwards L and Malvern J, Electronic control of incontinence: A critical 
review of the present situation. British journal of urology 44, 467-472 
(1972). 
 [131]  DeSoldenhoff R and McDonnell H, New device for control of female 
urinary incontinence. British Medical Journal 230 (1969). 
 - 227 - 
 
 [132]  Merrill DC, Conway C and deWolf W, Urinary incontinence: Treatment 
with electrical stimulation of the pelvic floor. Urology 5, 67-72 (1975). 
 [133]  Sotiropoulos A, Urinary incontinence management with electronic 
stimulation of muscles of pelvic floor. Urology 6, 312-318 (1975). 
 [134]  Alexander S, Rowan D, Millar W and Scott R, Treatment of urinary 
incontinence by electric pessary - A report of 18 patients. British journal of 
urology 42, 184-190 (1970). 
 [135]  TensCare. Continence products. Website . 2011. 14-2-2011.  
Ref Type: Electronic Citation 
 [136]  Netter FH and Colacino S, Atlas of human anatomy, CIBA-GEIGY Corp, 
1989. 
 [137]  Olsen IP, Wilsgaard T and Kiserud T, Transvaginal three-dimensional 
ultrasound: a method of studying anal anatomy and function. Ultrasound 
Obstet Gynecol 37, 353-360 (2011). 
 [138]  Glen ES, Intra-anal electrode: A stimulus to bowel and bladder control. 
Journal of Pediatric Surgery 6, 138-142 (1971). 
 [139]  Snell R, The perineum. In Clinical anatomy by regions. pp. 387-425, 
Lippincott Williams & Wikins, 2007. 
 [140]  Dauber W, Alimentary system. In Pocket atlas of human anatomy. pp. 134-
163, New York 2000. 
 [141]  Binnie NR, Kawimbe BM, Papachrysostomou M, Clare N and Smith AN, 
The importance of the orientation of the electrode plates in recording the 
external anal sphincter EMG by non-invasive anal plug electrodes. 
International Journal of Colorectal Disease 6, 5-8 (1991). 
 [142]  Ellis H, Logan B and Dixon A, Pelvis. In Human sectional anatomy - Atlas 
of body sections, CT and MRI images. pp. 149-192, Butterworth-
Heinemann, 1999. 
 [143]  Curtis J and Colas A, Medical applications of silicones. In Biomaterial 
science - An introduction to materials in medicine. (Ed. Dow Corning 
Corporation) pp. 697-706, Elsevier Inc, 2011. 
 [144]  Courtney J and Gilchrist T, Silicone rubber and natural rubber as 
biomaterials. Medical and Biological Engineering and Computing 18, 538-
540 (1980). 
 - 228 - 
 
 [145]  NuSil Technology. MED-4940 Liquid Silicone Rubber Product Profile.  
2007.  
Ref Type: Data File 
 [146]  Donaldson N. Electrodes 2.  2008. 15.  
Ref Type: Slide 
 [147]  Newson T. Stainless steel - A family of medical device materials. 1, 1-3. 
2002.  
Ref Type: Report 
 [148]  Prutchi D and Norris M, Stimulation of excitable tissues. In Design and 
development of medical electronic instrumentation. pp. 305-368, John 
Wiley & Sons, Inc., New Jersey 2005. 
 [149]  Craggs MD, Edirisinghe N, Leaker B, Susser J, Al-mukhtar M and 
Donaldson N, Conditional neuromodulation using trans-rectal stimulation 
in spinal cord injury. Neurology and Urodynamics 28, 836-837 (2009). 
 [150]  Wyndaele JJ, Correlation between clinical neurological data and 
urodynamic function in spinal cord injured patients. Spinal Cord 35, 213-
216 (1997). 
 [151]  Balasubramaniam AV. Neurophysiological assessment of the bladder 
guaring responses in spinal cord injury.  2007.  UCL.  
Ref Type: Thesis/Dissertation 
 [152]  Macfarlane MT, Voiding disorders. In Urology. pp. 134-144, Lippincott 
Williams and Wilkins, Philadelphia 2006. 
 [153]  Chapple CR and MacDiarmid SA, Urodynamic techniques. In Urodynamics 
made easy. pp. 19-73, Harcourt, Toronto 2000. 
 [154]  Lectromed UK Ltd. Lectromed 5361 isolated biopotential amplifier user 
manual.  1995.  
Ref Type: Catalog 
 [155]  Digitimer. Digitimer Constant Current Stimulator Operator's Manual. 9. 26-
9-2007.  
Ref Type: Catalog 
 [156]  Dolan L, Elnaqa A, Hosker G, Hunt D, Knight S, Lucas M, Neale T, Parker 
J, Ramage C, Singh G, Swithinbank L, Toozs-Hobson P, Townsend J and 
Webb R. Joint statement on minimum standards for urodynamic practice in 
the UK. 1, 7-31. 2009.  
Ref Type: Report 
 - 229 - 
 
 [157]  Dalsome AL, Rijkhoff NJM, Kirkeby HJ, Nohr M, Sinkjaer T and Djurhuus 
JC, Conditional stimulation of the dorsal penile/clitorial nerve may 
increase cystometric capacity in patients with SCI. Neurology and 
Urodynamics 22, 130-137 (2003). 
 [158]  Walters-Williams J and Li Y, Comparative study of distance functions for 
nearest neighbors. In Advanced techniques in computing sciences and 
software engineering. (Ed. Elleithy K) pp. 79-84, Springer science, 
Bridgeport 2009. 
 [159]  Previnaire JG, Soler JM, Perrigot M, Boileau G, Delahaye H, Schumacker 
P, Vanvelcenaher J and Vanhee JL, Short-term effect of pudendal nerve 
electrical stimulation on detrusor hyperreflexia in spinal cord injury 
patients: importance of current strength. Paraplegia 34, 95-99 (1996). 
 [160]  Vereecken RL, De Meirsman J, Puers B and Van Mulders J, 
Electrophysiological exploration of the sacral conus. Journal of Neurology 
227, 135-144 (1982). 
 [161]  Prévinaire JG, Soler JM, Perrigot M, Boileau G, Delahaye H, Schumacker 
P, Vanvelcenaher J and Vanhée JL, Short-term effect of th epudendal nerve 
electrical stimulation on detrusor hyperreflexia in spinal cord injury 
patients: importance of current strength. Paraplegia 34, 95-99 (1996). 
 [162]  Shah NC, Knight SL, Shah PJ and Craggs MD, Optimisation of stimulation 
for conditional neuromodulation of detrusor hyperreflexia. European 
Urology 35, 16 (1999). 
 [163]  Schalow G, Zach GA and Warzok R, Classification of human peripheral 
nerve fibre groups by conduction velocity and nerve fibre diameter is 
preserved following spinal cord lesion. Journal of the Autonomic Nervous 
System 52, 125-150 (1995). 
 [164]  Kestenbaum B, Screening. In Epidemiology and biostatistice:an 
introduction to clinical research. pp. 121-138, Springer Science, 
Washington, USA 2009. 
 [165]  Koldewijn EL, Van Kerrebroeck PE, Rosier PF, Wijkstra H and Debruyne 
FM, Bladder compliance after posterior sacral root rhizotomies and 
anterior sacral root stimulation. Journal of Urology 151, 955-960 (1994). 
 [166]  Ogino K and Kozak W. Spectrum analysis of surface electromyogram 
(EMG). Acoustics, Speech, and Signal Processing, IEEE International 
Conference. ICASSP '83. 8, 1114-1117. 1983. Ohio University Athens, 
Ohio.  
Ref Type: Conference Proceeding 
 - 230 - 
 
 [167]  Rangayyan RM, Introduction to biomedical signals. In Biomedical signal 
analysis. (Ed. IEEE press) pp. 1-59, Wiley-Interscience, Alberta, Canada 
2002. 
 [168]  Bartlett R, The anatomy of human movement. In Introduction to sports 
biomechanics: Analysing human movement patterns. pp. 223-280, 
Routledge, New York 2007. 
 [169]  De Luca CJ. Surface Electromyography: Detection and recording. 
Electronic publication . 2002.  
Ref Type: Electronic Citation 
 [170]  Mewett DT, Reynolds KJ and Nazeran H., Reducing power line 
interference in digitised electromyogram recordings by spectrum 
interpolation. Medical and Biological Engineering and Computing 42, 524-
531 (2004). 
 [171]  Mewett DT, Nazeran H and Reynolds KJ. Removing power line noise from 
recorded EMG. Engineering in Medicine and Biology. 23rd Annual 
International Conference of IEEE 3, 2190-2193. 2001.  
Ref Type: Conference Proceeding 
 [172]  Lu G, Brittain JS, Holland P, Yianni J, Green AL, Stein JF, Aziz TZ and 
Wang S, Removing ECG noise from surface EMG signals using adaptive 
filtering. Neruoscience Letters 462, 14-19 (2009). 
 [173]  D. T. Mewett, Reducing power line interference in digitised 
electromyogram recordings by spectrum interpolation. Medical & 
biological engineering & computing 42, 524-531 (2004). 
 [174]  Schweitzer TW, Fitzgerald JW and Bowden JA, Spectral analysis of human 
inspiratory diaphragmatic electromyograms. Journal of applied physiology: 
Respiratory, environmental and exercise physiology 46, 152-165 (1979). 
 [175]  Lectromed. Lectromed 5361 Isolate Bio-potential Amplifier.  2006. 
Lectromed UK Ltd, Herts.  
Ref Type: Catalog 
 [176]  CED. 1401plus.  1997. Cambridge, UK.  
Ref Type: Catalog 
 [177]  Nagel JH, Biopotential Amplifiers. In The Biomedical Engineering 
Handbook vol. 2. pp. 70-1-70-15, Florida 2000. 
 [178]  Berson AS and Pipberger HV, Skin-electrode impedance problems in 
electrocardiography. The American heart journal 76, 514-525 (1968). 
 - 231 - 
 
 [179]  Casas O and Pallas-Areny R, Optimal bias circuit for instrumentation 
amplifiers. Proceeding of 14th IMEKO world conference 4, 143-148 
(1997). 
 [180]  Burr-Brown Corporation. INA 118 - Precision, Low Power Instrumentation 
Amplifier.  1998.  
Ref Type: Data File 
 [181]  Spinelli E and Haberman M, Insulating electrodes: a review on biopotential 
front ends for dielectric skin−electrode interfaces. Physiological 
Measurement 31, 183-198 (2010). 
 [182]  Galjan W, Hafkemeyer KM, Tomasik JM, Wagner F, Krautschneider WH 
and Schroeder D. Highly sensitive biomedical amplifier with CMRR 
calibration and DC-offset compensation. EUROCON 2009. IEEE Xplore , 
152-155. 2009.  IEEE Xpolre. 18-5-2009.  
Ref Type: Conference Proceeding 
 [183]  Radio-Electronics. Operational amplifier / op amp notch filter circuit. 
Radio-Electronics.com . 2010.  
Ref Type: Electronic Citation 
 [184]  Graf RF, Filters (Notch). In Converter and Filter Circuits. pp. 77-89, 
Butterworth-Heinemann, 1996. 
 [185]  Kumngern M, Lerkvaranyu S and Dejhan K. Wide-band CMOS precision 
rectifier circuit. Communications and Information Technologies, 2008. 
ISCIT 2008. International Symposium on.  315-320. 21-10-2008.  
Ref Type: Conference Proceeding 
 [186]  Antoniou A., Design of precision rectifiers using operational amplifiers. 
Electrical Engineers, Proceedings of the Institution of 121, 1041-1044 
(1974). 
 [187]  Elliott R. Precision rectifiers. Website . 2009.  Elliott sound products. 24-7-
2010.  
Ref Type: Electronic Citation 
 [188]  Jones D and Stitt M. Precision absolute value circuit. Burr-Brown 
application bulletin . 1997.  Burr-Brown.  
Ref Type: Electronic Citation 
 [189]  Ballou G. AC 2 DC. Millimeter . 2001.  
Ref Type: Electronic Citation 
 [190]  Rectification and smmothing. Lecture note - EM08 . 2010.  
Ref Type: Electronic Citation 
 - 232 - 
 
 [191]  Bronzite M, Simple active filters - design procedure. Wireless world 117-
119 (1970). 
 [192]  Webster JG, Basic concepts of electronics. In Bioinstrumentation. pp. 28-
91, John Wiley & Sons, Inc, 2004. 
 [193]  De Lima JA and Cordeiro AS. A simple constant-current neural stimulator 
with accurate pulse-amplitude control. 23rd Annaual EMBS International 
Conference. IEEE proceedings , 1328-1331. 2001. 25-10-2001.  
Ref Type: Conference Proceeding 
 [194]  Digitimer Research Instruments. Stimulators. Digitimer website . 2010.  
Ref Type: Electronic Citation 
 [195]  Philips Semiconductors. Dual retriggerable precision monostable 
multivibrator.  1993.  
Ref Type: Data File 
 [196]  Kumar V, Astable and monostable multivibrator. In Digital electronics - 
theory and experiments. pp. 93-104, New Age International (P) Ltd, New 
Delhi, India 2006. 
 [197]  Texas Instruments. TLC251 LinCMOS programmable low-power 
operational amplifiers.  1983. Dallas, Texas.  
Ref Type: Data File 
 
 
 - 233 - 
 
Appendix 1 – Patient consent form 
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CONSENT FORM 
Agreement to participate in a clinical investigation 
 
Investigators:  Professor MD Craggs, Director of Spinal Research 
 Dr A Gall FRCP, Consultant Rehabilitation Physician 
Mr PJR Shah FRCS, Consultant Urological Surgeon 
Mr J Woodhouse MRCS, Clinical Research Fellow, Urologist 
  Sr J Susser, RGN, Clinical Nurse Specialist 
 
1. I have read the information sheet concerning this study and I 
understand what will be required of me if I take part in this study. 
2. My concerns regarding this study have been answered by  
……………………. 
3. I understand that at any time I may withdraw from this study without 
giving a reason and without affecting my normal care and 
management. 
4. I understand that the information from this study may be published in 
scientific journals, but that I will not be identified. 
5.  I agree to take part in this study.  
 
 
Patient’s signature or independent witness....................................... 
 
Name in BLOCK LETTERS .......................................................... 
 
Date ............................................................................................... 
 
Doctor’s signature ......................................................................... 
 
Name in BLOCK LETTERS ......................................................... 
 
Date .............................................................................................. 
      
www.spinalresearchcentre.org.uk 
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Appendix 2 – Multiple feedback filter design  
 
Nodal analysis at node 1 
( ) ( ) 041312111 =−+++− YVVYVYVYVV outin  Eq.  1 
Rearranging, gives 
( ) 01443211 =−−+++ YVYVYYYYV inout  Eq.  2 
Nodal analysis at node 2 
0315 =+ YVYVout  Eq.  3 
Rearranging, gives 
3
5
1 Y
YVV out−=  
Substituting V1 in equation 2, 
( ) 0144321
3
5
=−−+++− YVYVYYYY
Y
YV
inout
out
 
Finally, 
( ) 4343215
31
YYYYYYY
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V
V
in
out
++++
−
=  
